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“But for man, no rest and no ending. He must go on, conquest beyond conquest. First 
this little planet and all its winds and ways, and then all the laws of mind and matter that 
restrain him. Then the planets about him, and, at last, out across immensities to the stars. And 
when he has conquered all the deep space, and all the mysteries of time, still, he will be 
beginning." by Herbert George Wells in the Things to come (1936).  
These words best describe the dynamic process of science and moreover, present the 
keystone of a breakthrough research and outstanding researchers. First we need to study the 
past, then improve and fight for our present, which will give us an opportunity to build and 
nurture a better future. 
For the last 100 years, we have been facing a tremendous progress in nanotechnology, 
and more recently in immunology and cancer immunotherapy. In fact, nanomedicine is 
currently an emerging field with the successful application of nanotechnology to develop 
personalized tools to diagnose, prevent or treat specific pathological conditions. In addition, 
the recent stunning results obtained at clinical level with the use of T-cell therapy and 
immunecheckpoint inhibitors in patients presenting advanced stages of leukemia, melanoma, 
and lung cancers, have prompt the scientific community to critical role of the immune system 
in the destruction of those malignant cells. However, I believe that the up-to-date 
development procedure of nanosystems based on trial-by-error does not allow to control the 
overall physicochemical properties of these nanocarriers and thus may be underlying their 
premature failure at preclinical settings. Therefore, the present research project aims to 
combine both cancer immunotherapy and nanotechnology to develop a novel 
nanotechnology-based system to successfully modulate the activity and proliferation of 
immune cells, overcoming the tumor-stroma immunosuppressive microenvironment.  
This research work was developed between September 2012 and August 2016, mainly 
in two research laboratories: Prof. Florindo laboratory at Research Institute for Medicines 
(iMed.ULisboa), Faculty of Pharmacy, University de Lisbon, Lisbon, Portugal and Prof. Jung 
laboratory at the Department of Immunology, Faculty of Biology, Weizmann institute of 
Science, Rehovot, Israel.  
Under the supervision of Prof. Helena F. Florindo, I have developed, optimized and 
extensively characterized novel immunotherapeutic delivery systems for the delivery of both 
antigens and adjuvants to single targeted immune cells. Different types of NP have been 
developed in order to best attain the most efficient parameters for cancer immunotherapeutics. 
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The effect of multiple experimental parameters, such as nature of protein association 
(adsorbed vs. encapsulated) and polymers and surfactant concentrations on particle size, 
polydispersity index, zeta potential, encapsulation efficiency and integrity of the protein, 
surfactant residual amount, and integrity of the polymer after the formulation process were 
fully addressed. The effect of the optimal nanodelivery system on the viability of dendritic 
and cancer cells was also studied in order to ensure the safety of the system. 
The effect of the optimized nanoparticulate vaccine on immune cells, both in vitro an 
in vivo, were performed at Prof. Steffen Jung’s laboratory, at the Weizmann institute of 
Science, Rehovot, Israel. Professor Steffen Jung is a collaborator of Prof. Helena Florindo’s 
laboratory and in his laboratory, I gained an extensive knowledge about the complexity of 
immune response in steady state conditions. Moreover, having in consideration the promising 
data obtained regarding the effect in the proliferation of different subpopulations of immune 
cells, it was possible to assess the immunotherapeutic potential of developed vaccine on the 
melanoma tumor-bearing mice. Different techniques were developed and explored to 
accomplish those goals, namely lymph node isolation, dendritic cell plasticity characterization 
and determination of T cell proliferation and activation. 
Apart from those two research groups, existing collaborations with other laboratories 
and institutions were important to achieve the major goals of this multidisciplinary project. 
Prof. Carlos Afonso and Dr. Catarina Rodrigues from the Bioorganic chemistry group at 
iMed.ULisboa synthesized fluorophore-grafted polymer (PLGA-Rho) that was used for the in 
vitro and in vivo uptake studies. Prof. Ana S. Viana from Chemistry and Biochemistry Center, 
Sciences Faculty, Universitdade de Lisboa, Portugal provided further insight on the 
physicochemical characterization and diameter distribution of nanoparticle by atomic force 
microscopy. Prof. João Pinto and Dr Maria Paisana from the Innovative platforms for non-
parental delivery systems at iMed.ULisboa provided the assistance with DSC and FTIR for 
more detailed physicochemical characterization of developed nanoparticate vaccine. Prof. Lea 
Eisenbach from Department of Immunology, Faculty of Biology, Weizmann institute of 
Science, provided a B16.MO5 melanoma cell. These melanoma cells are transfected with the 
Ovalbumin gene and therefore allowed to evaluate the specific nature of the enhanced 
immune response. Prof. Zelig Eshhar,  from Department of Immunology at the Weizmann 
institute of Science, Rehovot, also supported the   assessment of the efficacy of our 
nanovaccines, using specific tumor associated antigens. Finally, Prof. Ronit Satchi-Fainaro 
and PhD student Eilam Yeini from the Department of Physiology and Pharmacology, Sackler 
School of Medicine, Tel Aviv University, Israel, helped with the simultaneously cytokines 
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and chemokines immunoassay in the serum of melanoma-bearing mice after the treatment 
with the nanoparticulate vaccine.  
The results reported in this PhD thesis were only possible due to this highly 









Biodegradable polymeric nanoparticles (NP) are promising tools for tumor 
eradication. Different nanovaccines based on the aliphatic-polyester (poly(lactic-co-glycolic 
acid) (PLGA) have been developed and optimized to investigate how different methods for 
antigen association to nanoparticulate carriers affect antigen uptake by antigen presenting 
cells (APC) and the generation and nature of antigen-specific immune responses. The 
different experimental parameters have been tested in order to predict the effect of the nature 
of protein association (adsorbed vs. entrapped) and polymers/surfactant concentrations, on NP 
average mean diameter, polydispersity index, surface charge, encapsulation efficiency, protein 
integrity and surfactant residual amount. This development procedure allowed for the rational 
identification of particle composition and experimental conditions that led to the antigen-
associated nanocarrier presenting the ideal product specifications previously identified for 
optimal immune cell modulation, having in consideration literature evidences and our 
previous data.  
We used PLGA and pegylated (PEG)-PLGA as a matrix polymer. When preparing NP 
with double-emulsion solvent-evaporation technique, we used α-lactalbumin (LALBA) as an 
antigen, glycol chitosan (CS) to increase the viscosity of the internal aqueous phase (IP) and 
polyvinyl alcohol (PVA) or Pluronic F127 (PF127) to stabilization the interphase of double 
emulsion. Various concentrations of surfactants has been used (2, 4, 5, 8, 10, 12 % v/v) to 
best meet the criteria of the most optimal nanoparticulate delivery system. We aimed for NP 
below 200 nm, polydispersity index (PDI) under 0.2 and ζ potential close to neutrality. 
The formulations with 10 % v/v PVA solution in IP and 0.3 % v/v PVA or PF127 in 
external aqueous phase (EP) presented stable and repetitive NP formulations with desired 
physiochemical properties. The highest encapsulation efficacy (EE) values were obtained for 
the formulation prepared with PVA (EntrapLALBA(PVA)), reaching 80 % of the integrated 
protein, while NP with PF127 (EntrapLALBA(PF127)) presented around 70 % EE. As 
regards the protein adsorbed, NP formulations prepared with PVA (AdsLALBA(PVA)) or 
PF127 (AdsLALBA(PF127), reached the values of 40 % and 50 %, respectively.  
Dynamic light scattering (DLS) and laser doppler velocimetry (LDV) were used to 
determine average particle size, polydispersity (PDI) and ζ potential, respectively. 
EntrapLALBA(PVA) presented the average size of 171 nm with PDI around 0.15 and ζ 
potential 0.51 mV. EntrapLALBA(PF127) had 185 nm with PDI 0.17 and ζ potential 0.37 
mV. On the other side AdsLALBA(PVA) and AdsLALBA(PF127) presented slightly bigger 
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size 188 nm and 195 nm, respectively, with more negative ζ potential, -1,89 and -1,42 mV, 
respectively. NP size, PDI and geometry were also confirmed by atomic force microscopy 
(AFM).  
Protein integrity was confirmed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Fourier transform infrared spectroscopy (FTIR) was further 
used to study the interaction of protein adsorption onto surfaces of polymeric NP. The 
presence of bands at the wavelengths 1662 cm-1 and 1562 cm-1, that are specific for primary 
amides and amines, were detected in formulations AdsLALBA(PVA) and 
AdsLALBA(PF127), where LALBA was adsorbed onto the surface of the NP. While in NP 
EntrapLALBA(PVA) and EntrapLALBA(PF127) this bands were absent indicating the 
protein incorporation into the polymeric matrix. Differential scanning calorimetry (DSC) 
showed that the formulation process did not alter the structure of the polymers used in the 
preparation of NP. 
The ability of the optimal formulations for systemic delivery and activation of DC was 
further evaluated in vitro and in vivo on bone marrow derived dendritic cells (BMDC). 
Similar activation and maturation profile of APC were obtained after the internalization of NP 
with antigen entrapped (EntrapNP) or adsorbed onto NP surface (AdsNP) evaluated at 3, 6, 16 
and 24 h (ImageStreamTM and flow cytometry). The DC-NP interaction increased with the 
incubation time, presenting internalization values between 50-60% and 30-40%, in vitro and 
in vivo, respectively. Interestingly, MHCII was upregulated after the immunization with 
AdsNP and MHCI after the vaccination with EntrapNP, suggesting more efficient cross-
presentation. 
To evaluate the activation of antigen-specific immune response, we replaced LALBA 
for ovalbumin (OVA). It is a highly immunogenic model antigen for which, in immunology, 
we have well-established animal models that can help to study the effect of the antigen on 
immune system without any unspecific immune response. Phenotype, frequency and efficacy 
of immune cell stimulation induced by NP loaded with OVA (EntrapNP or AdsNP) and 
with/without TLR ligands (CpG and Monophosphoryl Lipid A (MPLA)) were characterized 
and their specificity clarified by the engrafted OT-I (CD8+) and OT-II (CD4+) T cells. 
EntrapNP with OVA and adjuvants presented the strongest antigen-specific cytotoxic immune 
response, following NP with AdsOVA-Ajds. Moreover, long-lasting memory of cytotoxic T 
lymphocytes (CTL), was evaluated 8 weeks after a single immunization in response to the 
different ways of antigen delivery, PBS, OVA in solution, OVA & Adjs in solution and NP 
AdsOVA, AdsOVA-Adjs, EntrapOVA, or EntrapOVA-Adjs. Immunizations where we used 
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antigen alone did not induce efficient CTL reactivation. Overall, Entrap OVA-Adj NP 
presented the most robust immune response in inducing the memory, followed by AdsOVA-
Adjs NP and OVA & Adjs in solution.  
To explore whether the immunization with formulated NP results in efficient cross-
priming, an in vivo killing assay in steady-state conditions was performed. 24 h prior to 
immunization, animals were engrafted with CD8+ (OT-I) cells. 5 days p.i., mice were injected 
with an equal mix of targeted and untargeted CD45.1 splenocytes. Targeted cells were pulsed 
with OVA peptide, SIINFEKL, and labeled with higher dose of CFSE (CFSEhi) while un-
targeted control cells were labeled with a lower dose of CFSE (CSFElow). The in vivo 
clearance of both type of grafted cells was evaluated 16 h later in LN and spleens by flow 
cytometry. All NPs, with or without adjuvants, generated the most efficient in vivo killing 
activity towards the SIINFEKL-pulsed cells, as shown by the disappearance of the CFSEhi 
peak of cells. Indicating the successful induction of cross-priming and activation of antigen-
specific CTL that could potentially lead to a broad and effective immune response pivotal in 
case of tumor rejections.  
To test the efficacy of the therapeutic vaccine and to have a good read-out of the 
antigen-specific T cells, we used B16.MO5 melanoma-bearing mice using different 
vaccination schedules, single and three time immunization with OVA and adjuvants- loaded 
NP. The groups immunized with PBS and Empty NP served as a control and presented similar 
tumor growth. All treated groups showed a significant reduction in tumor growth. 
EntrapOVA-Adjs NP (3x immunization) presented the slowest tumor growth (more than 12x 
smaller final tumor volume), followed by the group immunized with AdsOVA-Adjs NP (3x 
immunization) (more than 9x smaller final tumor volume) and single vaccination with 
EntrapOVA-Adjs NP (more than 8x smaller final tumor volume). The highest amount of 
tumor infiltrating lymphocytes (TILs) at the tumor site was detected for EntrapOVA-Adjs NP 
(3x immunization), suggesting the best remission and survival prognosis of the treated group. 
Two inflammatory cytokines (TNF-α and IFN-γ) produced by TILs were quantified in 
tumor microenvironment. 4-time high levels of TNF-α upon 3-time immunizations were 
detected in tumor microenvironment which kept the tumor growth under control. On the other 
side in the spleens, repeated vaccination prevented upregulation of both inflammatory 
markers, TNF-α and IFN-γ, indicating absence of systemic inflammation.  
Overall, the present work shows that the design of safe but efficacious nanoparticulate 
cancer vaccines requires a deep understanding of NP biological effect on immune cells, both 
under steady-state and cancerous environment. A detailed characterization of the immune 
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cell-related pathways modulated by the optimal antigen-loaded NP and their correlation with 
the nature and anti-tumor efficacy of the induced immune response was performed in vivo in 
healthy and pathological conditions, showing that the nature of antigen delivery is crucial for 




Cancer vaccine, nanoparticles (NP), PLGA, PLGA-PEG, antigen presenting cells (APC), dendritic 





A demonstração do reconhecimento de células tumorais por células imunológicas 
evidenciou que o desenvolvimento de estratégias de vacinação poderá contribuir para a 
eliminação de células malignas, sem que se verifiquem os efeitos adversos associados aos 
tratamentos convencionais. No entanto, os antigénios associados a tumores (TAAs) 
identificados são na sua grande maioria fracamente imunogénicos, requerendo portanto a sua 
mistura com adjuvantes para que se obtenha uma resposta imunológica anti-tumoral forte. das 
nanoparticlas (NP) na interação com as células alvo e consequentes efeitos biológicos. 
Este trabalho tem como principais objectivos: 1) desenvolvimento de sistemas de 
transporte biodegradáveis e estáveis, com propriedades físico-químicas adequadas ao 
transporte de antigénios a células imunológicas; 2) manutenção da estabilidade a longo prazo 
da integridade do antigénio incorporado nas NP; 3) estudos de internalização das 
nanopartículas por células dendríticas (DC) primárias;  4) caracterização da internalização in 
vivo destas nanopartículas e o seu efeito na expressão de marcadores de activação e moléculas 
co-estimulatórias à superfície das membranas de DCs nos nódulos linfáticos; 5) determinação 
da activação e proliferação de linfócitos T, in vivo, a diferentes tempos após a administração 
de nanopartículas; 6) caracterização da activação e expansão dos linfócitos T citotóxicos 
(CTL) in vivo, após a imunização de ratinhos com a vacina desenvolvida; 7) avaliação da 
resposta imunológica subjacente à activação de linfócitos T de memória e 8) caracterização 
das respostas imunológicas induzidas pelos antigénios associados à NP no modelo de ratinho 
B16.MO5. 
NP de ácido láctico-co-glicólico peguilhadas (PLGA-PEG) foram preparadas pelo 
método da dupla emulsão com evaporação de solventes, utilizando ovalbumina (OVA) como 
antigénio modelo. O Glicolquitosano (CS) e o Pluronic F127 (PF127) foram utilizados de 
forma a que as NP desenvolvidas apresentassem as especificações adequadas à sua utilização 
em imunoterapia contra o cancro (diâmetro médio inferior a 200 nm, PDI inferior a 0,2 e 
carga de superfície perto de zero). Estas NP apresentaram um diâmetro médio (dm) de 167 
nm, com um índice de polidispersão (PDI) de 0,167 e um potencial zeta perto da neutralidade 
(-1,66 mV), o que é desejável para evitar a captura destes nanosistemas pelos macrófagos. A 
eficiência de encapsulação (EE) e a capacidade de carga (LC) destas NPs foi de 57,5 % e 29 
µg/mg, respectivamente. As NP modificadas pelo PF127 apresentaram um dm (180 nm com 
PDI 0,180) e um potencial zeta (1,78 mV) ligeiramente superiores, mas EE e LC inferiores 
(32 % e 16 µg/mg). Nenhuma destas formulações afetou a viabilidade de DC. 
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Consequentemente, procedeu-se à optimização da formulação utilizando α-lactalbumina 
(LALBA) como antigénio. Este foi o antigénio escolhido uma vez que se trata de uma 
proteína expressa em níveis muito elevados na maioria dos carcinomas mamários humanos, 
nomeadamente em 67 % de carcinomas mamários primários e 62 % das suas metástases, 
incluindo as encontradas nos nódulos linfáticos (LN), ossos, fígado, pulmão, pele e tecido 
subcutâneo. Além disso, LALBA apenas se encontra presente nas células epiteliais mamárias 
durante a lactação.  
As formulações preparadas com 10 % PVA na fase interna e 0,3 % de PVA 
(formulação F3) ou PF127 (formulação F12) na fase externa demonstraram originar NP 
estáveis, com as especificações definidas como alvo. Os valores de EE mais elevados foram 
obtidos para a formulação preparada com PVA (EntrapLALBA(PVA)), atingindo os 80 % do 
valor da proteína inicialmente utilizado na formulação. Quando o PF127 foi utilizado 
(EntrapLALBA(PF127)), a EE foi cerca de 70 %. De qualquer forma, importa referir que 
independentemente do tensioativo utilizado para garantir a estabilidade da formulação, os 
valores de EE referidos encontram-se muito acima daqueles mencionados em estudos 
recentemente publicados pela comunidade científica. No que diz respeito à adsorção da 
proteína, atingiram-se valores de 40 ou 50 % para as formulações preparadas com PVA 
(AdsLALBA(PVA)) ou PF127 (AdsLALBA(PF127), respectivamente. No que diz respeito às 
imagens das NP obtidas por Microscopia de Força Atómica (AFM), estas evidenciaram um 
dm 30 nm menor do que o diâmetro hidrodinâmico determinado por DLS. Importa referir que 
não foram observadas diferenças entre as formulações EntrapLALBA(PVA) e 
EntrapLALBA(PF127), e entre as AdsLALBA(PVA) e AdsLALBA(PF127), tendo em conta 
os resultados obtidos por DLS. A análise das NP por Espectroscopia no infravermelho por 
transformada de Fourier (FTIR) permitiu evidenciar a presença da LALBA à superfície das 
NP AdsLALBA(PVA) e AdsLALBA(PF127), enquanto que as bandas 1662 cm-1 e 1562 cm-1, 
características de aminas primárias e grupos –NH2, respectivamente, se encontram ausentes 
no caso das NP que incorporam a proteína dispersa na sua matriz. Os estudos de calorimetria 
diferencial de varrimento (DSC) permitiram verificar que o processo de formulação não 
alterou a estrutura dos polímeros utilizados na preparação das NP. Além disso, não foram 
igualmente observadas interações específicas entre a proteínas e os polímeros nas diferentes 
formulações de NP desenvolvidas. Ainda assim, foi possível verificar uma maior temperatura 
de transição vítrea (Tg) nas NP AdsLALBA, comprovando-se portanto a presença desse 
antigénio  à superfície destes transportadores. 
Resumo 
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A extensão e perfil de internalização das NP AdsLALBA(PVA), AdsLALBA(PF127), 
EntrapLALBA(PVA) e EntrapLALBA(PF127) por DC primárias in vitro foram avaliados a 3, 
6, 16 e 24 h (ImageStreamTM). A interação DC-NP aumentou com o tempo de incubação, 
apresentando valores de internalização entre 50-60 %. Estes valores foram superiores para 
EntrapOVA(PF127) quando comparados com NP AdsOVA(PF127). Estas NP foram 
administradas a  ratinhos C57BL/6 e os LN inguinais e popliteais foram isolados 16 h após a 
imunização A análise destas suspensões celulares por citometria de fluxo permitiu avaliar a 
expressão de marcadores de expressão de DC, nomeadamente MHCI e MHCII, bem como 
moléculas co-estimuladoras CD80 e CD86. As DC de animais tratados com NP 
EntrapOVA(PVA) e AdsOVA(PVA) apresentaram níveis de CD86 significativamente mais 
elevados do que os apresentados pelas DC de animais imunizados com as outras NP de teste, 
não tendo sido observadas diferenças entre os transportadores que incorporam a proteína ou 
aqueles cujos antigénios se encontram adsorvidos à sua superfície. O marcador MHCII apenas 
se encontrou aumentado significativamente nas DC de animais imunizados com NP 
AdsOVA(PVA), em comparação com os controlos.  
Observou-se que as DC que capturaram NP AdsOVA(PVA) apresentavam valores de 
CD80, CD86, MHCI e MHCII significativamente maiores do que aquelas que incorporaram 
NP AdsOVA(PF127). Do mesmo modo, NP EntrapOVA(PVA) induziram um aumento 
significativo na expressão de MHCI e MHCII, quando comparados com os valores 
apresentados por estas células obtidas de LN de animais imunizados com as NP 
EntrapOVA(PF127). Desta forma, observou-se que o tensioativo utilizado na formulação 
desta vacina teve impacto na ativação de APC.  
De forma a completar a caracterização da resposta imunológica induzida pelas NP, 
procedeu-se ao estudo do seu efeito na proliferação dos linfócitos T. Para tal, células OT-I e 
OT-II marcadas com CFSE foram administradas por via intravenosa (i.v.) a ratinhos, os quais 
foram posteriormente imunizados com NP EntrapOVA(PVA), EntrapOVA-CpG(PVA), 
AdsOVA(PVA), and AdsOVA-CpG(PVA). Três dias após o tratamento dos animais, 
observou-se que as células CD4+ OT-II e CD8+ OT-I T proliferaram extensivamente nos 
animais tratados com NP EntrapOVA(PVA). Esta proliferação foi a mais acentuada nos 
animais tratados com a combinação do antigénio e adjuvante  dispersos na matriz da mesma 
NP (EntrapOVA-CpG(PVA)). 
As NP Entrap e Ads(PVA) foram selecionadas para avaliar o seu efeito modelador da 
resposta imunológica em ratinhos saudáveis, bem como em modelos tumorais de melanoma 
que expressam OVA (B16MO5).  
 
xiv 
Avaliaram-se os níveis dos marcadores de ativação CD25, CD69 e CD44. Os 
linfócitos T de animais imunizados com NP EntrapOVA apresentaram valores de 
CD25+CD4+ e CD25+CD8+ 3-4 vezes superiores aos controlos, 48 h após o tratamento dos 
animais. Verificou-se igualmente um aumento gradual da expressão dos marcadores CD44, 
bem como do aumento do número total de linfócitos T, essencial para o desenvolvimento de 
uma resposta imunológica adaptativa eficaz.  
Posteriormente avaliou-se a estimulação de CTL de memória, 8 semanas após a 
imunização de ratinhos C57BL/6 saudáveis com PBS, OVA em solução, OVA & Adjs em 
solução e NP AdsOVA, AdsOVA-Adjs, EntrapOVA, ou EntrapOVA-Adjs, previamente 
inoculados com células OT-I. Apenas foi observada uma proliferação acentuada de OT-I nos 
animais imunizados com NP EntrapOVA-Adjs. 
OVA e os adjuvantes CpG e MPLA foram incorporados em NP e estas induziram uma 
resposta imunológica anti-tumoral eficaz no modelo de ratinho B16MO5 após a 
administração de uma ou três doses desta vacina. Os animais tratados com três doses das NP 
EntrapOVA-Adjs apresentaram o crescimento do tumor mais lento, seguidos por aqueles 
tratados com três doses de NP AdsOVA-Adjs e uma dose de NP EntrapOVA-Adjs. Também 
a administração de três doses de NP AdsOVA-Adjs ou EntrapOVA-Adjs tiveram um efeito 
significativo na infiltração de linfócitos no estroma tumoral, o que foi demonstrado pela 
análise histológica de amostras de massa tumoral coradas com hematoxilina e eosina (H&E) e 
por imunohistoquímica. 
Observou-se que a imunização com três doses das NP AdsOVA-Adjs ou EntrapOVA-
Adjs induziram a expressão de receptores antigénio 4 associado a linfócitos T citotóxicos 
(CTLA-4) isolados do baço e LN, sendo estes significativamente mais elevados para aqueles 
tratados com NP AdsOVA-Adjs.  
A resposta anti-tumoral induzida pelas NP foi confirmada mesmo sem que se tenha 
procedido à transferência de OT-I, evidenciando portanto a indução de uma resposta 
imunológica adaptativa especificamente induzida pela vacina desenvolvida. 
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The choice of moving abroad to do my PhD was not easy to make. But as Mark Twain 
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BMDC  Bone marrow derived dendritic cells 
BSA  Bovine serum albumin 
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CTLA-4  Cytotoxic T-lymphocyte-associated-antigen 4  
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integrin 
DD  Diferential display 
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FTIR  Fourier transform infrared spectroscopy 
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GM-CSF  Granulocyte macrophage colony-stimulating factor  
GMP  Good manufacturing practices 
HLA  Human leukocyte antigen  
HPLC  High-performance liquid chromatography 
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IL  Interleukin  
imDC  Immature dendritic cells 
LALBA  α-lactalbumin 
LC  Loading capacity 
LDV  Laser Doppler Velocimetry 
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mDC  Mature dendritic cells 
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MHCp  MHC-peptide complex 
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MPLA  Monophosphoryl lipid A  
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MTT  3-(4,5-dimethylthiazol-2-yl)-2,3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
MUC1  Human milk mucin 
NF-κB  Nuclear factor-κB 
NK  Natural killer 
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NP  Nanoparticles  
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PAMPs  Pathogen-associated molecular patterns 
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PBMCs  Peripheral blood mononuclear cells  
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PDI  Polydispersity Index 
PEG  Poly(ethylene glycol) 
PEG-b-PLGA  Poly(D,L-lactic-co-glycolide-b-ethylene glycol) 
PEI  Polyethylenimine 
PF127  Plurinic® F127 
PGA  Polyglycolide/polyglycolic acid 
List of abbreviations and acronyms 
xix 
PLA  Polylactide/polylactic acid 
PLGA  Poly(lactic-co-glycolide) or poly(lactic-co-glycolic) acid  
PRRs  Pattern recognition receptors 
R-PLGA  Rhodamine 6G derivative-grafted poly(lactic-co-glycolide) 
PSA  Prostate specific antigen 
PSMA  Prostate specific membrane antigen 
PVA  Polyvinyl alcohol 
QbD  Quality by design 
RES  Reticuloendothelial system 
RIG  Retinoic-acid inducible gene 
RLRs  Retinoic-acid inducible gene-like receptors 
s.c.  Subcutaneous  
scFv  Single-chain Fv antibody  
siRNA  Small interfering RNA 
ssRNA  Single-stranded RNA 
SUV  Small uni-lamellar vesicles 
TAA  Tumor associated antigens  
TAP  Transporter associated with antigen processing 
TCR  T cell receptor 
TGF  Tumor growth factor  
TIL  Tumor infiltrating lymphocytes 
Tg  Glass transition temperatures 
TGF  Tumor growth factor 
Th  T helper  
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Figure 1. Two main lineages of white blood cells. The myeloid lineage gives rise to 
effector cells of the innate immune response (DC, monocytes, macrophages). 
The lymphoid lineage originates cells of the adaptive immune response (T 
cells and B cells).  
9 
   
Figure 2. Examples of nanosystems for peptide delivery to potentiate anti-tumor 
immune responses. Polymeric nanoparticles are defined as submicron 
spherical nanosystems. Depending upon the formulation method, nanospheres 
or nanocapsules can be obtained. Nanospheres are systems in which antigens 
and adjuvants are physically and uniformly dispersed in polymer matrix, 
while in the case of nanocapsules antigens and adjuvants are encapsulated in 
polymer and surrounded by a polymer membrane. Hydrophilic and 
hydrophobic molecules can be entrapped inside the polymer or adsorbed to 
the surface. Polymeric micelles are self-assembled into this spherical entities 
formed by amphiphilic block-copolymers. The hydrophobic core is oriented 
inwards, while the hydrophilic regions of the polymer chains are oriented 
outwards the aqueous medium. Liposomes are self-assembled nanocarriers 
made of phospholipids and can be classified according to their size and 
lamellarity. Lipid bilayer membranes can incorporate hydrophobic 
compounds, while hydrophilic molecules can be incorporated in enclose 
aqueous core. Dendrimers are multi-branched three-dimensional globular 
structures of well-defined molecular weight polymers, formed by a 
hydrophobic central core, inner void space and symmetrical branches of 
repeating monomer units, resulting with a hydrophobic central core and a 
hydrophilic surface.  
 
16 
Figure 3. Examples of promising targets within tumor microenvironment to tackle an 
integrative and combined immune-mediated anti-tumor effect. A) In tumor 
microenvironment (TME), cancer cells overexpress VEGF. This growth 
factor is one of the major contributors to angiogenesis, which allows the 
tumor progression and metastasis; B) DC and tumor cells overexpress TGF-
β1 in TME which influence all leukocyte populations; C) In lymph nodes, the 
immune-checkpoint receptors CTLA-4 and PD-1 play important roles in 
cancer progression, inhibiting T cell activation; D) in TME, the latter also 
contribute to the inhibition of T cell activation. Examples of promising targets 




immune-mediated anti-tumor effect.  
   
   
Chapter 3   
Figure 1.  Circles (●) are for all the formulation (F1-F7), developed with PVA in the EP. 
Triangles (▲) are used for all formulations (F8-F14) prepared with Pluronic 
as EP. (A) Average size, (B) poydispersity index (PDI), (C) ζ potential, (D) 
entrapment efficiency (EE), (E) loading capacity (LC) and (F) percent of 
washed PVA were determine for all PLGA-PEG NP. All results are expressed 
as mean ± SD of three independent experiments of 3-5 formulations per group 
(n>3). 
58 
   
   
Chapter 4   
Figure 1. Size and morphology characterization of formulated NP by AFM. Section 
analysis of NP (A) EntrapLALBA(PVA) and (B) EntrapLALBA(PF127) with 
the matrix polymer PLGA-PEG and with entrapped antigen; (C) 
AdsLALBA(PVA) and (D) AdsLALBA(PF127) with PLGA polymer and 
adsorbed LALBA protein. 
 
78 
Figure 2. (A) FTIR spectrographs of NP and the components used for their 
formulations. The symbols on the top of the graph correspond to the specific 
band. Peak at 1720 cm−1 (§) is a specific band for C=O bond; 1662 cm-1 (*) 
is specific for primary amides; peak at 1562 cm-1 (Ϫ) corresponds to 
vibration of -NH2 groups; 2950 cm−1 (Ф) indicates the presence of C-H 
bond; 3400 cm-1 (‡) correlates to the hydroxyl and amine groups overlapping. 




Figure 3. SDS–PAGE (12 % separating gel) of protein LALBA before and after 
entrapment in NP. Lanes: (1) standard molecular weight (MW) markers, wide 
range 10 – 180 kDa; (2) LALBA standard solution at 2 µg; (3) 4 µg; (4) 8 µg; 
(5) 16 µg all LALBA’s bands may be seen at the 14 kDa; (6) 
Entrapblank(PVA); (7) EntrapLALBA(PVA); (8) Entrapblank(PF127);  (9) 
EntrapLALBA(PF127); (10) Adsblank(PVA); (11) AdsLALBA(PVA); (12) 
Adsblank(PF127). (13) AdsLALBA(PF127); A representative image of 3 
independent experiments is presented. 
 
81 
Figure 4. Circles (●) present formulation EntrapLALBA(PVA), squares (■) 82 
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EntrapLALBA(PF127), triangles (▲) AdsLALBA(PVA) and diamonds (▼) 
AdsLALBA(PF127) F4. (Figure 1A and 1B) Average size, (Figure 1C) 
poydispersity index (PDI), and (Figure 1D) ζ potential of polymeric NP were 
measured over 3 month period when dispersed in PBS pH 7.4 and kept at 4 
˚C. All results are expressed as mean ± SD (n>3). 
 
Figure 5. Cell viability (%) determined by the AlamarBlue® assay after 24 h incubation 
of murine immature BMDC with increasing concentrations of NP. Culture 
medium (0) and triton 0.5 % (w/v) were used as negative and positive 
controls, respectively (Mean ± SD; n=6). 
 
83 
Figure 6. In vitro NP internalization by BMDC. ImageStream analysis was performed 
to detect PLGA-Rho labeled NP in BMDC; 3, 6, 16 and 24 h after the in vitro 
incubation. Distribution of at least 30,000 cells was calculated by Amnis 
IDEAS software and presented with the histograms showing the percentages 
of CD11c+ cells interacting with NP (A) and of CD11c+ cells with internalized 
NP (B). Examples of representative images captured by the Amnis 
ImageStreamX Flow Cytometer of DC incubated for 16 h at 37 °C with 
AdsOVA(PVA) (C). First column shows brightfield (BF) images of the cells, 
second column shows images of PLGA-Rho labeled NPs (NP), third column 
shows APC-labeled CD11c+ DC (CD11c), forth column shows merged 
images of the precedent fields (BF/NP/CD11c) and fifth column shows DAPI 
signal for dead cells. (C.a) CD11c without NP. (C.b) NP on the surface of the 
CD11c+ cell. (C.c) Various NP, entering the cytoplasm of CD11c+ cell. (C.d) 
DC with various NP. (C.e) DC with start morphology, indicator of the DC 
maturation process. Results are mean ± SD, normalized to that of control non-
labeled cells, representative of three independent experiments (n=3). Scale 
bar, 7 µm. 
 
84 
Figure 7. (A) Gating strategies for CD11c+/MHCII+/NP+ or NP- DC in immunized and 
non-immunized female C57BL/6 mice 16 h following immunization. 
Histograms of expressed activations markers on DC with and without NP 
after hock immunization.  (B) Percentages of activated DC 16 h after 
immunization with different formulations of NP. (C) Expression of surface 
activation markers on DC with internalized NP and the DC without 
internalized NP in the same LN, 16 h after immunization with different 
formulation of NP. 
 
86 
Figure 8. Figure 8: T cell proliferation was studied using dilution of CFSE fluorescence 




3 days post-immunization with NP. The histogram plots show the CFSE 
profiles of viable CD4+ OT-II and CD8+ OT-I T cells after the immunization 
with different NP (dark gray histogram) relative to the generation zero CFSE 
profile of viable transferred CD4+ OT-II and CD8+ OT-I T cells in the absence 
of OVA NP (light gray histogram). Representative histogram plots were 
selected from tree independent experiments (n=6). 
 
Figure S1. Gating strategy of in vitro experiment on BM-derived DC with GM-CSF and 
IL-4. ImageStream analysis was performed to detect PLGA-Rho labeled NP 
internalized by DC; 3, 6, 16 and 24h after the in vitro incubation. At least 
30,000 cells were collected for each sample. Data were analyzed using a 
dedicated image analysis software (IDEAS 6.2; Amnis Corp). Images were 
compensated for fluorescent dye overlap by using single-stain controls. Cells 
were first gated for single cells using the area and aspect ratio features, and 
for focused cells using the Gradient RMS feature [35]. Cells were further 
gated using a bivariate plot for circularity (the degree of the mask’s deviation 
from a circle) based on the Object mask (a segmentation mask that creates a 
tight fit on the cell morphology) and intensity of the side scatter channel 
(illuminated by the 785 nm laser and collected in channel 12). Particle 
internalization was calculated by the Internalization feature, i.e. the ratio of 
the intensity inside the cell to the intensity of the entire cell, mapped to a log 
scale. To define the internal mask for the cell, the object mask of the bright 
field image was eroded by 5 pixels. Data are representative of tree 




Figure S2. Gating strategies for expression of TCRβ, TCRVα2, CD8α or CD4 of T cells 
isolated from immunized and non-immunized LN, 3 days following 
immunization. Data shown are representative of three different animals and 
three independent experiments. 
98 
   
Chapter 5   
Figure 1. Section analysis and diameter distribution of nanoparticle by atomic force 
microscopy. (A) PLGA-PEG NP with entrapped OVA protein (EntrapOVA 
NP), (B) PLGA NP with adsorbed OVA protein (AdsOVA NP). ImageStream 
analysis was performed to detect in vivo Rho labeled NP internalization by 
APC 16 h p.i. at 37 °C. Distribution of at least 30,000 cells was calculated by 
Amnis IDEAS software and presented with the histograms showing the 
percentages of APC with internalized NP (C) and % of MHCII activated APC 
(E). Examples of representative images with AdsOVA NP (D). First column 
115 
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shows brightfield (BF) images of the cells, second column shows images of 
Rho labeled NP (NP), third column shows CD11b+ cells (CD11b), forth 
column CD11c+ cells (CD11c), fifth column shows MHCII+ cells (MHCII), 
sixth column presents merged images of the precedent fields (BF/NP). (D.a) 
CD11c+ with upregulated MHCII. (D.b) NP internalized by CD11b+ cell. 
(D.c) NP taken up by double positive cells CD11b+CD11c+ cell. Results are 
represented as mean ± SD, normalized to that of control non-labeled cells, 
representative of three independent experiments (n = 3). Scale bar, 7 µm. (F) 
ImageStream representative plots showing the gating of cells with surface 
makers CD11b, CD11c and PDCA-1. 
 
Figure 2. Activation profiles of T cells isolated from the draining LN. Time dependent 
phenotypic changes in the expression of activation surface molecules (CD25, 
CD69, and CD44) on CD4+ (A) and CD8+ (B) transgenic T cell stimulated in 
vivo. The expression of CD25, CD69, and CD44, was measured on freshly 
isolated cells by flow cytometry. Histograms present the mean values of three 
independent experiments, each with n=3 mice per time point.  
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Figure 3. Cytotoxicity ability of antigen-specific cytotoxic T lymphocytes (CTL) 
obtained from naïve C57BL/6 mice seven days after treatment with PBS, 




Figure 4. Immunization with protein and adjuvant in the uniformed delivery system 
drives development of memory CTL. Proliferation of antigen-specific 
memory T cells was determined by flow cytometry 8 weeks p.i. FACS plots 




Figure 5. Anti-tumor therapeutic efficacy of the nanoparticulate vaccines. (A) Schedule 
of the assay. (B) Mean tumor growth curves given by mean tumor volume 
over time, determined by V = ½ × (L × W2), where L (length) is the longest 
dimension and W (width) is the perpendicular dimension to the length. (C) 
Representative images of removed melanoma tumors from each treatment 
group at the end of the assay. (D) The tolerability of the vaccine was 
evaluated by monitoring body weight of the treated mice. (E) Mean final 




Figure 6. (A) Representative flow cytometry plots of the percentages of tumor 121 
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infiltrated lymphocyte (TIL) CD45.1+ versus CD3e+ T cells. (B) Mean 
percentages of TIL present on tumor suspensions obtained from each 
treatment group. Mean ± SD, n=6. *p < 0.05, **p < 0.01 
 
Figure 7. Images are representative histology sections with H&E staining and 
immunohistochemistry staining for CD8 and CD4, of multiple fields and 
magnifications in a three independent experiments. Bars, 200 µm.  
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Figure 8. Activation of cytotoxic CD8+ (OT-I) T lymphocytes (CTL) in (A) spleen and 
(B) LN. (A & B) Histograms show frequency of the activated CD107a+ CD8+ 
CTL. (C) Representative flow cytometry plots of LN single–cell suspension 
from the control and EntrapOVA-Adjs NP (3x) groups, gated for CD45.1, 
CD3e, TCR Vα2 cells. (D & E) Histograms show frequency of the activated 
CTLA-4 T cells in (D) spleens and (E) LN in tumor-bearing mice. Mean ± 
SD, n=6, *p < 0.05, **p < 0.01, ***p < 0.001 
 
123 
Figure 9. Intracellular staining of CD8+ T cells and cytokine levels in (A-C) spleens and 
(D-F) tumors. Representative flow cytometry plots of TNF-α and IFN-γ in (A) 
spleens and (D) tumors from the control, AdsOVA-Adjs NP EntrapOVA-Adjs 
NP, AdsOVA-Ajs NP (3x), and EntrapOVA-Adjs NP (3x) groups. (B & E) 
Histograms show frequency of the activated TNF-α T cells in (B) spleens and 
(E) tumors. (C & F) Histograms show frequency of the activated IFN-γ T 
cells in (C) spleens and (E) tumors. Mean ± SD, n=6, ***p < 0.001. 
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Figure 10. Anti-tumor therapeutic efficacy of the nanoparticulate vaccines without the 
previous transfer of transgenic T cells. (A) Mean tumor growth curves given 
by mean tumor volume over time. (B) Representative images of removed 
melanoma tumors from each treatment group at the end of the assay. (C) 
Mean final tumor weight per 100 g of final body weight. Mean ± SD, n=6, 
***p < 0.001. 
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Figure S1. Gating strategy of the in vivo experiment of antigen-loaded nanoparticle 
uptake by APC. At least 30,000 cells were collected for each sample. 
ImageStream analysis was performed to detect Rho-labeled NP internalized 
by DC 16 h after the immunization. Images were compensated for fluorescent 
dye overlap by using single-stain controls. Cells were gated for single cells 
using the area, aspect ratio features, and bivariate plot for circularity (the 
degree of the mask’s deviation from a circle) based on the Object mask (a 
segmentation mask that creates a tight fit on the cell morphology) and 
intensity of the side scatter channel (illuminated by the 785 nm laser and 
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collected in channel 12). Particle internalization was calculated by the 
Internalization feature, i.e. the ratio of the intensity inside the cell to the 
intensity of the entire cell, mapped to a log scale. To define the internal mask 
for the cell, the object mask of the bright field image was eroded by 5 pixels. 
To measure the activation of CD11b+, CD11c+CD11b+, and CD11c+CD11b-, 
intensity of MHCII was compared against the intensity of CD11c or CD11b, 
respectively. Data are representative of tree independent experiments after the 
16 h incubation of DC with NP. Scale bar, 7 µm. 
 
Figure S2. Gating strategies for the expression of CD45.1, TCRVα2, CD3e or CD4 of T 
cells isolated from immunized and non-immunized LN, 6, 16, 24 and 48 h 
following immunization. Data shown are representative of three different 
animals and three independent experiments form the 16 h p.i.. 
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Figure S3. Gating strategies for the expression of CD45.1, TCRVα2, CD8α or CD4 of T 
cells isolated from immunized and non-immunized LN. Data shown are 
representative of three different animals and three independent experiments. 
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Figure S4. (A) Single-suspension of LN was gated for DAPI-, TCRβ+, CD45.1+, and 
CD8α+. (B) Representative FACS plots 8 weeks p.i. after the immunization. 
Protein and adjuvant in the uniformed delivery system drives development of 
memory CTL. Data shown are representative of at least three independent 
experiments with 2-3 mice per group. 
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Figure S5. Extracellular staining of tumors infiltrated lymphocytes (TIL). This is a 
representative gating strategy for the analyzed tumor cell suspensions from 
two independent experiments, n=6-8 animals/group. 
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Figure S6. (A) Representative gating strategy for CD45.1, CD3, CD8, PD-1, CTLA-4 
and CD107A in spleens and LN (B & C) Representative flow cytometry plots 
of PD-1 and/or CTLA-4 upregulation in spleens (B) and LN (C) from the 
control, AdsOVA-Adjs NP EntrapOVA-Adjs NP, AdsOVA-Ajs NP (3x), and 
EntrapOVA-Adjs NP (3x) groups in tumor-bearing mice. Representitive 




Figure S7. Intracellular staining of tumor and splenic IL-4, TNF-α, IFN-γ producing 
cells. This is a representative gating strategy for tumor CD45.1+, CD3e+, 
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Objectives of the doctoral thesis 
The overall goals of this PhD research work were the development and 
characterization of a novel immunotherapeutic nanoparticulate delivery system. Of particular 
interest were the determination of vaccine efficiency in vivo under steady-state conditions and 
finally the characterization of the anti-tumor immune response in tumor-bearing mice.  
 
Specific aims: 
1. Development of high reproducible and stable biodegradable polymeric 
nanoparticulate delivery systems with desired physicochemical characteristics for 
optimal immune cell targeting. 
2. Integrity of NP-entrapped protein and long-term stability of developed 
nanoparticulate vaccine. 
3. In vitro time-dependent internalization studies of antigen-loaded nanoparticles by 
bone marrow derived dendritic cells (BMDC). 
4. In vivo characterization of NP uptake, and effect on the activation markers and co-
stimulatory molecule expressed on DC at draining lymph nodes  
5. Determination of T cell activation and proliferation at different time points after 
NP immunization 
6. In vivo cytotoxic T lymphocyte (CTL) assay for the characterization of the 
effective activation and priming of antigen-specific CTL  
7. Evaluation of the long-lasting CTL memory achieved after NP administration 
8. Characterization of anti-tumor immune response in Ovalbumin transfected 
melanoma B16.MO5 bearing-mice. 
 
The following chapters describe and discuss the major achievements of the research work 
pursued in order to achieve the above mentioned goals of this PhD research project. 
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Examples of promising targets within tumor microenvironment to tackle an integrative and combined immune-
mediated anti-tumor effect. A) In tumor microenvironment (TME), cancer cells overexpress VEGF. This growth 
factor is one of the major contributors to angiogenesis, which allows the tumor progression and metastasis; B) 
DC and tumor cells overexpress TGF-β1 in TME which influence all leukocyte populations; C) In lymph nodes, 
the immune-checkpoint receptors CTLA-4 and PD-1 play important roles in cancer progression, inhibiting T cell 
activation; D) in TME, the latter also contribute to the inhibition of T cell activation. 
 
Abstract 
Cancer is a heterogeneous disease that results from a multi-step process, being 
characterizedby uncontrolled proliferation, invasion and metastasis. The understanding 
that tumor cells can be recognized by host immune cells has highlighted the potential 
advantages of using vaccination purposes to eliminate cancer cells, while avoiding 
severe side effects associated to conventional cancer treatments. Interesting outcomes 
have been obtained with the new identified tumor associated antigens (TAA), including 
recombinant proteins and peptides. However, these molecules are weakly immunogenic, 
demanding the concomitant use of adjuvants to boost and achieve a strong tumor-
specific immune response. Different classes of nanosystems have been used to protect 
and deliver several vaccine components. In vitro and preclinical studies have 
emphasized their promising role to attain a prolonged eradication of cancer cells, 
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including metastasis. However, some studies support the co-entrapment of multiple 
adjuvants and TAA within a single particulate carrier, while others indicate that stronger 
immune responses were obtained using a mixture of nanocarriers entrapping different 
combinations of TAA and adjuvants. These apparently contradictory results may be 
related to nanocarrier physicochemical properties, which have a profound impact on 
their interaction with targeted cells and consequent biological effects.  
This review discusses the application of nanoscale systems as cancer vaccines, 
highlighting the particular characteristics of tumor biology and immunology that have 
been used to guide the design of these nanodelivery tools. We also aim to explore the 
major weaknesses that have prevented their wide application in the clinic to overcome 
the delivery, efficacy and safety issues associated to biological entities. 
 
 
Keywords: cancer vaccines; dendritic cells; immune modulation; nanosystems; peptide 





Cancer is still one of the leading causes of death worldwide, despite considerable 
improvements in treatment and diagnosis approaches. In fact, the majority of tumors are 
known to be heterogeneous, phenotypically and functionally diverse with several biological 
subtypes, which seem to be one of the major causes for the impaired outcomes of diverse anti-
tumor strategies [1, 2]. The main goal of cancer therapy is to promote the eradication of 
malignant cells, while preventing the damage to healthy tissues. However, conventional 
strategies for cancer treatment (chemotherapy, surgery, and radiotherapy) are not specifically 
directed to tumor cells [3, 4]. As a result, those can lead to severe side effects and limited 
effectiveness, thus compromising patient quality of life. Several studies have been dedicated 
to the development of effective and targeted cancer treatments to improve patient overall 
survival rate, while avoiding off-target toxic effects. Recent advances in distinct but 
complementary fields, as nanotechnology, tumor immunology, biotechnology, and cancer 
biology have led to alternative forms of cancer treatment [5-7]. Immunotherapeutic strategies, 
in particular cancer vaccines, are one of the most challenging but promising tools that take 
advantage of patient’s own immune system to foster the successful eradication of cancer cells. 
Cancer vaccines are envisioned to be administered after the detection of disease, thus being 
considered as therapeutic rather than prophylactic vaccines [8-10]. They have many 
theoretical advantages over other conventional therapies like low toxicity, high specificity, 
and continued anti-tumor effect attributed to immunologic memory, which protects 
individuals from an eventual recurrence [11, 12]. Effective cancer vaccines present the ability 
to target defined antigens expressed on tumor cell membrane and to induce specific and long-
lasting anti-tumor immune responses [12, 13]. Most used tumor associated antigens (TAA) 
are proteins which peptide epitopes are recognized by T cells in combination with major 
histocompatibility complex (MHC) class molecules, by activating antigen presenting cells 
(APC), namely dendritic cells (DC). Therefore, different vaccination approaches have been 
devoted to explore the use of single or multiple peptides of different TAA, as antigens to 
potentiate the induction of an effective immune response directed specifically towards tumor 
cells overexpressing those entities [4]. In fact, most of soluble antigens are weakly 
immunogenic requiring their combination with adjuvants to induce effective anti-tumor 
immunity [14, 15].  
The use of nanodelivery systems as adjuvants has been extensively explored, offering 
several advantages over traditional vaccines. These carriers have been shown to protect and 
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entrap considerable amounts of multiple antigens, especially low immunogenic peptide 
molecules [16, 17]. In addition, these vehicles have the ability to potentiate the recognition, 
capture, processing and presentation of peptide epitopes to effector T cells [18, 19]. On the 
other hand, increasing knowledge on tumor immunology has provided deeper insight into the 
complex interplay between cancer and immune cells within tumor microenvironment (TME), 
which can be used in a rational manner to guide the successful development of effective 
nanotechnology-based cancer vaccines [20-22].  
 On the other hand, different cell-targeting peptides have been explored to attain the 
site-specific delivery of different cargoes (e.g. drugs, oligonucleotides) to distinct cells within 
tumor site, such as stroma, fibroblasts and tumor blood cells [23]. These targeting moieties 
hold various advantages over monoclonal antibodies or their fragments, such as low 
immunogenicity, size and easy production process [24]. Besides being out of the scope of this 
review, interesting recent studies point out the promising use of these non-immunogenic 
peptide-based alternative therapies to attain the eradication of the disseminated form of this 
malignant disease through the activation of multiple effector mechanisms [25].  
 This review presents an overview of the tumor immunology, highlighting the critical 
immune cells and immune-related pathways essential for the induction of a cytotoxic immune 
response against cancer cells. In addition, we will discuss the development of effective cancer 
vaccines and elucidate the advantages of different nanosystems as platforms for the delivery 
of tumor peptide antigens, but also to modulate and regulate multiple TME signaling 
pathways towards an integrative approach to overcome tumor immune evasion and 
consequent proliferation. 
 
1. General immune response 
The immune system is divided into two branches, the innate and the adaptive 
immunity that usually act together. The innate immunity represents the first line of host 
defense by surveying the local microenvironment to provide “danger” signals to trigger a 
swift and non-antigen-specific response. Moreover, it plays a crucial role in the initiation and 
subsequent direction of adaptive immune responses through the secretion of pro-inflammatory 
cytokines by innate immune cells, as monocytes, macrophages and neutrophils (Figure 1) [26, 
27]. The adaptive immune response allows for a versatile and long-lasting specific host 
defense. In contrast to innate immunity, this antigen-specific immune response will only be 
achieved after several days, due to the clonal expansion of effector T and B cells (Figure 1) 
[27, 28]. The generation of effective antigen-specific adaptive immunity requires antigen 
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presentation to selected T cells, which activation will trigger their differentiation to provide 
various effector mechanisms to eliminate any cell that will express the specific antigens, such 
as microorganisms and tumor cells [28, 29]. 
 APC are essential regulators of the innate immune response, acting as a key bridge 
between the two branches of the immune system. These cells are involved in the uptake of 
antigens and presentation of epitope peptides to naïve T cells, resulting in the activation of 
innate and adaptive immunology or tolerance to self-antigens, due to their ability to deliver 
activating signals [28]. The three types of APC (DC, B cells and macrophages) differentially 
express MHC class and costimulatory molecules, being involved in different immune 
response pathways [10, 30]. B cells contribute to adaptive immunity by secreting antibodies 
and constitutively expressing MHC class II molecules, and through the expression of 
costimulatory molecules only upon their activation. Macrophages can also mediate innate 
immune responses directly and make a crucial contribution to the effector phase of the 
adaptive immune response over the expression of the MHC class II and costimulatory 
molecules [10, 27]. 
 
 
Figure 1: Two main lineages of white blood cells. The myeloid lineage gives rise to effector cells of the innate 
immune response (DC, monocytes, macrophages). The lymphoid lineage originates cells of the adaptive immune 





1.1. Dendritic cell biology 
DC are classified according to their developmental origin, anatomical location, surface 
antigens, cytokine activators, and immune response final outcome [17, 31, 32]. 
DC are divided in two major populations, referred to as conventional DC (cDC) and 
plasmacytoid DC (pDC) [32]. cDC are further subdivided in Langerhans cells and myeloid 
DC (mDC). Langerhans cells are found in oral, respiratory and genital mucosa, and in 
epidermis, being named dermal, submucosal or interstitial DC depending on their anatomic 
location [33, 34]. Moreover, mDC are the only DC subset that presents the ability to cross-
present antigens [35]. Their protective tumor immunity was previously demonstrated in 
several studies by the cross-presentation of antigens, leading to an effective induction of 
antigen-specific CD8+ T cell responses [36] and secretion of interleukin (IL)-12 [37, 38]. 
Despite the differences between DC subtypes, they are all able to express high quantities of 
MHC molecules [32]. The plasmacytoid pathway generates the major subset of DC, the pDC. 
These APC were found in blood and lymphoid organs [39], where they induce a strong innate 
immune response by secreting high amounts of type 1 interferons (IFN) [40, 41], which 
facilitate T cell activation, expansion, and survival for disease-free survival. Combined 
stimulation of pDC and mDC seems to prime T helper 1 (Th1) effector cells, resulting in the 
generation of more potent and strong immune responses [39, 41].  
All DC subtypes go through three stages of differentiation: DC precursors, immature 
DC (iDC), and mature DC [42]. Precursors and iDC are produced continuously in the bone 
marrow and are delivered through the blood to peripheral tissues for screening the presence of 
“danger” signals. Upon encountering foreign antigens, DC detect pathogen-associated 
molecular patterns (PAMPs) by pattern recognition receptors (PRRs) expressed at their 
surface, promptly triggering the innate immune system by inducing the production of multiple 
inflammatory molecules, namely cytokines and chemokines [26, 27, 43]. In fact, the 
recognition of PAMPs by iDC leads to their migration towards the afferent lymph nodes, 
where these APC undergo a maturation process. Once mature, DC have low ability to capture 
antigens, but present a potent immunostimulatory capacity for priming T cells due to their 
capacity to efficiently present processed antigen-MHC molecule complexes [27, 32]. 
Additionally, mature DC synthesize high levels of IL-12, enhancing both innate (Natural 
killer cells, (NK cells)) and adaptive (B and T cells) immunities [28, 44]. 
On the other hand, DC can also lead to antigen-specific tolerance or anergy, through 
the development of IL-10 secreting inducible regulatory T cells (Tregs), which present a 
strong capacity to suppress lymphocyte responses and to prevent autoimmunity [36]. 
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1.2. DC critical role to overcome tumor-mediated mechanisms of immune 
evasion 
Cancer cells have the ability to evade the immune system through multiple 
mechanisms, which involve the manipulation of tumor-immune microenvironment cells and 
signaling pathways, impairing antigen presentation by APC, and promoting immune 
suppressive mechanisms. In theory, vaccinated patients could mount an immune response 
able to either eliminate the tumor or keep it under constant restraint, prolonging patient 
survival [45, 46]. 
DC are central players in tumor immunology and present the unique ability to migrate 
from the site of infection to the draining lymph nodes to activate the effector immune cells, 
determining tolerance/immunity balance. Therefore DC-based targeting strategies can be 
exploited against autoimmune and infectious diseases, as well as cancer [36, 47].  
Maturation of DC is critical for the tumor-specific immune response. Processed 
peptide fragments are coupled to MHC class I or MHC class II molecules, being then 
translocated to the DC surface and presented to naïve T lymphocytes (CD8+ or CD4+ T cells) 
[48, 49]. 
Two main pathways for antigen presentation have been categorized for peptide 
loading-processes onto MHC molecules to activate specific subsets of T cells. These 
pathways are the MHC class I for the presentation of endogenous antigen, and MHC class II 
for processing and presenting antigens from exogenous origin.  
Extracellular antigens are taken up through endocytosis by APC. In the endosomes 
and lysosomes, proteins are degraded to generate peptides of 10 to 30 amino acids (aa) in 
length. These peptides then interact with MHC class II molecules to form a stable MHC class 
II-peptide complex that is then transported to cell surface for expression and potential 
interaction with the T cell receptor (TCR) on CD4+ T cells [50, 51]. MHC class II molecules 
are exclusively expressed by APC. Even though, the fate of exogenous antigen is not limited 
to MHC class II molecules. An alternative antigen presentation pathway is the “cross-
presentation”, in which Ds, namely mDC, present antigens onto MHC class I molecules. This 
mechanism activates CD8+ T cells to generate an immune response [52, 53]. 
Intracellular antigens are translocated into the endoplasmic reticulum (ER) from the 
cytoplasm, through the proteasomes, where they are cleaved into peptides of 8-12 aa in 
length. The peptides in the ER are bound to MHC class I molecules and resultant complexes 
will be then transported from the ER to the cell surface, where they interact with the TCR of 
CD8+ T cells [50, 54], which proliferate and differentiate into cytotoxic T lymphocytes 
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(CTL). However, MHC class I molecules are not exclusively expressed by these APC, being 
also found in all nucleated cells [50, 55]. 
Once CD4+ T cells have recognized and bind to MHC class II molecules, they become 
activated and secret cytokines that can stimulate B cells, macrophages and CTL. These 
immune cells do not secret cytokines, being rather fundamental to recognize and eradicate 
cells overexpressing those targeted antigens, such as tumor cells [56].  
iDC are highly motile cells, continuously sampling antigens through peripheral tissues 
and lymph nodes. In the absence of any costimulatory signal, T cells will not be activated, 
becoming tolerant or anergic. Naïve T lymphocytes in the DC-T cell synapse, require three 
signals to become activated: first signal arises from the interaction between the TCR on naïve 
T cell and the MHC molecule in the presence of a foreign antigen [57]; second signal stems 
from co-stimulatory molecules expressed on mature DC, such as CD80, CD86, and CD40, 
interacting with the cognate receptors on T cells, CD28 and CD40L, respectively [58]; and a 
third signal that directly affects T cells, through cytokines and chemokines, like IL-12 and 
IFN (IFN-α/β/γ), produced by DC. These signals enable DC to translate pathogenic signals to 
naïve T cells and trigger adaptive immune responses by promoting T cell migration, 
differentiation, survival and acquisition of effector functions [49, 59, 60]. 
The activation of naïve T cells ensures the induction of appropriate immune responses, 
either cellular or humoral. The cellular response is characterized by the generation of CTL, 
which are critical for the generation of an optimal anti-tumor immunity able to mediate tumor 
destruction. In fact, CD8+ T cells principally recognize endogenous intracellular antigens 
presented by MHC class I molecules. Once activated, these T cells can directly kill infected or 
malignant cells, but also acquire a long-lasting memory phenotype, allowing a fast response if 
a second contact with those antigens occur under repeated infections or cancer recurrence [61, 
62]. Theoretically, this should be best achieved by targeting the TAA to DC that would 
efficiently present processed epitopes loaded onto MHC class I molecules for effective CD8+ 
T cell priming. However, recent findings indicate that both CD4+ and CD8+ T cells need to be 
involved [63]. CD4+ T cells seem to be required for the optimal activation of CD8+ T cells, 
but also for an effective generation of memory T cell populations. In fact, CD8+ T 
lymphocytes fail to maintain functionality in vivo mostly because of the absence of CD4+ T 
cell help. Therefore, to ensure optimal killer T cell immunity, CD8+ T cells need to be 
differentiated into effector CTL and memory T cells, while CD4+ T cells need to proliferate 
and differentiate into effective helpers, which is fundamental to activate antigen-specific 
effectors and attract innate immune cells [64-66]. 
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Classically, the effector CD4+ T cells were thought to differentiate into Th1 and Th2 
cells, but other subsets have been recently described as Th17, Th9 and Tregs [67]. Even if 
both Th1 and Th2 cells showed to mediate anti-cancer function, IFN-γ-secreting Th1 cells 
appeared to be more effective [67]. 
Most conventional vaccines result in the production of antibodies and stimulation of 
Th cell-mediated immune responses, rather than activation CTL. This could be best 
accomplished by providing additional adjuvants to potentiate DC activation [68, 69].  
 
2. Cancer vaccines as an immunotherapeutic strategy 
Immunotherapeutic strategies take advantage of patient’s own immune response by 
activating in vivo immune effectors against specific TAA to overcome the tolerance to tumor 
cells. Within cancer therapy, cancer vaccines are one of the most challenging but promising 
tools. Prophylactic cancer vaccines are envisioned to prevent the development of cancer in 
certain high-risk individuals [8, 13, 17]. U.S. Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) have approved Gardasil® and Cervarix®, two preventable 
cancer vaccines expected to, confer protection against HPV infection [70, 71]. There is also 
an approved prophylactic vaccine for hepatitis B virus infection, to prevent liver cancer [72].  
The FDA has recently approved one therapeutic cancer vaccine, Provenge®, as an 
alternative treatment for metastatic prostate cancer patients [73]. This is a cellular based 
approach, in which APC are isolated by leukapheresis and cultured ex vivo with the antigen 
prostatic acid phosphatase (PAP) and the protein granulocyte-macrophage colony-stimulating 
factor (GM-CSF). These ex vivo cultured cells will be then administered back to the patient to 
stimulate the immune system to destroy cells that overexpressed this particular antigen [74, 
75]. 
Despite the antigenic variations between healthy and malignant cells, tumors have also 
evolved various immune escape mechanisms to evade destruction by the immune system [29, 
76]. The activation of DC seems to be the limiting step for the induction of selective and 
strong anti-tumor immune responses. Ex vivo manipulation of DC, as that described for 
Provenge®, is a personalized type of cell therapy, being thus a very complex, time consuming 
and costly approach. In addition, these ex vivo DC have poor migratory capacity and limited 
clinical efficacy [77]. Thus, in vivo targeting of DC is highly desirable and should involve the 
administration of the most immunogenic TAA along with the most effective adjuvants, to 
prime host tumor-specific immune effector mechanisms [13, 78, 79]. 
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An important step for vaccine development has been and still is the identification of 
TAA. These antigenic entities may be derived from proteins usually expressed on cell surface, 
secreted or exclusively present at intracellular level. Ideally, these TAA should be mutated or 
exclusively confined to malignant cells, being thus absent or minimally expressed by normal 
cells [13, 80]. Unfortunately, certain TAA can also be found in healthy cell populations, being 
recognized as “self” antigens by immune cells thus rendering them tolerant. In addition, their 
presence at non-malignant tissues can not only compromise cancer vaccine efficacy but also 
result in important side effects [81, 82]. Therefore, antigens are chosen based on their ability 
to induce robust anti-tumor immunity, including cellular (CD4+ and CD8+ T cell) and 
humoral (B cell) immune responses, while ensuring the establishment of long-lasting T cell 
memory [83, 84].  
TAA can be classified in different categories according to their function or expression 
pattern in different tissues [80, 85]: (i) Antigens specific for certain tumors, such as the 
melanocyte differentiation antigens (e.g. Mart1/Melan A, gp100, tyrosinase) or prostate-
expressed antigens (e.g. prostate specific antigen (PSA) and prostate specific membrane 
antigen (PSMA)). (ii) Cancer testis antigens are promising TAA (e.g. MAGE melanoma 
antigen, carcinoembryonic antigen (CEA) and alphafetoprotein (AFP)) for the induction of 
specific anti-tumor immune responses. This is a family of proteins present at different tumor 
cells, being absent from all other normal adult tissues, except germ cells and placenta. (iii) 
Overexpressed oncogenes or mutated tumor suppressor genes (HER-2, MUC1, Ras, p53).  
In either case, these antigens tend to be poorly immunogenic, and thus a single antigen 
may not be sufficient to induce an immune response capable of destroying cancer cells, due to 
tumors’ heterogeneity and phenotypic diversity [4]. As a result, multivalent vaccines are 
expected to induce more effective cytotoxic immune response against multiple targeted cancer 
cells in comparison to single-antigen containing vaccine [14].  
The safety of these peptide-based cancer vaccines has been demonstrated in many 
trials, which have highlighted several of their advantages. Aside from their low cost and 
relatively easy manufacture process, they exhibit low toxicity/immunogenicity compare to 
proteins and whole-cell lysate [14]. Moreover, peptide vaccines are quite flexible in terms of 
chemical modifications performed to improve their immunization efficiency. Some of those 
alterations include the introduction of specific D-amino acids [86] or peptide sequences [87], 
the fusion of two or more functionalized peptides [88] or the conjugation of peptides with 
chemotherapeutic agents [4, 89]. Even though, due to their size, peptides can be rapidly 
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degraded and eliminated from the blood circulation, being thus inefficiently taken up by APC 
when used in vivo [90]. 
In fact, these vaccines containing TAA in solution have low in vivo stability and often 
require multiple administrations. In addition, soluble antigens have low membrane 
permeability and get rapidly degraded by enzymes once internalized [91]. Several studies 
have shown that the administration of a single antigen tends to elicit strong Th2 responses, 
while activates only 1-5% of circulating CD8+ T cells [14, 92, 93]. On the other hand, the co-
administration of a single antigen with an adjuvant, often led to more prominent Th1 immune 
responses [17]. As so, both antigen and adjuvants are essential for an efficient activation of 
DC, otherwise the tolerance or anergy to the antigen may be induced [14, 15, 47]. In fact, 
most of cancer vaccines under clinical trials are based on the administration of various TAA 
combined with adjuvants in solution to boost anti-tumor immune responses (e.g. IFN-α2b, 
GM-CSF, IL-2) [47, 94, 95]. 
 
3. Nanoscale systems as fundamental tools for cancer vaccines 
To overcome antigen low specificity and unresponsiveness in many patients, an ideal 
cancer vaccine formulation should comprise not only antigens and adjuvants, but also a 
delivery system able to modulate antigen presentation pathways. In fact, optimal tumoricidal 
activity of cancer vaccines can be only attained when both CD4+ and CD8+ T cell responses 
are efficiently induced [35, 63]. 
Nanosized carriers have been widely explored as promising platforms for cancer 
vaccination [96, 97]. These nanodelivery systems present a large surface area to volume ratio, 
which physicochemical properties (e.g. size, surface charge and hydrophobicity) can be 
exploited to impart desired in vivo behavior and interaction with different cells within TME 
[98, 99]. In addition to their nanoscale size, these nanoparticulate systems are able to entrap, 
encapsulate or embed considerable amounts of different types of molecules, including drugs, 
polypeptides, proteins and oligonucleotides [100]. In the field of cancer immunotherapy, 
particulate nanosystems have been investigated to offer protection and prolonged release of 
single or multiple TAA and immune-stimulatory molecules to immune cells, for optimal 
presentation in a targeted and prolonged manner [13, 47, 101]. The nature of antigen 
association (adsorbed/conjugated onto nanocarrier surface or entrapped within matrix) is 
defined by antigen solubility and stability [102]. Additionally, similarly to the 
structure/composition of each class of nanomedicines (Figure 2), it will have a considerable 
effect on the payload release profile [103].  
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Generally, TAA carried by nanosystems have the ability to escape degradation in the 
endosomes and reach the cytosol in higher concentrations than those antigens administered in 
the soluble form. These loaded antigens will be thus presented by MHC class I molecules 
more effectively and for longer periods of time, leading to effective antigen recognition and to 
the activation of humoral and/or cellular immune responses fundamental for the successful 
eradication of cancer cells [17, 104]. Moreover, different studies have reported the successful 
co-entrapment of cancer antigens and adjuvants into the same particulate delivery system, 
which is critical for the efficient activation and subsequent maturation of DC [105, 106]. 
 
Figure 2: Examples of nanosystems for peptide delivery to potentiate anti-tumor immune responses. Polymeric 
nanoparticles are defined as submicron spherical nanosystems. Depending upon the formulation method, 
nanospheres or nanocapsules can be obtained. Nanospheres are systems in which antigens and adjuvants are 
physically and uniformly dispersed in polymer matrix, while in the case of nanocapsules antigens and adjuvants 
are encapsulated in polymer and surrounded by a polymer membrane. Hydrophilic and hydrophobic molecules 
can be entrapped inside the polymer or adsorbed to the surface. Polymeric micelles are self-assembled into this 
spherical entities formed by amphiphilic block-copolymers. The hydrophobic core is oriented inwards, while the 
hydrophilic regions of the polymer chains are oriented outwards the aqueous medium. Liposomes are self-
assembled nanocarriers made of phospholipids and can be classified according to their size and lamellarity. Lipid 
bilayer membranes can incorporate hydrophobic compounds, while hydrophilic molecules can be incorporated in 
enclose aqueous core. Dendrimers are multi-branched three-dimensional globular structures of well-defined 
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molecular weight polymers, formed by a hydrophobic central core, inner void space and symmetrical branches of 
repeating monomer units, resulting with a hydrophobic central core and a hydrophilic surface. 
 
The composition, formulation methodologies, and consequent morphology, size, and 
surface physicochemical properties of nanomedicine-based systems, have a profound impact 
on NP nanocarrier interaction with cell membranes, determining their ability to overcome 
these physiological barriers, but also to favor specific biophysical intracellular events [107, 
108]. 
Nanocarriers can be prepared from a variety of materials, which will ultimately 
determine their biological outcome. Their selection depends on formulation process and route 
of administration, being intimately linked and dictated by the expected physicochemical 
properties (size, surface charge, hydrophobicity) and immunotherapeutic effects [109, 110]. 
Extensive research works have shown that the ideal dimensions of nanosystems for 
local intratumoral administration should be in the range of 10–100 nm [109]. On the other 
hand, nanocarriers within 100 to 500 nm are efficiently taken up by DC after being 
administered through the subcutaneous administration route. Even though, carriers with sizes 
between 200 nm and 500 nm will be taken up by DC and then delivered to lymph nodes, 
while nanoparticles smaller than 200 nm will arrive at lymphoid organs through the lymph 
drainage within hours after their administration [35]. These carriers are known to avoid the 
reticuloendothelial system (RES), such as liver and spleen, presenting then a prolonged 
circulation time in blood [111]. 
Modification of surface characteristics is often required to target specific cells. One 
promising approach encompasses nanosystem functionalization with specific ligands, such as 
peptides, proteins or antibodies, which will have a considerable effect on in vivo 
biodistribution of nanocarriers [36, 112]. These ligands can provide selectivity and higher 
binding efficiency to cell surface receptors, minimizing the accumulation of nanomedicines at 
off-target cells. 
Different studies have reported the successful use of different classes of nanosystems 
for the delivery of cancer peptide antigens and/or immune-modulators to activate strong, 
selective and long-lasting anti-tumor humoral and cellular immune responses [101] (Table 1). 
 
3.1. Peptide-loaded polymeric nanoparticles and micelles 
Polymeric nanoparticles (NP) have been explored to achieve a sustained release 
profile for antigens and adjuvants over prolonged periods of time [101, 113]. These molecules 
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can be encapsulated by a polymer membrane (nanocapsules) or be dispersed into the polymer 
matrix (nanospheres) (Figure 2). As they normally present a uniform size with narrow 
polydispersity index, these nanocarriers are highly stable, capable of displaying a predicted 
controlled drug release [99, 114].  
On the other hand, polymeric micelles are self-assembled spherical nanocarriers 
formed of amphiphilic block-copolymers composed by hydrophilic and hydrophobic 
monomers. In aqueous solution, the block-copolymers assemble into a core–shell structure. 
The hydrophobic parts of their chains form a hydrophobic core, while the hydrophilic regions 
of the polymer chains are oriented outwards the aqueous medium [115, 116].  
Biodegradable synthetic and/or natural homopolymers or copolymers are commonly 
used in the preparation of these polymeric nanoscale systems. The aliphatic polyesters, as 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly (lactic and glycolic acid) (PLGA), 
and poly(ε-caprolactone) (PCL) are among the most studied polymers for drug delivery 
purposes, being FDA approved biomaterials suitable for the delivery of vaccine formulations 
via several routes of administration, including oral, nasal, dermal and parenteral [117, 118]. 
Polymeric nanosystems possess many advantages over other types of nanocarriers. 
Aliphatic polyesters comprise several requirements needed for the formulation of optimal 
delivery systems for human use. In fact, these materials are nontoxic, nonimmunogenic, 
biocompatible, biodegradable, and have been investigated as successful and cost-effective 
formulation components under Good Manufacturing Practices (GMP) scale-up processes 
[109, 119, 120].  
PLGA-based nanoscale carriers are able to protect loaded antigens from immediate 
degradation or premature elimination, and present the ability to control antigen release rate. 
This property can be tailored towards a specific need, being indeed predicted by the molecular 
weight and specific ratio of lactic and glycolic acid monomers [121, 122]. Additionally, 
chemical modification of aliphatic polyester with targeting ligands has allowed the delivery 
and subsequent active cellular uptake of entrapped entities, including TAA and adjuvants, to 
wide spectrum of specific cell types within tumor site [98, 109, 123]. 
Silva and colleagues (2014) developed untargeted NP and mannose-grafted NP to 
target CD206 DC surface receptors using a mixture of three aliphatic polyesters [17, 124]. 
The first ones were composed by PLGA, PEG-b-PLGA and PEG-b-PCL, in a 70:15:15 w/w 
ratio. Mannose was conjugated to the PEG-b-PCL copolymer used for the formulation of the 
CD206-targeted polymeric PLGA/PCL nanosystem. These NP were able to entrap different 
combinations of MHC class I (Melan-A:26; ELAGIGILTV and gp100:209; IMDQVPFSV) 
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and class II (gp100:44-59; WNRQLYPEWTEAQRLD) restricted melanoma associated 
antigens (MAAs) and two TLR ligands, Polyinosinic-polycytidylic acid (Poly(I:C)) and 20-
deoxyribo (cytidinephosphate-guanosine (CpG)-oligodeoxynucleotide (ODN). The 
subcutaneous administration of these cancer antigens and adjuvants co-entrapped in those NP 
improved immune responses in a B16F10 melanoma metastatic model, in both prophylactic 
and therapeutic settings. These results support their use as a promising component of a 
multiple immunotherapeutic approach to improve or even achieve the complete eradication of 
tumor cells. The most significant tumor growth rate reduction was observed in the group 
treated with the combination of mannose-NP containing MHC class I and MHC class II 
restricted peptides entrapped in different carriers, but in association with both TLR ligands, 
suggesting the importance of the activation of both CD4+ and CD8+ T cells in the efficacy of 
the anti-tumor immune response against this metastatic cancer model [125].  
Similarly, Ma et al. (2012) also reported that a multivalent vaccine based on PLGA 
NP co-entrapping three peptides (MART-1:27–35, gp100:154–162 and gp100: 209–217) 
generated stronger cytotoxic activity in a murine melanoma model than those NP containing 
only two of those peptides (MART-1:27–35 and gp100:154–162). Moreover, they have also 
studied the difference of the CTL cytotoxicity through DC after their activation with PLGA-
NP encapsulating peptides or pulsed with free peptides. NP encapsulating peptide induce a 
significantly stronger anti-tumor response even though the peptide dose was lower [126]. A 
comparable observation has also been previously suggested by Clawson (2010), when he and 
his coworkers observed that Hp91 conjugated onto the surface of PLGA-NP induced a more 
prominent activation of DC that the peptide in solution [127]. 
The anti-tumor effect of PLGA-NP co-encapsulating the tyrosinase-related protein 2 
peptide (TRP2: 180–188; SVYDFFVWL) and the 7-acyl lipid A, a TLR4 ligand, was 
assessed in a murine melanoma B16 tumor model. The therapeutic anti-tumor effect was 
induced by antigen-loaded NP, with or without the 7-acyl lipid A. In the absence of the 
adjuvant, antigen-loaded NP showed higher number of activated CD8+ T cell in lymph nodes. 
On the other hand, NP co-encapsulating both antigen and adjuvant led to higher number of 
activated CD8+ T cells in the spleen, showing stronger migration abilities. Moreover, 
increased levels of inflammatory cytokines were also shown at the TME [128]. 
Tan et al. (2014) developed lipid-coated NP, using PLGA, 1,2-dioleoyl-sn-glycero-3-
phosphocholine phospholipid (DDPC) and 1,2-distearyl-sn-glycero-3-phosphoethanolamine-
N-PEG 2000 (DSPE-PEG). These NP were able to entrap various combinations of MHC I 
class restricted peptides (TRP2: 180–188; SVYDFFVWL, gp100: 25–33; KVPRNQDWL and 
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p15E: 604–611; KSPWFTTL) with a TLR4 ligand, the monophosphoryl lipid A (MPLA). 
The authors assessed the ability of these different nanoparticulate systems to prevent tumor 
growth in a B16 murine tumor model. The main goal of this study was to compare the anti-
tumor effect obtained with the administration of a single particulate carrier encapsulating one 
type of antigen, with the one induced by a mixture of NP carrying each a different peptide. 
The mice immunized with NP loaded with a single peptide seem to induce a more pronounced 
antigen-specific T cell response. Interestingly, these formulations were not able to alter 
tumor-growth, in contrast to the combination of multiple NP containing different single 
antigens, which induced a significant suppression of tumor growth [129]. 
Wu and colleagues (2010) prepared pH responsive polymeric micelles with the tumor 
targeting AP peptide (CRKRLDRN) that binds to IL-4 receptors, which are highly expressed 
in breast tumor cells. Micelles were loaded with the doxorubicin and the fluorescence dye 
TRITC, to evaluate micelles binding affinity both in vitro and in vivo. These carriers 
presented a pronounced anti-cancer therapeutic efficacy in a MDA-MB-231 human breast 
tumor-bearing mice, which was significantly different from that obtained in animals treated 
with either the drug in solution or encapsulated in micelles without the AP protein [130]. 
 
3.2. Peptide-loaded liposomes 
Liposomes have been studied extensively as carriers particularly for anti-cancer 
therapies. These are lipid (natural or synthetic) composed self-assembled vesicles within the 
range of 50 to 1000 nm (Figure 2) [131, 132]. 
As mentioned for polymeric nanosystems, liposomes also present the ability to protect 
the therapeutic agents from degradation, thus prolonging their biological half-life. In addition, 
these carriers are easily functionalized with targeting ligands to deliver payloads to the site of 
action, which can promote (immune) therapeutic efficacy, but also and equally important, 
reduce important side effects [133]. However, unlike polymeric nanosystems, liposomes have 
the ability to carry hydrophilic molecules in an aqueous core and simultaneously incorporate 
or embed hydrophobic compounds inside the lipid bilayer [134]. These features, together with 
their biocompatibility and biodegradability, make liposomes unique delivery systems [135].  
Several types of liposomes can be prepared by different preparation methods, 
depending on the required application, size, lamellarity and final amount of the encapsulated 
antigen [136]. Liposomes can be classified into multi-lamellar vesicles (MLV), large uni-
lamellar vesicles (LUV), and small uni-lamellar vesicles (SUV), depending on their size and 
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number of bilayers. MLV, are usually composed of 5-25 lipid bilayers, presenting dimensions 
above 500 nm. Liposomes with only one bilayer, such as LUV are generally larger than 100 
nm, whereas SUV present smaller sizes [133, 137]. 
Cruz et al. (2011) prepared liposomes using a lipid mixture of egg 
phosphatidylcholine/ phosphatidylglycerol/palmitoyl peptide (EPC/PG/palmitoylpeptide) at 
80:20:10 molar ratio. Targeted liposomes were prepared by conjugating Fc fragment of 
human IgG conjugated to DSPE-PEG-Mal added to lipid mixture. These targeted liposomes 
were able to effectively bind to human DC, inducing a stronger immunological response than 
the untargeted system [138]. The same lipid composition was used to co-entrap a soluble 
cancer-testis peptide antigen (NY-ESO-187-111, with the sequence 
LLEFYLAMPFATPMEAELARRSLAQ) with an immunostimulatory peptide adjuvant 
(Palm-IL-1 and MAP-IFN-γ). Similarly, the most potent immunological response was 
presented by liposomes which surface was modified by targeting moieties for human DC via 
Fc receptor. These results suggest that this targeted vaccine strategy is a promising tool to 
improve immunotherapeutic outcomes against cancer disease, but also in other 
immunocompromised states [139].  
MUC1 is a glycoprotein widely overexpressed on distinct types of cancers, such as 
lung cancer, breast cancer, prostate cancer and colorectal cancer. L-BLP25 is a peptide 
liposomal vaccine, containing 25-aminoacid sequence of MUC1 
(STAPPAHGVTSAPDTRPAPGSTAPP), corresponding to the exposed core peptide of 
MUC1 protein. Sangha et al. 2007 studied the effect of that liposomal vaccine in combination 
with the adjuvant MPLA. This delivery system was used to facilitate the uptake of the 
antigenic peptide by APC, leading to an antigen-specific T cell immune response that acts on 
MUC1-expressing tumors both in preclinical MUC1-transgenic lung cancer mouse model and 
patients [140]. 
Sarkar and colleagues formulated 1,2-dipalmitoyl-sn-glycero-3-phosphatidyl- choline 
(DPPC) liposomes to entrap a 20 aminoacid MUC1 peptide containing a GalNAc-O-Thr (Tn) 
conjugated to a TLR2 ligand, Pam3Cys, which works as adjuvant and lipid anchor in the 
liposomes. Mice immunized with this liposome-based vaccine demonstrated increased T cell 
proliferation, compared to non-treated mice [141].  
Mansourian and coworkers encapsulated HER-2 derived peptide, p5 peptide, in 
liposomes formulated using various lipids (dioleoyl phosphatidylethanolamine (DOPE) and/or 
fusogenic 1,2- dioleoyl-3-trimethylammonium-propane (DOTAP)) and in combination with 
the adjuvant CpG-ODN to obtain the most optimal in vivo immune response. This study 
Chapter 1 
22 
reports the increased delivery of p5 by DOTAP-cholesterol-DOPE liposomes admixed with 
CpG-ODN. Moreover, tumor sizes and animal survival rates support the successful induction 
of both CD8+ and CD4+ T cell-mediated immune responses [142]. 
 
3.3. Dendrimers 
Dendrimers are multi-branched three-dimensional globular structures of well-defined 
molecular weight polymers, formed by a hydrophobic central core, inner void space and 
symmetrical branches of repeating monomer units (Figure 2). Moreover, their 
biocompatibility, nanometric size, narrow polydispersity index, long-term circulation, and 
possibility of presenting multiple functional groups at the periphery, makes dendrimers 
promising new platforms for peptide-based vaccine delivery [143-145]. Dendrimer synthesis 
methodology can be divergent, which starts from the core element in the center outwards; or 
convergent, beginning from the peripheral branching units towards the center. Both strategies 
will lead to a structure that presents a hydrophilic surface and a hydrophobic central core 
[145, 146]. TAA and immune-modulators can be encapsulated into the hydrophobic inner 
cavities, while targeting moieties will be conjugated to the terminal functional groups of 
dendrimers to interact with specific molecules expressed on targeted cells.  
Liu et al. (2013) created a highly promising vaccine candidate to treat HPV-related 
cancers. These researchers conjugated the HPV peptide antigen E744−62 (8Q epitope; 
QAEPDRAHYNIVTFCCKCD) to the polyacrylate polymer, leading to a peptide conjugated 
dendrimer that reduced or eradicated tumor growth in a mouse model for cervical cancer (TC-
1) after a single immunization. Moreover, in this study no additional adjuvants were used 
[147]. 
 
4. Nanothechnological-based startegies for immune cells and tumor 
microenvironmental targeting 
As previously mentioned, conventional cancer therapies do not specifically target the 
tumor, leading to several and severe side effects. Thus, nanocarrier-based cancer vaccines 
have emerged as an alternative therapeutic strategy and have already shown promising results 
[113]. This targeted immunotherapy is being explored to overcome the heterogeneity of 
malignant cells and the immune suppression induced by both the tumor and its 
microenvironment. The main goal of this therapeutic strategy is not only to target and kill 
tumor cells in a specific manner, but also to alert the immune system to eliminate residual 
cancer cells [148]. 
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There are two main mechanisms for the targeted delivery of peptide-loaded 
nanovehicles to tumors: (i) passive targeting, through leaky vasculature surrounding the 
tumors; and (ii) active targeting, by grafting specific ligands of different cells within TME 
(e.g. tumor cells or angiogenic endothelial cells) to the nanocarrier surface [149]. In contrast 
to normal cells, cancer cells present anatomical defectiveness, in addition to functional 
abnormalities. Unpaired angiogenesis is responsible for the unique pathophysiological 
characteristics of tumor blood vessels. They present irregular shape, and are highly 
disorganized and dilated with a high number of pores, resulting in enlarged gap junctions 
between endothelial cells [149, 150]. This compromised architecture and regulation of tumor 
blood vessels allow the selective migration and accumulation of molecules up to 400 nm 
diameter into the surrounding tumor region within tumor interstitium due to the “Enhanced 
Permeability and Retention (EPR) effect” [102, 151]. 
In addition, it has been shown that nanoparticles persist in the tumor for a period 
during which occurs their local disintegration and consequent release of entrapped agents, as 
drugs, immunoadjuvants or antigens [152, 153]. However, passive targeting suffer from 
limitations, since not all tumors exhibit a considerable EPR effect, and the vascular 
permeability may not be similar within a single tumor [151]. One strategy followed to 
overcome this limitation aims to modify the nanocarrier surface with targeting moieties to 
recognize and bind overexpressed molecules at immune or cancer cells. Antibodies and their 
fragments, but also other proteins, peptides, nucleic acid based ligands, and small molecules 
are some of the most used recognition ligands for the specific delivery of nanocarriers [150]. 
However, to achieve high specificity and a considerable effect on the biodistribution of these 
surface-modified nanosystems, those receptors should be highly expressed on tumor cells, but 
absent on normal cells, minimizing their accumulation in healthy tissues. Targeted cells will 
internalize nanovaccines by receptor-mediated endocytosis, promoting the accumulation of 
higher amount of TAA and/or adjuvants and immune modulators, thus improving their 
biological effect. Delivery system strategies aiming to achieve immunomodulation are now 
part of the pharmaceutical companies’ pipeline [154]. The importance of this immunological 
framework, resulting from nanomedicines potential for selective immune system stimulation, 
has recently become apparent with a massive number of scientific publications and awarded 




Table 1. Examples of peptide-associated nanosystems for sustained and targeted delivery of antigens 




Adjuvant(s) Composition Immune-mediated response REF 
Self-assemble 
micelles 
Entrapped OVA cytotoxic 
T-cell epitope 
(EQLESIINFEKLTE) 
Dipalmitic acid tail 
(diC16) associated to 
peptide antigen N-
terminus 
Subcutaneous administration of 
diC16-OVA micelles and controls 
(PBS, OVA in PBS, OVA+ 
incomplete Freud’s adjuvant 
(IFA) on days 0, 1 and 20). 
Cancer cells expressing OVA 
were inoculated on days 30 
diC16-OVA micelles were able to 
decrease tumor growth rate 
compared to controls. 
[156] 




forms of single chain 
antibody fragments 
(ScFv) to CD11c and 
DEC-205 DC receptors 
onto highly metastatic 
murine melanoma (B16-
OVA) plasma membrane 
vesicles (B16-OVA-
derived PMV) 





In vitro and in vivo targeting of 
DC by modified PMV;  
Stimulation of strong B16-OVA-
specific CTL responses, 
prominent protection against 
tumor growth and prolonged 
disease-free survival 
[157] 
Dendrimers PAn DR (PADRE) + 
OVA encoded plasmid 
Polyamidoamine 
(PAMAM) dendrimers 
Administration of a single dose of 
PADRE-conjugate dendrimers 
and OVA encoding plasmid by 
subcutaneous administration 
protected animals against tumor 
growth for 25 days.  
[158, 
159] 





gp70) conjugated with 
Generation 5 
polyamidoamine (G5-
PAMAM) cross-linked  
with PADRE epitope 
(aKXVAAWTLKAAaZC
) and HemoAgglutinin 
HA:110–120 
(SFERFEIFPKEC) 
Subcutaneous injection of DNA-
peptide-dendrimer complexes, 
followed by dermal 
electroporation, transfected APC, 
mostly DC, in vivo directly in the 
lymph nodes, induced T cell 
immunity and humoral response, 
and reduced tumor growth in a 
B16F10 melanoma model.  
[160] 
Liposomes Entrapped influenza 
hemaglutinin peptide HA 
307-319-C 
(PKYVKQNTLKLAT- 
C) peptide conjugated 
onto liposomal surface 
through diacylated and 
triacylated lipopeptides 




DL-glycerol (PG) and 
cholesterol (75/20/50 





The conjugation of thiol carrying 
HA 307-319-C peptide epitope 
onto liposomes previously 
functionalized with thiol-reactive 
lipopeptides did not induced 
maturation of DC in vitro. On the 
other hand, the incorporation of 
those lipopeptides into SUV did 
not change the 
immunostimulatory capacity of 
these lipopetides, being able to 
stimulate DC in vitro and induce 








The encapsulation of peptide and 
specific targeting to DC receptors, 




peptide   (80/20/10 molar ratio), 
containing 1% DSPE-
PEG-Mal to conjugate Fc 
fragments of human IgG  
antigen uptake and T-cell 
response in vitro 
Liposomes TLR agonists (zymosan 
(TLR2), R848 (TLR7/8), 
poly(I:C) (TLR3), LPS 
(TLR4) and CpG 
(TLR9)); 















TLR9 or TLR3-complexed 
liposomes encapsulating antigens 
induced strong CD8+ and CD4+ T 
cell responses and IFN-α 
production after administered by 
i.p. route. Trp-2 –loaded TLR-
complexed liposomes 
significantly reduced melanoma 
tumor growth, demonstrating a 
therapeutic anti-tumor activity. 
[162]  
Liposomes CTL epitope SIINFEKL  
Co-encapsulated with the 
TLR3 ligand poly(I:C)  
 
Antigen and adjuvant 
loaded cationic liposomes 
composed of DOTAP and 
DOPC 
Immunogenicity of formulated 
liposomes was determined in 
vitro and in vivo. In vitro, 
liposomes were efficient in the 
delivery of antigen to DC, while 
in vivo activation of CD8+ T cell 
immune response was triggered. 
The activation of CTL by 
liposomes was 25 fold stronger 
than the CTL activation induced 
by adjuvant and antigen in 
solution. 
[163] 
Liposomes  CTL epitope peptide 
derived from human 
ErbB2 (p36-71: CG-
TYLPTNASL), Th 
peptide epitope from 
influenza haemagglutinin 
( HA 307-319: 
PKYVKQNTLKLAT-C) 
associated with TLR2/1 
(Pam3CAG) or TLR2/6 
agonists (Pam2CAG and 
Pam2CGD) 
Liposomes were prepared 
by mixing phospholipids 
(PC, PG), cholesterol, 
anchor 
(DPGMal or DPGBr*) 




CTL and Th peptide 
epitopes were conjugated 
to DPGMal or DPGBr 
anchors of mannosylated 
liposomes loaded with 
various adjuvants. 
In vivo studies showed that either 
prophylactic or therapeutic 
vaccination was successful in a 
BALB/c mouse model challenged 
with renal carcinoma cells 
expressing human ErbB2.  
Both type of liposomes 
(Pam3CAG/DPGMal or 
DPGBr/ErbB2/HA) triggered an 
efficient tumor eradication in 














Covalent linkage of 
peptides and adjuvant on 
the surface of the 




Both glycosylated and non-
glycosylated vaccine induced 
CTL immune response. Immunity 
triggered by glycosylated 
tripartite vaccine had significantly 
better results regarding tumor 
prevention. 
[165] 
Liposomes HPV16 E6- and E7- 







95 (CYSLYGTTL); E6 
98-106, (QYNKPLCDL) 




HPV16 E6- and E7- 
derived peptides 
In vitro studies on HPV-16 
positive cervical carcinoma 
patient’s peripheral blood 
mononuclear cells (PBMCs) 
showed the highest 
immunogenicity for E6-derived 
peptide (E6 66-74). Moreover, 
this study also demonstrates that 
oligomannose-coated liposomes 
containing peptides are more 
efficient than vaccination with 




60, (HYNIVTFCCK); E7 
83-93, (LMGTLGIVCPI)) 
Liposomes CTL epitope peptides 
(Hantaan nucleocapsid 
protein (HTN M6; 








lipid A (MPLA) 
(POPE/CHOH/MPL 
7:3:0.01 molar ratio)  
  
pH-sensitive liposomes were able 
to reduce melanoma tumor 
growth and induce antigen-
specific CTL immune response 





P17 (ICAM-4: 37-58)  
and P18 (ICAM-4: 149-
177) 
and one 12-mer cyclic 
peptide (P30) to bind to 









engrafted with peptides 
In vitro and in vivo strong binding 
to CD11c+ and CD11b+ cells; 
Intravenous administration of 
liposomes induced humoral 
immune responses and T cells, 
while liposomes were  able to 
protect against tumor growth in 
both lung and subcutaneous B16-










PLGA nanoparticles  Intradermal administration of 
peptide-loaded PLGA NP were 
able to induce prolonged antigen-
specific immune responses. The 
subcutaneous administration of 
co-encapsulted  TRP 180e188 
peptide and MPLA in PLGA NP 








Hp91-loaded PLGA NP 
and PLGA NP 
functionalization with 
Hp91 peptide 
The incorporation of Hp91 
peptide strongly stimulated DC in 
vitro, in comparison to free 
antigen; however antigen 
delivered at NP surface was 4-




Nanoparticles EphA2 peptide  L-phenylalanine (Phe)-
conjugated poly(Υ -
glutamic acid) (Υ-PGA-
Phe NP)  
 
Amphiphilic peptide-immobilized 
prevented MC38 tumor cells 
growth and successfully induced 
an antigen-specific cytotoxic 
immune response in vivo. This 
formulation did not elicit severe 
side effects, in contrast to the 
mixture of this peptide antigen 




4.1. Nanosystems as fundamental tools for in vivo DC targeting 
Attentions have been focused on the development of novel DC-based cancer vaccines 
to provide durable anti-tumor immunity and avoid tumor progression [171]. As previously 
mentioned, DC represent the sentinels of the immune system and are known as the most 
potent APC able to modulate the adaptive immunity [172]. DC can process TAA into the 
MHC class I and MHC class II pathways to interact with CD8+ and CD4+ T cells, respectively 
[173]. Moreover, DC populations present the unique capacity to efficiently cross-present 
antigens, in particular human BDCA3C+ (CD141C) blood mDC [174, 175] and murine 
CD8α+/DEC205+ DC [176], which is essential for the development of anti-tumor cytotoxic 
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immune responses [177]. DC have also been presented as immunocompetent in initial stages 
of tumor progression [178]. In this regard, new nanovaccine-based strategies have been 
designed to selectively target DC, enhancing the antigen uptake efficiency and consequently, 
the activation of cellular motility to secondary lymphoid tissues (spleen, lymph nodes and 
mucosal lymphoid system) for further activation of naïve T cells [179, 180].  
To overcome the disadvantages of individual ex vivo DC-based approaches (section 
3.), peptide-based vaccines have been suggested to deliver antigens directly to DC in vivo 
[77]. However, their weak immunogenicity has demanded for their combination with delivery 
nanosystems to increase their recognition and uptake by DC, but also to modulate antigen-
presentation pathway [102, 181]. 
Passive targeting of DC can be achieved by directing nanovaccines to DC-rich locals, 
such as lymph nodes and peripheral tissues, as skin. For this purpose, nanovehicle size and 
coating are important physicochemical factors playing crucial roles in the interaction and 
internalization by DC, affecting the subsequent processing of antigens via MHC class I, MHC 
class II or cross-presentation pathways [182]. Tolerance can also be induced if the maturation 
stimulus is given too late after antigen capture by DC. On the other hand, antigens will not be 
efficiently presented if they reach already mature DC, being important to highlight that the 
time period at which antigen and adjuvant reach DC is crucial, affecting the overall immune 
outcome. [183]. It has been well established that nanosize is among the most crucial factors 
that determine the antigen delivery, internalization and processing by lymph-node-resident 
immature DC instead of only peripheral immature DC, providing a more potent immune-
stimulation [184, 185]. As previously described, small nanovaccines (< 100 nm) are directly 
transported to DC at lymph nodes, into the lymphatic system by interstitial flow; larger 
carriers (>500 nm) are predominantly internalized by skin iDC (dermis, epidermis and to a 
lesser extent subcutis), draining subsequently to the lymph nodes; and intermediate sized 
nanovaccines (100-500 nm) follow both pathways [186]. Nanosized vaccine delivery vehicles 
may be also preferable to induce cytotoxic immune responses by cross-presentation pathway, 
extremely important for cancer immunotherapy [187]. Moreover, studies have shown that DC 
preferentially internalize particles within viral-sized range, whereas those presenting 
dimensions similar to bacteria are preferentially ingested by macrophages [188]. Nanosystem 
surface properties constitute additional and important factors that influence the kinetic of 
uptake by DC. The improvement in bloodstream circulation half-life of nanosized systems has 
been achieved through the “PEGylation” process. This consists in coating nanosystems 
surface with hydrophilic PEG molecules by conjugation, grafting or adsorption, especially to 
Chapter 1 
28 
avoid their immediate recognition as non-self, and consequent capture and destruction [17, 
102, 189].  
However, besides the ability inherent to nanosystems to act as an intrinsic “danger 
signal” inducing DC maturation and consequently adaptive immune responses, in vivo studies 
have demonstrated that delivery vehicles alone are not sufficiently strong to activate a 
sustained immunity [185]. Therefore, DC maturation stimuli are critical for the induction of 
potent anti-tumor immune responses [171]. 
The active targeting of DC may facilitate nanovaccine uptake and DC maturation, 
being a relevant alternative to have in consideration while developing an effective cancer 
vaccine strategy [186]. To improve the efficacy but also the specificity of interaction with 
DC, nanosystem surface have been decorated with bioactive ligands, including peptides, 
antibodies, proteins, polysaccharides, glycolipids, glycoproteins, and lectins, which 
particularly bind to DC-surface receptors [17, 190, 191]. Moreover, the delivery of both 
cancer antigens and adjuvants within the same platform, to a single DC population is expected 
to improve immune outcome [192]. 
In mammals, TLR are the most studied class from the broad spectrum of PPRs 
predominantly expressed on DC, and can be divided into surface bound receptors (TLR1, 2, 4, 
5, 6 and also TLR10 in humans and TLR11 in mice) and intracellular receptors present in the 
endosomes (TLR3, 7, 8 and TLR9) [193-195]. TLR identify PAMPs and are involved in the 
initiation, promotion and execution of immune response through DC activation and 
maturation. This process results in the secretion of co-stimulatory molecules (CD80, CD86 
and CD40), chemokines and inflammatory cytokines (IL-6 and TNF-α) required to potentiate 
TAA presentation through MHC class I pathway to CD8+ T cells, increasing cancer 
immunotherapeutic efficacy [17, 43, 196, 197]. Extracellular TLR recognize bacterial 
invaders, but also fungi and some enveloped viruses, while intracellular TLR recognize 
nucleic acids from viral or bacterial pathogens [17]. 
The discovery of TLR and their crucial role in orchestrating both innate and adaptive 
immune responses have led to the development of an entire class of potent 
immunomodulatory adjuvants, namely the TLR ligands [198]. Therefore the use of TLR 
agonists as vaccine adjuvants is an attractive strategy to be explored in the design of these 
nanotherapeutic systems [199]. 
CpG DNA motifs present in bacterial and viral genomes can be incorporated into 
liposomal [200, 201] and polymeric [202] nanosized vehicles acting directly on DC 
maturation by binding intracellular TLR9 [203-206]. Also, poly(I:C) adjuvant, mimicking a 
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double stranded RNA (dsRNA) produced by most viruses during replication, can bind to 
TLR3 and have been associated to stronger anti-tumor immune responses [102, 206, 207]. 
This receptor still contributes to the initiation of immune responses against the induction of 
dsRNA replication in infected cells [208]. Co-administration of TLR3 and TLR9 ligands 
within the same liposome demonstrated an enhancement in cross-presentation of loaded 
exogenous TAA, being associated with stronger anti-tumor immune responses [209]. In 
addition, MPLA ligand can also be delivered when associated with liposomal [140] or 
polymeric [169] nanosystems to target TLR4, which recognizes components of bacterial cell 
wall, similarly to TLR2 [183, 210, 211]. It has been recently shown that IL-6 secreted by 
TLR4-activated DC is capable of reversing the Treg suppressive effects, activating T cell 
functions [212]. Otherwise, mouse TLR7 and its homologous human TLR8 can recognize 
imidazoquinoline-like molecules and viral single-stranded RNA (ssRNA) [213]. The ability 
of Imiqiuimod and Resiquimod to activate respectively the homologous of TLR9, TLR7 and 
TLR8, involved in viral recognition, is also being currently tested in clinical trials [214]. The 
administration of other TLR agonists such as Flt3L or CD40L also showed to enhance DC 
activation and maturation in vivo [215]. Moreover, different DC populations express distinct 
sets of TLR. Consequently different TLR ligands will induce the activation of different DC. 
TLR1–6 and TLR8 ligands activate human mDC [216], while TLR7 and TLR9 ligands 
activate exclusively pDC in lymph nodes [217]. Furthermore, the same TLR ligand can 
induce different cytokines according to the DC subset, which influence T cell response [218]. 
TLR9 ligand only activates pDC present on lymph nodes. As a result, and despite the active 
targeting with TLR9 ligand, carriers within nanometer dimensions can directly reach the 
draining lymph nodes to be efficiently taken up by pDC over the exclusive peripheral DC 
[187]. Additionally, a combination of different TLR ligands, such as TLR3 and TLR7, can be 
co-delivered by a singular nanosystem to DC, being expected a synergistic effect of sustained 
secretion of cytokines (IL-6 and IL-12) and development of higher resistance to Treg-
mediated immune suppression by CD4+ and CD8+ T cells, unlike those obtained in the 
presence of a single TLR ligand [219]. The delivery of TLR ligands and TAA by the same 
nanosystems may not only alert the immune system by potentiating the presentation of TAA 
via MHC I to CD8+ T cells, but also allow for a sustained TLR signaling and TAA release in 
DC, reducing the need for high doses or repeated administrations of those compounds, 
consequently, limiting their toxicity and/or the non-specific immune activation [220, 221]. 
The effective dose of TLR for in vivo T cell activation can be reduced until 100 fold when 
delivered in nanosystems [202]. In this regard, the combination of TLR ligands with TAA 
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may have a massive impact on the efficacy of cancer vaccines for melanoma, lymphoma, 
glioblastoma, breast, prostate, ovarian and lung cancers. This combination can in fact act as a 
potent immune modulator, as well as a safe and effective vaccine adjuvant through the 
induction of Th1 immune responses [17].  
Among the most expressed receptors by DC, C-type lectin receptors (CLR) are 
characterized by the presence of carbohydrate binding domains involved in the recognition 
and internalization of many glycosylated self-antigens and pathogens, such as viruses, 
bacteria, and fungi, making them popular targets for cancer vaccine delivery [17]. Targeting 
antigens to CLR was demonstrated to enhance humoral and cellular immunity against tumors 
[222]. CLR, such as DEC-205, DC-SIGN, CLEC9A, mannose receptor (CD206), Dectin-1, 
Langerin and DCIR2, can recognize binding and endocytosis ligands with a terminal sugar, 
such as mannose, fucose and N-acetylglucosamine conjugated onto nanosystem surface [171, 
223, 224]. These receptors have been proposed as another promising approach for DC-active 
targeting on cancer immunotherapy due to their particular engagement in antigen 
internalization, processing and loading on MHC class I or MHC class II molecules [225, 226]. 
Among others, the active targeting of mannose receptor has been reported to increase vaccine 
effectiveness by promoting the TAA cross-presentation pathway and consequent induction of 
effective CD8+ T cell-mediated immune responses [227].  
Other effective approach for DC targeting is based on Fc receptor (FcR). Nanosystems 
can be functionalized with IgG, IgA or IgE Fc fragments against FcγRIIa (CD32a) [191], 
FcαRIa (CD89a) and FcεRI, respectively, inducing the activation of DC to directly prime 
CTL responses [228]. 
On the other hand, other ligands or cytokines can be conjugated onto the surface of 
nanodelivery platforms to enhance T-cell immunity. DC-specific antibodies, such as anti-
CD11c (myeloid marker), anti-CD40 [229] and anti-DEC-205 [230] have been used to 
modify nanosystem surface, not only to enhance the specificity of DC targeting in vivo, but 
also to foster their uptake, promote antigen processing and consequent DC effective 
maturation [157]. Recent studies have indicated that CD8+ T cell effectors may be generated 
by triggering CD40 on APC, not requiring the simultaneous stimulation by MHC II-related 
Th cells via CD40 ligands [231].  
Notwithstanding, polymer “PEGylation” has also been used as a fundamental strategy 
to stabilize the conjugation process [232], where functional ligands are attached to the surface 
of nanosystems via terminal ends of PEG-grafted polymers, for targeting specific organs or 




4.2. Targeting and modulation of tumor microenvironment 
Despite improvements made on peptide-associated nanosystems for cancer vaccines, 
most of the clinical trials have shown that only a small number of these candidates induced an 
effective tumor regression [16]. As previously described, the immune system has the ability to 
recognize, eliminate, and protect the body from tumor cells by mounting robust innate and 
adaptive immune responses. However, tumor is able to induce sophisticated immune escape 
mechanisms where both cancer cells and immune cell populations are involved, explaining 
this poor clinical outcome [236]. Contrarily to stroma healthy cells that acts as a barrier 
against cancer development, the presence of tumor cells induces crucial stroma alterations 
with the recruitment of fibroblasts and immune cells, matrix remodeling, and development of 
vascular networks, leading to the formation of the TME and supporting tumorigenesis [237]. 
Different cytokines, chemokines and growth factors can be found within TME extracellular 
matrix, which along with tumor stromal cells (immune suppressor cells, myofibroblasts 
(MFs), and endothelial cells) account for the complexity of this tumor-stromal interplay [238, 
239]. TME constitutes a physical barrier to tumor-targeting molecules, but it also has a major 
role in tumor immunosuppression, growth, invasion and angiogenesis [240, 241]. Thus, 
stromal TME cells constitute a promising target for integrative, targeted and immune-
mediated anti-tumor approaches. Therefore, improved clinical outcomes would benefit from 
the successful modulation of tumor associated cytokine network and cell communication 
within TME, which could be promoted by the use of those NP to stromal targeted cells, 
avoiding off-targeted effects [242]. 
An effective strategy to modulate the heterogeneous population and signaling 
pathways within tumor site requires a combinatory approach involving, namely 
chemotherapy, vaccination and cancer-immune network modulation within TME. The 
association of these approaches presenting complementary mechanisms of action may be the 
key to overcome the multiple factors and mechanisms involved in the promotion of pro-
tumorigenic behavior and dissemination [243-245]. To improve or even achieve the complete 
eradication of tumor cells, it is essential to follow an integrative strategy able to i) prime the 
immune system potentiating antigen presentation; ii) regulate immunosuppressive processes 
and tumor-related pathways within TME to prevent the inhibition of anti-tumor responses; iii) 
suppress the development of tumor vascular networks (angiogenesis), and iv) downregulate 
proliferation of malignant cells [246]. 
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TME key population MFs are directly implicated in the suppression of anti-tumor 
immune responses and thus in the subsequent invasion and metastasis. MFs present common 
features on primary and metastatic tumors, thus being less likely to acquire mutations than 
tumor cells. MFs highly express fibroblast-activating protein (FAP), which has not yet been 
found in normal tissues or cells. In adults, FAP expression seems to be limited to pathologic 
sites, constituting a promising target within stromal environment [247]. MFs are the major 
source of collagen deposits within stroma and are also deeply involved in drug resistance and 
in the evasion of effective anti-tumor immune responses through several MF-derived factors 
[248]. Tumor growth factor- β1 (TGF- β1), a cytokine essentially secreted by DC and tumor 
cells, is able to induce i) the differentiation of fibroblasts into MFs; ii) the promotion of tumor 
angiogenesis; but also iii) tolerance against tumor cells, playing a key role in tumor-induced 
immunosuppression [199]. This immune suppressive cytokine affects all populations of 
leukocytes in a stimulatory or inhibitory manner. For instance, TGF- β1 decreases DC’ 
maturation and antigen presentation capacity, but can also affect monocytes and macrophages 
by decreasing their phagocytic and effector functions, compromising their consequent ability 
to present antigens (Figure 3). Moreover, this cytokine decreases CD4+ T cells effector 
function and even convert the latter into immunosuppressive Treg cells [242, 249]. Cancer 
patients present high levels of TGF-β1 in the plasma and at the invasive fronts of human 
cancer tissues, being thus commonly related to tumor metastasis and poor prognosis [250]. 
Recent studies have demonstrated that blocking the TGF-β1 signaling pathway may represent 
an attractive therapeutic strategy for the treatment of human cancer, by directly increasing the 
efficacy of both immunosurveillance and current immunotherapeutic strategies [251]. A 
strategy for disrupting this tumor-promoting pathway is silencing TGF-β1 by small interfering 
RNA (siRNA) [252]. siRNA is a promising technique in oncotherapy that can selectively 
inhibit target gene expression, and therefore overcome the limitations presented by other 
therapies [253]. To the best of our knowledge, there is only one study that reports the use of 
TGF-β1 siRNA loaded-nanoparticles to enhance an anti-tumor immune therapeutic effect. 
Accordingly, Xu et al. (2014) developed a mannose-modified lipid-calcium-phosphate NP to 
co-deliver Trp2 peptide and CpG to DC. The efficacy of that vaccine in a metastatic B16F10 
melanoma model was significantly improved when combined with a TGF-β1 siRNA 
liposome-protamine-hyaluronic acid nanoparticle [6]. 
In addition to proliferation, angiogenesis is one of the main features of tumor tissues. 
This process is driven due to hypoxic conditions in tumor, where cells take advantage of the 
formation of new blood vessels from pre-existing vasculature to progress and satisfy their 
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need in nutrient and oxygen [254]. Studies performed in breast cancer patients have showed a 
positive correlation between angiogenesis and the degree of metastasis, as well as the tumor 
recurrence, and shorter survival rates, which reveal the importance of this process in tumor 
growth, progression and metastasis [255, 256]. In a pathological condition such as cancer, 
angiogenesis is mediated by the release of molecules by both healthy (endothelial cells, 
epithelial cells, mesothelial cells and leucocytes) and transforming cells [257], being the 
vascular endothelial growth factor (VEGF) considered as one of the most important pro-
angiogenic factor and one of the major contributors to this process. This molecule was found 
overexpressed in various human cancers, including breast [258], prostate [259], liver [260], 
colorectal [261] and gastric cancers [262]. Different studies have shown that blocking VEGF 
signaling pathway, by blocking its receptor (VEGFR) or decreasing VEGF expression, allows 
reducing tumor associated angiogenesis and blood vessel-dependent metastasis (Figure 3) 
[263]. Many VEGFR inhibitors have been developed and tested so far, including small-
molecule inhibitors, anti-VEGF monoclonal antibodies, and aptamers that strongly 
antagonizes the VEGF-VEGFR binding with high specificity [264-266]. Nevertheless, several 
limitations have been associated with these strategies, including unfavorable 
pharmacokinetics, poor tumor accumulation, and undesired interaction with the immune 
system [267]. Another strategy that has been exploit for disrupting this angiogenic pathway, 
but still at less extension, is the silencing of VEGF using siRNA. However, the in vivo use of 
naked siRNA to targeted tissues and cells remains a challenge due to the fragile nature of the 
molecule, which can be rapidly degraded by nucleases in plasma, its renal elimination, and 
limited penetration across the capillary endothelium. Moreover, siRNA molecules are too 
large (~13 kDa) and too negatively charged to enter cells by a passive diffusion mechanism, 
leading to an inefficient cellular uptake [268, 269]. Polymeric NP are a valuable approach to 
enable the protection of those biomolecules from degradation and potentiate their cytoplasm 
delivery providing their escape from endo-lysosomal compartments [270-273].  
The activation of T cells is critical to the immune surveillance of tumors, being 
specially regulated by a balance between co-stimulatory signals and immune checkpoints. 
Most of the immune checkpoints, defined as a set of immune inhibitory pathways, are 
essential to preserve the quality and amplitude of physiological immune responses and 
prevent autoimmunity under normal physiological conditions [237]. However, the secretion of 
immune-checkpoint proteins and their receptors can be deregulated in tumors. The 
overexpression of inhibitory ligands and receptors that regulate CTL effector functions in 
tissues has been extensively reported particularly on tumor cells or on non-transformed cells 
Chapter 1 
34 
in the TME [274]. Thus, blockade of immune checkpoints seems an important target to 
improve human cancer therapeutics and a powerful approach to enhance the anti-tumor 
immunity. Antagonist monoclonal antibodies (mAbs) can be manufactured to readily block 
immune checkpoints through the lymphocyte inhibitory receptors targeting, attaining the 
amplification of antigen-specific T cell responses and consequently a sustained endogenous 
anti-tumor activity [275]. In the context of clinical cancer immunotherapy, cytotoxic T-
lymphocyte-associated-antigen 4 (CTLA-4; also known as CD152) and programmed cell 
death protein 1 (PD-1; also known as CD279) are the two immune-checkpoint receptors most 
actively studied, showing different mechanisms to regulate anti-tumor immunity in order to 
enhance the potential to produce durable clinical responses [276]. CTLA-4 receptor plays a 
critical role acting as a signal damper through the regulation of T cell early activation. CTLA-
4 is a homolog of CD28 with 100-fold greater affinity for CD80/CD86 ligands. The binding 
of this competitive ligand interrupts the second signal, suppressing T cell activation and 
consequently contributing to the tumor growth [277]. Blockade of CTLA-4 with mAbs such 
as Ipilimumab and Tremelimumab, recently approved by the FDA for use as first-line or 
second-line therapy for patients with advanced melanoma, was associated with enhancement 
of T cell responses and tumor destruction [278, 279]. PD-1 is associated with the inhibition of 
anti-tumor T cell responses, being expressed by the majority of tumor infiltrating 
lymphocytes, in response to the common overexpression of their ligands, such as B7-H1 (PD-
L1) or B7-DC (PD-L2), by tumor and stromal cells [280]. Thus, the inhibition of the 
interaction PD-1-ligands with mAb, such as anti-PD-1 monoclonal antibody BMS-936558 
(also known as MDX-1106 and ONO-4538), can enhance T cell responses and mediate 
preclinical anti-tumor activity, in cancer immunotherapy (Figure 3) [281].  
On the other hand, miRNAs are important gene expression regulators. They are short 
oligonucleotides (18-22 nucleotides) involved in multiple pathways related to the 
development and differentiation of cells, and in the pathogenesis of cancer [282]. These 
molecules are misregulated in cancer, being up or down-regulated depending on miRNA and 
cancer type. For example, the downregulation of the pigment-cell-enriched miRNA-211 was 
detected in melanoma cells and it has been associated to their invasiveness due to its key role 
in the tumor progression [283]. Thus, this melanoma tumor-suppressing miRNA constitutes 
an important target, being expected to provide therapeutic benefit [282]. Similarly, recent 
evidence revealed that miRNA-21 is overexpressed both in stromal fibroblasts and colorectal 
cancer cells, enhancing the tumor cells invasiveness. However, despite the important outcome 
expected by using miRNA to regulate tumor progression in vivo, their biological effect 
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depends on the development of cell-specific delivery approaches that are currently 
underexplored [284, 285]. As it was mentioned for siRNA, nanocarriers are promising 
systems to overcome cellular barriers and modulate intracellular trafficking to increase their 
bioavailability in the cytoplasm [269, 286]. 
 
Figure 3: Examples of promising targets within tumor microenvironment to tackle an integrative and combined 
immune-mediated anti-tumor effect. A) In tumor microenvironment (TME), cancer cells overexpress VEGF. 
This growth factor is one of the major contributors to angiogenesis, which allows the tumor progression and 
metastasis; B) DC and tumor cells overexpress TGF-β1 in TME which influence all leukocyte populations; C) In 
lymph nodes, the immune-checkpoint receptors CTLA-4 and PD-1 play important roles in cancer progression, 
inhibiting T cell activation; D) in TME, the latter also contribute to the inhibition of T cell activation. Examples 
of promising targets within tumor microenvironment to tackle an integrative and combined immune-mediated 
anti-tumor effect. 
 
5. Translation of peptide-loaded nanosystams into the market 
It has long been recognized that nanomedicines could significantly benefit transversely 
all pharmaceutical areas. The broad applicability of the nanotechnology in areas where 
significant biomedical advances were obtained, explains why nanomedicines have emerge as 
a promising tool for developing more effective pharmaceutical products. The substantial role 
of nanotechnologies has been confirmed by the number of filled patents in the biomedical 
field [154, 287]. In fact, the significant repercussions in the future of patients’ access to 
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innovative therapeutic strategies will only be possible by pursuing industrial property 
strategies, including inventions, patents, trademarks, industrial designs, and geographic 
indications of source.  
Higher targeted specificity, superior efficiency in the clinical outcomes and a better 
understanding of the role, modulation and regulation of the pathophysiology dynamics at the 
molecular level, could enable nanomedicines to achieve a disease control with an 
unprecedented precision. Even though, no particulate-based cancer vaccines have been 
registered for clinical usage. 
From a technological point of view, the lack of control of nanomaterials’ intrinsic 
properties and formulation process, especially related to the random conjugation of those high 
affinity ligands to nanocarrier surface, constitute an important drawback responsible for NP’ 
low reproducibility and consequent limited translation into clinical use. The need for a 
detailed characterisation of NP-cell interaction has thus been increasingly recognized within 
research community and pharmaceutical companies as a crucial step to provide efficient drug 
delivery, avoiding its future failure in clinical settings [154, 155].  
An important part of the strategy has to take into consideration the appropriate 
identification of relevant disease-specific targets. Relevance has to be brought from the 
clinical setting pointing to specificity in disease stage and disease evolution, both from 
pathophysiological and cellular perspectives. A better integration of physiological dynamics 
with molecular accuracy of delivery systems is therefore needed. 
A significant lesson arises therefore from the need of better integration between 
clinical and basic research teams, preferably in an adequate oncology clinical setting. 
From a quality perspective, linking chemistry characterization and biological 
relevance, as well as updated production technologies (incorporating quality by design (QbD) 
strategies) are essential for paving the way for process analytical technologies (PAT) and 
more efficient industrial production lines. 
 
6. Conclusions and future perspectives 
Besides the strong demand to develop vaccines to address unmet clinical needs, the 
novel nanotechnology-based platforms have important underexplored challenges for drug 
delivery researchers, industry and government agencies [155]. Experimental design and risk 
analysis are central to provide the necessary requisites for accessing vaccine quality and 
safety to reduce to a minimum the product quality variations, but also any risks to the targeted 
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population (short and long term). Highly interconnected with this is the need to incorporate 
high-throughput methods coming from the PAT palette to allow a real-time and highly 
efficient control of possible changes in product(s) quality. These PAT devices are based on 
different concepts, as the use of Dynamic Light Scattering (DLS) and Quartz Crystal 
Microbalance with Dissipation Monitoring (QCM-D) for protein folding and aggregation 
monitoring, efficient robust total particle quantification techniques, characterization of ligands 
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Nanoparticles (NP) have great potential as advanced delivery systems for cancer 
immunotherapy. PEGylated-Poly-lactide-co-glycolic acid-based (PLGA-PEG) NP were 
prepared by double-emulsion solvent evaporation technique, using ovalbumin (OVA) as a 
model antigen. Glycol chitosan and block co-polymer Pluronic F127 were used in order to 
best attain the most efficient parameters for cancer immunotherapy. OVA-loaded PLGA-PEG 
NP presented a narrow size distribution with an average size of 167 nm with a polidisperity 
index (PDI) 0.167 and ζ potential values close to neutrality (-1.66 mV), which is desired for a 
particulate cancer vaccine to overcome their premature capture by macrophages. The 
encapsulation efficiency (EE) and loading capacity (LC) of these NP were 57.5 % and 29 
µg/mg, respectively. PLGA-PEG NP modified with Pluronic F127 presented slightly higher 
average size (180 nm with a PDI 0.18), and ζ potential (-1.78 mV), but lower EE and LC (32 




Keywords: nanoparticles; PLGA-PEG; Pluronic F127; ovalbumine; dendritic cells. 
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1. Introduction 
Breast cancer is one of the most commonly diagnosed malignancies, being thus the 
leading cancer-related cause of death among women worldwide [1]. The conventional forms 
of treatment do not specifically target this tumor cells, leading to adverse effects that heavily 
decrease patient’s quality of life. Therefore, there is an urgent and critical need for new 
therapeutic strategies against this disease. Therapeutic cancer vaccines are used to overcome 
host immunosupression, mostly induced by tumor cells. Nanomedicine-based systems have 
been emerging as promising tools to promote tumor associated antigens (TAA) recognition, 
capture and presentation by professional antigen presentation cells (APC), leading to an 
extensive, specific and long-lasting immune response, while the parenteral administration of 
soluble antigens would be rapidly removed from circulation [2]. A polymeric platform 
consisting on antigen-loaded PLGA-PEG-based nanoparticles (NP) is being developed to 
ultimately deliver breast cancer antigens to dendritic cells (DC) and improve their recognition 
by T cells within tumor microenvironment. This type of NP is appealing due to their 
biocompatibility, biodegradability and low toxicity [3].  
 
2. Materials, Methods and Results 
2.1. Preparation of nanoparticles 
Polymeric NP were aseptically prepared by double emulsion (w/o/w) solvent 
evaporation method, described elsewhere4. Briefly, PLGA-PEG polymer was dissolved in 
dichloromethane (DCM) and emulsified by sonication (Sonifier Vibracell VC 375, Sonics & 
Materials Inc, USA) under continuous conditions for 15 s at 70 W with a glycol chitosan (CS) 
solution that contained OVA (5% wOVA/wpolymer). A surfactant solution (internal aqueous 
phase; IP) was added to this o/w single emulsion and a second sonication was performed 
under the same conditions. The double emulsion w/o/w was added dropwise to a surfactant 
solution (external aqueous phase; EP), and magnetically stirred at 37°C during 1 h for organic 
solvent evaporation, thus enabling the formation of NP. The polymeric NP were harvested 
three times by centrifugation (22000 x g, 45 min, 4˚C; Beckman Coulter, lnc, Avanti® J-E 
Centrifuge JA-20, USA), and washed with ultrapure water to remove excess of surfactant and 
non-encapsulated antigen. NP were dispersed in phosphate buffered saline (PBS pH 7.4) and 
kept at 4˚C until analysis. Three groups of formulations were defined, depending on the 
nature of the surfactant used to stabilize both primary and second emulsions: i) sodium 
cholate as a surfactant in both IP and EP; ii) PVA in both IP and EP and iii) PVA in IP and 
Pluronic F127 (PF127) in EP.  
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Table 1: Composition of nanoparticles. 
Formulation Aqueous phase Surfactant IP* Surfactant EP** 
NP_1b CS ,PBS 1 % (w/v) Na-cholate 0.3 % (w/v) Na-cholate 
NP_2b CS ,PBS 2 % (w/v) Na-cholate 0.3 % (w/v) Na-cholate 
NP_3b CS, PBS 1 % (w/v) PVA 0.3 % (w/v) PVA 
NP_4b CS, PBS 2 % (w/v) PVA 0.3 % (w/v) PVA 
NP_4OVA CS, OVA 2 % (w/v) PVA 0.3 % (w/v) PVA 
NP_5b CS, PBS 4 % (w/v) PVA 0.3 % (w/v) PVA 
NP_5OVA CS, OVA 4 % (w/v) PVA 0.3 % (w/v) PVA 
NP_6b CS, PBS 10 % (w/v) PVA 0.3 % (w/v) PVA 
NP_6OVA CS, OVA 10 % (w/v) PVA 0.3 % (w/v) PVA 
NP_7b CS , PBS 2 % (w/v) PVA 0.3 % (w/v) PF127 
NP_8b CS , PBS 4 % (w/v) PVA 0.3 % (w/v) PF127 
NP_8OVA CS, OVA 4 % (w/v) PVA 0.3 % (w/v) PF127 
NP_9b CS, PBS 10 % (w/v) PVA 0.3 % (w/v) PF127 
NP_9OVA CS, OVA 10 % (w/v) PVA 0.3 % (w/v) PF127 
* internal phase, ** external phase 
 
OVA-loaded NP were prepared with a loading of 5 % wOVA/wpolymer. All formulations 
described in Table 1 were prepared using PLGA-PEG polymer and 1 % (wCS/wpolymer) CS in 
aqueous IP.  
 
2.2. Physicochemical characterization of nanoparticles 
NP mean size and polidispersity index (PDI) were determined by Dynamic Light 
Scattering (DLS) using the Malvern Nano S (Malvern Instruments, UK). NP surface charge in 
PBS (pH 7.4) was inferred from the determination of ζ potential that was assessed by Laser 
Doppler Velocimetry (LDV) with Malvern Nano Z (Malvern Instruments, UK). All 
measurements were performed in triplicate (Table 2).  
 
Table 2. NP physicochemical properties. (Mean ± SD; n ≥ 3) 
Formulation Size (nm) PDI ζ ptential (mV) 
NP_1b NA Flocculated system NA 
NP_2b NA 2 % (w/v) Na-cholate 0.3 % (w/v) Na-cholate 
NP_3bƚ 330 ± 2 0.239 ± 0.03 0.081 ± 0.87 
NP_4b 263 ± 15 0.266 ± 0.021 -1.21 ± 0.87 
NP_4OVA 247 ± 9 0.250 ± 0.012 -1.77 ± 0.80 
NP_5b* 150 ± 9 0.166 ± 0.030 -1.27 ± 1.05 
NP_5OVA* 167 ± 13 0.171 ± 0.022 -1.66 ± 0.79 
NP_6b* 194 ± 17 0.162 ± 0.028 -0.90 ± 0.62 
NP_6OVA* 227 ± 18 0.254 ± 0.032 -1.05 ± 0.82 
NP_7b 360 ± 30 0.363 ± 0.043 -0.95 ± 0.49 
NP_8b* 159 ± 9 0.189 ± 0.036 -1.17 ± 0.54 
NP_8OVA* 180 ± 6 0.180 ± 0.019 -1.78 ± 0.93 
NP_9b 219 ± 18 0.183 ± 0.003 -0.060 ± 0.21 
NP_9OVA NA Flocculated system NA 
*n = 9; ƚn = 2 
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Overall, NP formulations were required to comply with two conditions: i) NP should 
present a mean size between 50 and 200 nm with a PDI below 0.2 and ii) NP surface charged 
should be close to neutrality, owing to lower toxicity and prevention of their premature 
phagocytosis by macrophages in circulation. 
Formulations were divided into three groups based on the nature of the surfactant used 
to promote the stabilization of the double emulsion (w/o/w). The first group of formulations 
was developed using sodium cholate as a surfactant of both IP and EP. However, the system 
was not stable, due to the increased viscosity of the IP. Sodium cholate was not strong enough 
to lower the surface tension between organic and aqueous phases, and the coalescence of the 
droplets of this emulsion occurred immediately after its preparation. As a result, sodium 
cholate was replaced by the nonionic surfactant PVA, which is a strong colloidal stabilizer. In 
this second group, different concentrations (1, 2, 4 and 10% w/v) of surfactant on IP were 
used in order to assess its effect on NP physicochemical properties. Accordingly, higher 
concentrations of PVA have generally potentiated emulsion stability and thus the size of both 
plain and antigen-loaded NP decreased when higher concentrations of surfactant were used to 
emulsify aqueous and organic phases (Table 2). Moreover, the results also show that higher 
surfactant concentrations decreased NP polidispersity. On the other hand, OVA-loaded NP 
prepared with 4% (w/v) PVA solution had a average size significantly higher than NP without 
encapsulated antigen (P = 0.074). Based on these results, the 4% (w/v) PVA solution used in 
NP formulation also promoted the formation of a nanoparticulate population with lower 
polidispersity values. However, when higher amount of PVA (10% (w/v)) was used as IP, the 
NP size was higher by 50 nm than that presented by NP prepared with 4% (w/v) PVA 
solution (Table 2). This increase in average size occurred due to the higher viscosity of the 
10% (w/v) PVA solution used as IP, leading to system instability having in consideration the 
small volume of this phase. All of these NP had ζ ptential close to neutrality, between -1.8 
and 0.08 mV. However, ζ ptential of antigen-loaded NP was slightly lower, due to the fact 
that OVA is a negatively charged protein at pH 7.4, and if absorbed on the surface of particles 
can influence NP surface charge. 
In the third group of NP formulations, PF127 was used as a surfactant in the EP (0.3% 
w/v) and different concentrations of PVA were tested as IP (2, 4, 10% w/v). These NP 
showed a similar trend as the second group. With increasing concentrations of surfactant in 
the IP (Table 2), plain NP showed lower mean diameters. Formulations obtained using 4% 
(w/v) of PVA solution (NP_8b and NP_8OVA) presented the best parameters among all 
formulated particles within this group. Those plain NP had an average size of 159 nm with 
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PdI of 0.19, and ζ ptential of -1.17 mV; while NP containing OVA presented a mean diameter 
of 180 nm, PdI of 0.18, and ζ ptential of -1.78 mV. Moreover, ζ ptential of antigen-loaded NP 
is slightly more negative, owing to the charge of the protein. Interestingly, when 10% (w/v) 
PVA solution was used (NP_9OVA), the system flocculated. This is likely due to the 
interactions between OVA, PF127 and increased concentration of PVA. However, this 
instability was not observed for plain particles (NP_9b), even if they showed higher mean 
diameter in comparison to the formulation prepared with 4% (w/v) PVA solution.  
Overall, formulated nanosystems are expected to be suitable for parenteral 
administration and for the adjuvant effect needed to enhance host immune response, being 
possible to predict their extensively uptake by APC, namely DC [4]. 
 
2.3. Antigen loading 
The amount of encapsulated protein OVA was quantified indirectly by the 
MicroBCATM assay [5]. Supernatants from each centrifugation were collected in triplicates. 
Plain NP were used as controls. The absorbances were determined using a Fluostar Omega 
microplate reader (BMG LAbtech, Germany) and cthe entrapment efficiency (EE% (w/w), 
Eq. (1)) and the loading capacity (LC µg/mg, Eq. (2)) of protein were calculated.  
 
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝐸𝐸 % = !"!#!$% !"#$%& !" !"#$% – !"#$%& !" !"#$% !" !!! !"#$%&'('&(
!"!#!$% !"#$%& !" !"#$%
 ×100                        (1) 
 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦 𝐿𝐶 µ𝑔 𝑚𝑔 = !"!#!$% !"#$%& !" !"#$% – !"#$%& !" !"#$% !" !!! !"#$%&'('&(
!"!#$ !"#$%& !! !"#$%&'
                        (2) 
 
Table 3. EE (%) and LC (µg/mg) of protein in formulated NP. (Mean ± SD; n ≥ 12) 
Formulation EE% (w/w) LC (µg/mg) 
NP_4OVA 44.5 ± 1.6 22.24 ± 0.82 
NP_5OVA 57.5 ± 13.2 28.77 ± 6.61 
NP_6OVA 59.4 ± 6.2 29.69 ± 3.10 
NP_8OVA 31.8 ± 4.0 15.87 ± 1.10 
*n = 3 
CS polymer is able to protect biomolecules not only during particle formulation 
process, but also throughout release in physiologic media. The higher viscosity that is 
expected for IP after its dissolution may decrease the interaction between proteins and the 
interface of droplets of the primary (w/o) emulsion, promoting the maintenance of their 
structure and activity, as well as, enhancing NP LC by preventing protein leakage to the 
external aqueous phase. PLGA-PEG NP prepared using CS dissolved in 2% (w/v) PVA 
solution (NP_4OVA) presented an EE of 44.5% and a LC of 22 µg/mg. Higher concentration 
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of emulsifier (PVA) in the IP increased NP EE and thus led to higher LC (57.5% and 29 
µg/mg for those formulated with 4% (w/v) PVA solution (NP_5OVA) and 59% and 30 µg/mg 
for 10% (w/v) PVA solution (NP_6OVA) as IP. It is important to emphasize however that the 
EE and LC obtained for those formulations were not statistically different, suggesting that the 
concentration of the emulsifier (PVA) and its increase from 4% (w/v) to 10 % (w/v) in the IP 
phase does not significantly contribute to higher entrapment efficiencies (P > 0.05). However, 
NP prepared with lower amounts of PVA in the IP (2% (w/v) PVA) showed significatively 
lower EE and LC. 
In addition, when PVA was replaced by PF127 in EP (NP_8OVA), only 32% (w/w) of 
protein was found to be associated to polymer matrix (Table 3). This shows that the co-
polymeric surfactant PF127 allowed an extensive leakage of OVA to this external phase 
probably due to its lower ability to decrease free energy at this specific emulsion droplets 
interface. 
 
2.4. Evaluation of protein integrity by SDS PAGE  
The assessment of protein integrity was determined by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) using MW markers (Sigma MarkerTM, 6.5-
200 kDa) and OVA standard solution (250 µg/ml) as controls [5]. Protein band patterns of 
migration obtained for OVA standard solution and those extracted from loaded NP 
(NP_OVA) are identical, suggesting that protein molecular weight had not be affected by NP 
formulation process. Additionally, these observations are corroborated by the absence of 
those bands at 45 kDa for control NP (NP_blank). 
 
2.5. In vitro cell viability assay 
The cytotoxicity of PLGA-PEG NP was inferred by the determination of cell viability 
using AlamarBlue® assay that was performed on immature murine DC (JAW SII). This cell 
line was incubated with increasing concentrations of three different PLGA-PEG-based NP: (i) 
NP with CS and PVA in IP and EP, (ii) NP with CS and PVA in IP and PF127 in EP, and (iii) 
NP without CS and with PVA in IP and PF127 in EF. DC viability was not affected by any 
type of NP.  
These results support the safety and biocompatibility of PLGA-PEG and CS polymers 
used in the formulation of these polymeric NP [6-9]. It reinforces the fact that the organic 
solvent used in the formulation process might have been completely evaporated during the 
evaporation time, as verified previously in our laboratory [10], and thus no toxic residues 
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remain in NP. Also the excess of surfactants used in NP formulation might have been 
completely washed at the final stage of production process where three centrifugations and 
washings were performed. The presence of PEG on the surface of NP might also contribute to 
the absence of a cytotoxic effect, as this polymer is highly biocompatible due to its high 
hydrophilicity and due to particle surface charge close neutrality [11]. 
 
3. Conclusions 
From NP physicochemical properties, LC and effect on cell viability we can conclude 
that the most promising formulations are NP_5 and NP_8. NPs within this size range are 
expected to stay longer time in circulation and be efficiently taken up by DC enhancing cross-
presentation in mice. Moreover their average sizes and surface charge may prevent their 
premature capture by macrophages and also increases their ability to promote a tumor specific 
immune response. Having in consideration the results herein described, it is possible to state 
that the developed PLGA-PEG-based NP constitute a promising platform for the delivery of 
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The major goal of this study was to demonstrate the complexity of developing a 
reproducible and stable colloidal nanoparticulate suspension with the desired physicochemical 
properties for an efficient immune cell targeting and activation. By controlling various 
parameters of the formulation process, the average size, polydispersity index, ζ potential, 
encapsulation efficiency and loading capacity were optimized to obtain highly reproducible 
Polyethylene glycol (PEG)-grafted poly(lactic-co-glycolic acid) (PLGA)-NP nanoparticles 
presenting the targeted features for the successful modulation of immune cells’ activity. 
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Recent advances in the fields of immunology and molecular oncology, combined with 
the knowledge raised from clinical and translational studies have provided deeper insights 
into the interaction between cancer and immune cells. Consequently newer forms of cancer 
treatments have been devised, including promising immunotherapeutic approaches [1]. These 
developments within tumor immunology have stemmed from the identification of tumor 
associated antigens (TAA) overexpressed in these malignant cells. Efficacious cancer 
vaccines potentiate the delivery of those TAA to dendritic cells (DC) to ultimately improve T 
cell efficiency within tumor microenvironment towards the induction of a specific and long-
lasting anti-tumor immune response [2-4]. The specificity of the induced adaptive immunity 
is highly increased if tumor cells exclusively express those antigens delivered by the vaccine. 
However, these antigens are poorly immunogenic in solution and thus vaccines containing 
these entities generally require the use of potent immunological adjuvants in order to boost 
the anti-tumor immune responses.  
The use of nanomedicine-based systems appears to be a promising strategy to achieve 
a strong and long-lasting immunity against cancer diseases. These carriers have many 
theoretical advantages over other conventional therapies like low toxicity, possible targeted 
delivery and thus high specificity. In addition, when used to deliver antigens, nanoparticles 
(NP) can lead to a continuous anti-tumor effect attributable to the successful induction of an 
immunologic memory. Moreover, it has been shown that the entrapment of both antigens and 
adjuvants by a singular carrier ensured an optimal processing and presentation of epitopes in a 
targeted and prolonged manner [5, 6]. 
The rate and extend of passive targeting towards DC are dictated by NP size, 
geometry, surface charge, hydrophobicity and hydrophilicity [7, 8]. 
NP size influences their endocytic pathways in antigen presenting cells (APC) and 
thus their accumulation and degradation [9]. Particles below 200 nm are usually transported 
through lymph drainage to lymph nodes (LN), where they are internalized by immature DC 
via classic clathrin-mediated endocytosis and tend to generate both cytotoxic T lymphocytes 
(CTL) and T helper (Th)1 immune responses [10-13]. Furthermore, NP within this size range 
are known to avoid the reticuloendothelial system (RES), such as liver and spleen, presenting 
then a prolonged circulation time in blood [14]. 
On the other side, larger NP (>0.5 µm) require peripheral immature DC and active 
cellular migration to the draining LN, where micropinocytosis occurs. This will preferentially 
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generate an immune response based on the activation of Th2 cells and production of 
antibodies [15, 16].  
Furthermore, spherical-shaped NP display higher cellular uptake compared to non-
spherical counterparts [17]. A number of studies have shown that positively charged NP 
present extended internalization profiles due to their ionic interactions with the negatively 
charged cell membrane [18-20]. Hence, negatively charged and neutral NP preferentially co-
localize within the acidic pH at lysosomes, while positively charged NP could escape, being 
thus released into cell cytoplasm [21, 22]. Surface charge of NP mainly depends on the 
chemical nature of the polymer and stabilizing agent [23]. 
The poly(lactic-co-glycolic acid) (PLGA)-based NP are promising tools for the 
modulation of immune cells’ activity. The properties of this aliphatic polyester polymer can 
be manipulated in order to control antigen release towards its extensive capture and prolonged 
presentation, promoting the expansion of effector T cells [24, 25].  
Aliphatic copolymer PLGA is negatively charged at pH 7.4. Therefore, PLGA NP 
become positively charged in the endosomal and lysosomal compartments, due to their acidic 
pH, being thus released into the cytosol, where the antigen cross-presentation through the 
major histocompatibility complex (MHC) class I pathway promotes the generation of CTL 
[20, 26-28]. However, surface charge of aliphatic polyester-based NP can be easily shifted to 
the neutral or positive charges by using PEG-coated polymers or adding cationic polymers, 
such as chitosan (CS) [29-31]. All these advantages listed above make aliphatic polyester-
based NP a promising cancer immunotherapeutic strategy.  
The major goal of this work was the development of a colloidal suspension of 
polyethylene glycol (PEG)-grafted PLGA-NP for the passive targeting of APC, preferentially 
DC. Having in consideration previous evidences related to the interaction of nanocarriers with 
phagocytic cells, NP composition and formulation process were optimized in order to obtain 
NP with mean size below 200 nm, neutral surface charge and spherical shape. Nanosystems 
were developed by the double-emulsion solvent evaporation technique, using α-lactalbumin 
(LALBA) as an antigen. Other polymers (glycol CS, polyvinyl alcohol (PVA) and block co-
polymer Pluronic® F127 (PF127)) were used in order to best attain the most efficient 
parameters for an optimal antigen delivery to APC. This chapter particularly explored the 
impact of surfactant physical and chemical properties, and concentration on the characteristics 
of those PLGA-PEG- NP, including batch stability. The optimal NP will be selected for in 




2. Materials and methods 
2.1. Materials 
Poly(lactic-co-glycolic acid) (PLGA) conjugated with polyethylene glycol (PEG), i.e. 
PLGA-PEG (5050 DLG mPEG 5000, 10 wt % PEG, molecular weight (MW) = 17 kDa), 
Alpha-lactoalbumin (LALBA, average MW = 14 kDa), Polyvinyl alcohol (PVA, MW = 13-
23 kDa) with hydrolyzation 87-89 %, Pluronic® F127 (PF127, MW = 12.6 kDa), Glycol 
Chitosan (CS), and Dichloromethane (DCM) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). All other chemicals and reagent used in the study were of analytical grade.  
Dulbecco’s Phosphate Buffered Saline (PBS) (1×) was purchased to Life 
Technologies (Carlsbad, CA, USA).  
Double distilled water was used after filtration in a Millipore® (Millipore, Billerica, 
MA) system. 
 
2.2. Preparation process of PLGA-PEG nanoparticles 
Biodegradable polymeric NP were prepared by the state of the art double emulsion 
solvent evaporation technique (w/o/w) [32], with specific modifications. This method is based 
on the emulsification of an aqueous phase into an organic polymeric solution, where NP result 
from single volume shrinkage of the initial emulsion droplet by ultrasonication. Accordingly, 
the aqueous solutions containing the antigen LALBA dispersed in PVA solutions at different 
concentrations (2, 4, 6, 8, 10, 12 or 14 % (v/v)) were added to the PLGA-PEG polymer 
solutions (50 mg/ml in DCM) and emulsified using an ultrasonic processor for 15 s at 70 W. 
A second emulsion was performed with 2 % (w/v) PVA aqueous solution under the same 
conditions. The double emulsion w/o/w was added dropwise to a surfactant solution 
containing 0.3 % (w/v) PVA or Pluronic F127 (PF127), the external aqueous phase (EP), and 
stirred at 37 °C for 1 h. The NP suspension was then washed twice with ultrapure water by 
centrifugation at 22000 × g for 45 min, 4 °C (Beckman Coulter Avanti® J-E Centrifuge JA-
20) and finally re-suspended in phosphate buffered saline (PBS pH 7.4) and kept at 4 ˚C until 
further analysis. 
 
2.3. Particle size and ζ potential analysis 
NP size and polydispersity index (PDI) were determined by Dynamic Light Scattering 
(DLS) using the Malvern Nano S (Malvern Instruments, UK). Briefly, the final 20 mg/ml NP 
suspension was diluted to 1 mg/ml in PBS pH 7.4. Nanoparticles’ surface charge was inferred 
by their ζ potential assessed by Laser Doppler Velocimetry (LDV) with Malvern Nano Z 
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(Malvern Instruments, UK). Each analysis was carried out in triplicate at 25 °C. The 
conditions were kept constant in order to have comparable results. 
 
2.4. Protein loading assay 
The supernatants obtained from NP centrifugation were collected and the entrapment 
efficiency (EE, %) and the loading capacity (LC, µg/ml) of proteins were quantified indirectly 
by a reverse-phase high-performance liquid chromatography (HPLC) (RP-HPLC) using 
Beckman System Gold: UV-Vis detector (Beckman 166) at 220 nm, Beckman 126 solvent 
module and Midas autosampler. Samples (20 µl) were injected onto a Shodex Protein KW-
803 series column (8.0 mm ID x 300 mm, 5 µm particle size, 300 Å pore size) and eluted with 
50 mM sodium phosphate buffer (pH 7.0) plus 0.3 M NaCl at 1 ml/min for 16 min at room 
temperature. Plain NP were used as controls and all measurements were performed in 
triplicate. The amount of protein in each sample was calculated using a linear standard curve 
generated in the range of 0.5 – 5.0 mg/ml, r2 = 0.9987. The EE (%) and the LC (µg/mg) of the 
protein were calculated as indicated in Equations 1 and 2. 
 
𝐸𝐸 % =  !"!#!$% !"#$%& !" !"#$%&"!!"#$%& !" !"#$%&" !" !"#$%&'('&(
!"!#!$% !"#$%& !" !"#$%&"
 𝑥 100                                                    (1) 
 
𝐿𝐶 µ𝑔 / 𝑚𝑔 = !"!#!$% !"#$%& !" !"#$%&"!!"#$%& !" !"#$%&" !" !"#$%&'('&(
!"!#$ !"#$%! !" !"#$%&'
 𝑥 100                  (2) 
 
2.5. Determination of residual surfactant at nanoparticle vaccine 
Surfactant washing efficiency was indirectly quantified HPLC using Beckman System 
Gold: UV-Vis detector (Beckman 166), Beckman 126 solvent module, Midas autosampler, 
and Shodex Protein KW-803 column (8.0 mm ID x 300 mm, 5 µm particle size, 300 Å pore 
size). The PVA washing efficiency was calculated as the percentage of PVA quantified in 
supernatants comparing to the total amount of surfactant used for NP formulation. 
 
3. Results 
The NP size distribution and surface charge are key parameters for carrier 
biodistribution and fate. In addition, the NP size also influences their EE and LC [10, 18, 25]. 
The major goal of this study was to develop NP smaller than 200 nm with uniform size 





Table 1: Composition of tested PLGA-PEG nanoparticles. 








2 % (w/v) PVA, CS, LALBA 
2% (w/v) PVA 0.3 % (w/v) PVA 
F2 4 % (w/v) PVA, CS, LALBA 
F3 6 % (w/v) PVA, CS, LALBA 
F4 8 % (w/v) PVA, CS, LALBA 
F5 10 % (w/v) PVA, CS, LALBA 
F6 12 % (w/v) PVA, CS, LALBA 




2 % (w/v) PVA, CS, LALBA 
2% (w/v) PVA 0.3 % (w/v) PF127 
F9 4 % (w/v) PVA, CS, LALBA 
F10 6 % (w/v) PVA, CS, LALBA 
F11 8 % (w/v) PVA, CS, LALBA 
F12 10 % (w/v) PVA, CS, LALBA 
F13 12 % (w/v) PVA, CS, LALBA 
F14 14 % (w/v) PVA, CS, LALBA 
* internal phase, ** external phase 
 
 
All formulations described in Table 1 were developed using 0.5 % (wCS/wpolymer) CS 
solution and 2.5 % (wLALBA/wpolymer) LALBA solution in the aqueous phase. For each 
formulation, blank NP were formulated as controls. 
 
Figure 1: Circles (●) are for all the formulation (F1-F7), developed with PVA in the EP. Triangles (▲) are used 
for all formulations (F8-F14) prepared with Pluronic as EP. Average size (A), poydispersity index (PdI) (B), ζ 
potential (C), entrapment efficiency (EE) (D), loading capacity (LC) (E) and percent of washed PVA (F) were 
determine for all PLGA-PEG NP. All results are expressed as mean ± SD of three independent experiments of 3-




Various concentrations of PVA (2, 4, 6, 8, 10, 12 and 14% (w/v)) in the IP were tested 
to produce highly reproducible and stable NP, with the required physicochemical properties 
for DC targeting. The targeted NP size, surface charge and PDI were achieved with 
formulations F5 & F12. Even though, the effect of PVA higher concentrations in the IP on NP 
parameters and suspension overall stability was further evaluated.  
PVA concentration influenced the average size of formulated NP and their EE (Figure 
1). DLS results were recorded in triplicate (n = 3) of at least three independent batches of NP 
formulations (Figure 1). DLS studies yielded consistent and reproducible results. It is 
observed that higher concentrations of the PVA in aqueous phase led to smaller NP and lower 
PDI. The highest decrease on the average mean diameter of NP was determined when PVA 
concentration in the aqueous phase ranged from 2 % (w/v) to 4 % (w/v). However, NP with 
size bellow 200 nm were only obtained when the concentration of PVA was at least 8 % (w/v) 
in the primary aqueous phase (Figure 1A). PDI of the formulation F11 was still higher than 
0.2 (Figure 1B), and therefore out of the targeted specifications.  
ζ potential was determined by LDV of all formulated batches of NP (from F1 to F14). 
It was slightly positive (Figure 1C) but close to neutrality, despite the nature of the surfactant 
used at the external phase (PVA or PF127). This could be due to the PEG–chains expected to 
be on the surface of the NP and also to the presence of positively charged CS dispersed within 
the nanoparticulate matrix.  
It is also possible to infer that smaller NP with low PDI, led to higher antigen EE and 
LC (Figure 1D & E), both validated by HPLC method. The best EE was determined for 
formulations F5, F6, and F7, being close to 80 %. Lower EE were presented by F12, F13, and 
F14 NP prepared with PF127 in EP, being close to 70 %.  




In this study we focused on the design of reproducible batches of NP vaccines with 
desirable physicochemical characteristics. To achieve this goal, it is important to understand 
the physical and chemical properties of raw materials and correlate those with critical 
parameters within formulation process. 
A significant amount of research has been conducted on numerous nanoparticulate 
systems, which show that physical and chemical properties of NP are crucial for their 
biological outcome as delivery system [11, 33]. 
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In this study, we developed and precisely characterized different nanoparticulate 
delivery systems for the systemic delivery of a protein antigen to DC, the key APC with a 
determinant role in the stimulation and enhancement of T cell immunity. Consequently, 
having in consideration previous evidences, we aimed to develop a highly stable and 
reproducible colloidal suspension of NP smaller than 200 nm with narrow size distribution, 
and ζ potential close to neutrality.  
LALBA was selected as a model antigen to be associated to the modified DC-targeted 
polymeric NP. LALBA is a breast specific differentiation protein expressed at high levels in 
the majority of human breast carcinomas [34], expressed in 67 % of primary mammary 
carcinomas and in 62 % of their metastases, including lymph nodes, bone, liver, lung, skin, 
and subcutaneous tissue. In contrast, it is present only in mammary epithelial cells during 
lactation [34-36]. Due to its characteristics it is a perfect target for anti-cancer 
immunotherapeutic approach.  
The aliphatic polyester copolymer PLGA-PEG has been chosen not only due to its 
biodegradable and biocompatible characteristics, but especially having in consideration the 
expected exposure of PEG chain at the surface of the resultant nanocarrier [7, 25]. The 
PEGylated layer will overcome the negative charge of PLGA carboxylic groups, leading to 
neutral nanoparticulate surfaces. PLGA-PEG NP are expected to present PEG-chains oriented 
towards the external aqueous phase, which will act as a barrier, by suppressing the adsorption 
of serum proteins and reducing the extent of cell recognition by steric and hydrated repulsion, 
leading to an enhanced shelf stability [37, 38]. It has been shown that the protein repellant 
ability of PEG-containing surfaces depends on PEG chain molecular weight, interfacial 
density and architecture [39]. Moreover, different works have evidenced that Pegylated 
PLGA NP presented smaller average size in comparison to the non-PEGylated ones. All of 
these parameters resulted in better release kinetics and reduction of systemic clearance rates in 
vivo, and prolonged the circulation time of formulated NP [30]. 
The production of the PLGA-PEG di-block (10% PEG with 5 kDa) co-polymer by 
Boehringer Ingelheim (Germany), used in chapter 2, was interrupted and therefore it was 
necessary to choose a different supplier. In fact, anticipating the possible changes in the 
properties of this polymer when produced by another company, it was necessary to ensure 
that a considerable amount would be available for the future studies. New PLGA-PEG 
polymer was thus purchased from Sigma-Aldrich and its effect on formulation physical and 
chemical properties was further evaluated. 
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PVA is a commonly used polymeric non-ionic surfactant with a HLB value of 18 [40]. 
Due to its ampiphilic character, it has excellent emulsifying properties, being commonly used 
for stabilization of w/o/w double emulsion at the formation of NP. However, EMA (European 
Medicines Agency) and FDA (Food and Drug Administration) attention has been attracted by 
several studies evidencing the possible effect of this surfactant in cell viability. We performed 
an indirect quantification of PVA by HPLC to determine the surfactant washing efficiency. 
Our data attested the successful removal of this surfactant.  
PF127, on the other hand, is a triblock copolymer (polyoxyethylene-block–
polyoxypropylene-block-polyoxyethylene; PEO-b-PPO-b-PEO), being the most 
cytocompatible polymer among the Pluronics. Thus, it has been widely applied in a variety of 
pharmaceutical formulations due to its surfactant (HBL value between 18 and 23) and protein 
stabilizing properties [41]. In our studies, PF127 was used to develop an alternative 
formulation with possible improved mechanisms of interaction in vitro and in vivo with 
immune cells. 
The PVA surfactant concentration in IP dictated NP average mean diameter, PDI, ζ 
potential, EE and LC. All of the above mentioned parameters were monitored in order to 
select the best formulation composition.  
NP based on the PLGA-PEG polymer, now supplied by Sigma Aldrich, were firstly 
developed using 2 and 4 % (w/v) PVA surfactant concentration in the internal aqueous phase 
(IP), as this was the concentration previously used with polymer perches from Boehringer 
Ingelheim (Chapter 2). The average size of these NP was not comparable to the previous ones 
obtained for NP developed in Chapter 2. Formulations F1 and F8 presented an average size 
above 300 nm when using 2 % (w/v) PVA, while it was dramatically increased in formulation 
F2 when a 4 % (w/v) PVA solution was used in the IP. However, this trend was not observed 
for formulation F9 when PF127 was used as a stabilizer of EP. 
Having in consideration these results regarding NP size and low reproducibility, as 
anticipated, it was necessary to optimize the formulation by testing various concentrations of 
PVA (2, 4, 6, 8, 10, 12 and 14% (w/v)) in the IP, to produce highly reproducible and stable 
NP, with the required physicochemical properties for DC targeting.  
Overall, NP presented neutral ζ potential, while DLS studies showed that higher 
concentration of the PVA surfactant in the IP led to lower particle size and size distribution. 
Moreover, NP with smaller size and PDI, resulted in more stable colloidal nanoparticulate 
suspensions and thus favored the entrapment of the model antigen. The highest EE was 
obtained for the formulations F5, F6 and F8, being close to 80 %. When using PF127 in the 
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EP, the EE was 70 % (F12, F13, and F14). However, the developed NP presented EE higher 
than those reported in recently published studies, despite the nature of surfactant present at the 
EP [27, 42, 43]. 
High EE and LC were also related to the presence of CS in the IP. CS increases the 
viscosity of this aqueous phase [44, 45] and it is also expected to potentiate protein 
entrapment due to the establishment of electrostatic interactions between the negative charge 
of the model protein at PBS pH 7.4 (isoelectric point 4.2) and CS positively charged amines at 
that pH. Both properties may thus be underlying an improved physical and chemical stability 
of the internal phase, and thus to the higher EE and LC obtained for NP prepared using CS in 
the IP (Figure 1).  
Overall, according to these results, the physicochemical properties of developed 
PLGA-PEG NP are composition dependent, as expected. The formulations F5 and F12 best 
meet the criteria enlisted above. Both formulations presented high reproducibility and stability 
with NP smaller than 200 nm, with a uniformed size distribution and high LC and EE. The 
percentage of washed PVA, detected by HPLC, was higher than 97 % for both formulations. 
 
5. Conclusions 
The aim of this study was to develop a nanoparticulate delivery system with optimal 
physicochemical properties to passively target APC, principally DC. A reproducible 
formulation method has been developed using biodegradable and biocompatible aliphatic 
polyester copolymer PLGA-PEG to produce ~175 nm NP with narrow particle size 
distribution and ζ potential close to neutrality. This property constitutes a basic advantage to 
enhance the interaction of a vaccine delivery system with DC, by avoiding their premature 
recognition and capture by macrophages- the first line of body defence. These results 
highlight the importance of NP composition, as expected, as small differences in the 
surfactant concentration can may result in altered and unsuited NP average size, PDI and EE.  
These optimal formulations were selected for further in vitro and in vivo evaluation of 
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Vaccination is a promising strategy to trigger and boost immune responses against 
cancer. Here we designed biodegradable polymeric nanoparticles (NP) using different 
surfactants and polymers for particle stabilization to develop a nanoparticle delivery system 
with unique properties for clinical applications in immunotherapy and to optimize particle 
uptake by specific immune cells.  
We report the design and development of safe and efficacious nanoparticulate 
vaccines including an extensive characterization of physiochemical NP parameters, such as 
average size, ζ potential, loading efficiency, thermodynamic stability, and protein integrity. In 
vitro uptake of these NP by murine bone marrow-derived dendritic cells (DC) was observed 
and quantified by imaging flow cytometry. In vivo activation of DC by NP was analyzed in 
lymph nodes (LN) of immunized animals. Induction of activation markers and upregulation of 
co-stimulatory molecules by specific NP was studied post-immunization. Antigen-specific 
immune responses towards ovalbumin (OVA)-loaded NP were monitored through analysis of 
proliferation and expansion of OVA-specific T cell receptor transgenic CD4+ and CD8+ LN T 
cells. We show how physicochemical properties of particle surfaces, dictated by surfactant 
selection or the antigen association method, can alter fundamental particle properties and 
thereby influence cellular uptake, leading to distinct antigen presentation efficacy and 
resultant antigen-specific responses. 
Our studies highlight the need for comprehensive characterization of NP to optimize 
their use for vaccination strategies. These findings support the notion that the delivery system 
itself is a potential and versatile adjuvant platform. 
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1. Introduction 
Effective immune responses result from a complex interplay between the innate 
(antigen-nonspecific) and the adaptive (antigen-specific) immune cell compartments. 
Dendritic cells (DC) are the most potent antigen presenting cells (APC) and have, owing to 
this property, an important role in translating innate into adaptive immunity. Given their 
capacity to capture and process internalized antigens, DC efficiently prime naive T cells 
against foreign antigens and polarize them towards distinct effector fates [1-3]. Moreover, the 
specific DC subsets and their activation mode after antigen engulfment are pivotal steps that 
control whether clinically relevant responses are dominated by cytotoxic CD8+ T cells, or 
CD4+ T cells with helper activity [4].  
Vaccination protocols that target DC are promising strategies for the initiation and 
enhancement of immune responses for cancer treatment [5, 6], as well as viral and microbial 
infections [7-9].  
Specifically, the concept of the immunotherapeutic vaccination aims to harness the 
patients’ own immune system to specifically target malignant or infected cells by activating in 
vivo immune effectors against specific tumor associated antigens (TAA) or microbes [5].  
Nanoparticulate delivery systems have major potential as immunotherapeutic platform 
towards the tailored and effective targeting of immune cells, which have a pivotal role in 
enhancing the immune response towards a specific antigen. Nanoparticles (NP) can improve 
antigen stability and have high surface to volume ratios, thus improving loading capacity. NP 
often are biocompatible and biodegradable, with tunable sub-cellular size, and a possibility of 
controlled release [10, 11]. NP can therefore extend antigen exposure of immune cells, 
facilitate uptake and antigen access to DC, modulate the antigen presentation pathway, and 
enhance the subsequent antigen-specific immune responses.  
Herein we describe the rational development of different nanoparticulate delivery 
systems with the ability of systemic antigen delivery to DC for potential anti-cancer 
treatment.  
We address the reproducibility and stability of the colloid suspension with the targeted 
physicochemical parameters, by controlling various parameters of the formulation process of 
poly(lactic-co-glycolic acid) (PLGA)-based NP, using alpha-lactalbumin (LALBA) or 
ovalbumin (OVA) as antigens. 
PLGA polymers have been chosen due to their biocompatibility and biodegradable 
properties [12, 13] Under physiological environment, PLGA matrix faces hydrolytic 
Chapter 4 
70 
degradation into the monomeric components, lactic and glycolic acid, [14] both compatible 
with cell proliferation. Pharmaceutical products containing PLGA have already been 
approved by EMA (European Medicines Agency) and FDA (Food and Drug Administration) 
for parenteral use [15, 16]. Poly(ethylene glycol) (PEG) was also used as a carrier surface 
modifier with hydrophilic shielding properties, to increase polymer water-solubility and thus 
biocompatibility, greatly reducing intrinsic immunogenicity and toxicity [17]. LALBA 
protein was selected as targeted vaccine antigen, since this breast specific protein is 
overexpressed in 67 % of primary breast carcinomas and in 62 % of metastatic ones [18-20], 
being only conditionally present in healthy breast tissue at the time of lactation [21, 22]. Thus, 
LALBA meets the criteria for antigen selection in the development of a cancer vaccine [19]. 
OVA is commonly used as a model antigen in preclinical studies and well characterized in 
studies, which focus on specifics of induced immune responses, not the least due the 
availability of OVA-specific T cell receptor (TCR) transgenic mice [23, 24]. 
Antigens can be either adsorbed or entrapped into NP. Entrapment allows stronger 
interaction between these carriers and the antigen, which may lead to prolong and controlled 
antigen release [25]; on the other hand, antigen adsorption based on charged and hydrophilic 
interactions is weaker and therefore antigen is expected to dissociate from the NP surface 
much faster. However, both high entrapment and adsorption strongly depend on the 
physicochemical properties of the nanoparticulate delivery system [26-29].  
To develop a highly stable colloid suspension with the desired specifications for 
optimal vaccination purposes, we optimized the NP composition and formulation procedure in 
order to achieve an average size below 200 nm, ζ potential close to neutrality, high loading 
efficiency, thermodynamic stability, and ensure protein integrity [11, 30, 31].  
This work explores the development of safe and efficacious nanoparticulate vaccines, 
which physicochemical properties were fully characterized in detail. In addition, we evaluated 
NP uptake by DC, both in vitro and in vivo, including effects on activation and maturation of 
these APC, which are critical checkpoints for effective immune responses. We report that 
immunization with antigen-loaded NP results in successful DC stimulation and extensive T 
cell expansion. Most importantly, our well-characterized nanosystem allowed to correlate NP 
functionality with major physicochemical properties, namely presence of antigen at the 
surface or antigen dispersion within the matrix. 
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2. Materials and methods 
2.1. Materials 
Poly(lactic-co-glycolic acid) (PLGA) conjugated with polyethylene glycol (PEG), i.e. 
PLGA-PEG (5050 DLG mPEG 5000, 10 wt % PEG, molecular weight (MW) = 17 kDa), 
Resomer® RG 502 Poly(lactic-co-glycolic acid) PLGA (MW = 7–17 kDa), Alpha-
lactoalbumin (LALBA, average MW = 14 kDa), Ovalbumin (OVA, average MW = 45 kDa), 
Poly(vinil alcohol) (PVA, MW = 13-23 kDa) and hydrolyzation 87-89 %, Pluronic® F127 
(MW = 12.6 kDa), Glycol Chitosan (CS), sucrose and Dichloromethane (DCM) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Double distilled water was used after 
filtration in a Millipore® (Millipore, Billerica, MA) system. All other chemicals and reagent 
used in the study were of analytical grade. 
MW markers for SDS PAGE (Thermo Fisher Scientific, PageRulerTM Prestained 
Protein Ladder 10-180 kDa #SM0671) were purchased from Thermo Fisher Scientific (MA, 
USA).  
The Roswell Park Memorial Institute medium (RPMI 1640), heat inactivated fetal 
bovine serum (FBS), L-glutamine 200 mM, 0.25 % (w/v) Trypsin/ 0.53 mM ethylenediamine 
tetracetic acid (Trypsin-EDTA) solution penicillin/streptomycin (Pen-Strep) 10000 
Unit/ml/10000 µg/ml and AlamarBlue® were purchased from Life Technologies (Carlsbad, 
CA, USA).  
Granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukine-4 (IL-
4) were purchase from PeproTech Inc. (Rocky Hill, NJ, USA). 
The CpG ODN 1826 VaccigradeTM (TCCATGACGTTCCTGACGTT) was 
purchased from the InvivoGen (San Diego, CA, USA). 
Antibodies anti-mouse CD11c (clone: N418), CD11b (clone: M1/70), CD4 (clone: 
CK1.5), CD8α (clone: 53-6.7), I-Ab (MHCII; clone: AF6-120.1), H-2Kb (MHCI; clone: AF6-
88.5), CD45.1 (clone: A20), TCRβ (clone: H57-597), TCRVα2 (clone: B20.1) and 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) were purchased from BioLegend 
(San Diego, CA, USA). 
 
2.2. Mice 
Female OT-I (C57BL/6) TCR transgenic mice harboring OVA-specific CD8 T cells 
[23] and OT-II (C57BL/6) TCR transgenic mice harboring OVA-specific CD4 T cells [24] 
were in-house bred at the Weizmann Institute of Science (Rehovot, Israel), under 
conventional, specific pathogen-free (SPF) conditions. Female C57BL/6 mice (6 - 8 weeks 
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old) were purchased from the Envigo RMS LTD (Jerusalem, Israel). All animals were 
handled according to protocols approved by the Weizmann Institute Animal Care Committee 
(IACUC) as per international guidelines. 
 
2.3. Preparation of NP 
Polymeric NP were aseptically prepared by double emulsion (w/o/w) solvent 
evaporation method [32]. Briefly, the single emulsion (o/w) was formed emulsifying an 
organic solution of the polymer, which was dissolved in dichloromethane (DCM) with an 
aqueous solution (IP) using an ultrasonic processor (Sonifier Vibracell VC 375, Sonics & 
Materials Inc, USA) under continuous conditions for 15 s at 70 W in an ice bath. Two 
different types of NP were formulated: with antigen dissolved in the IP for future Entrapped 
(Entrap) protein NP or without a protein in IP, being rather adsorbed onto the surface of the 
NP for future Adsorbed (Ads) protein NP. Fluorescent NP were formulated by replacing one 
tenth of the polymer mass by Rho-PLGA, synthesized in-house as previously described [33], 
or by replacing 50 µL of organic polymer solution with (2 mg/mL) Rhodamine G6 (Sigma-
Aldrich) solution in DCM. A 2 % (w/v) polyvinyl alcohol (PVA) solution was added to the 
o/w primary emulsion and a second sonication was performed under the same conditions. The 
double emulsion w/o/w was added dropwise to a surfactant solution containing 0.3 % (w/v) 
PVA or Pluronic F127 (PF127), which constituted an external aqueous phase (EP). 
Afterwards, the solvent evaporation was carried out by gentle magnetic stirring at 37 °C 
during 1 h, thus enabling the formation of NP. The polymeric NP were harvested by 
centrifugation (22000 x g, 45 min, 4 ˚C; Beckman Coulter, lnc, Avanti® J-E Centrifuge JA-
20, USA), and rinsed with ultrapure water three times to remove excess of surfactant and non-
associated antigen. NP were resuspended in phosphate buffered saline (PBS) pH 7.4 and kept 
at 4 ˚C until further analysis. 100 µl of LALBA solution (10 mg/ml) was adsorbed to NP by 1 
h incubation at room temperature. Protein-adsorbed NP were washed with ultrapure water and 
centrifuged at 22000 x g for 20 min at 4 ˚C.  
 
2.4. Characterization of NP size and ζ potential 
NP size and polydispersity index (PDI) were determined by Dynamic Light Scattering 
(DLS) using the Malvern Nano S (Malvern Instruments, UK). Briefly, the final 20 mg/ml NP 
suspension was re-suspended in PBS pH 7.4 to prepare 1 mg/ml NP suspensions. The 
conditions were kept constant in order to have comparable results. Readings were obtained 
based on the scattering of laser light within the equipment by the Brownian motion of NP. 
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Each analysis was carried out in triplicate at 25°C. NP’ surface charge was inferred by their ζ 
potential that was assessed by Laser Doppler Velocimetry (LDV) with Malvern Nano Z 
(Malvern Instruments, UK). Since ζ potential is highly dependent on measurement conditions, 
mainly pH and ionic strength of the dispersant and concentration of NP in the suspension, 
those conditions were always maintained. All measurements were performed at 25 °C in 
triplicate. 
 
2.5. Atomic force microscopy 
The morphology of formulated NP was investigated by Tapping mode atomic force 
microscopy (AFM) (Nanoscope IIIa Mulimode AFM, Digital Instruments, Veeco), using 
silicon tips (ca. 300 kHz) at a scan rate of ca. 1.6 Hz. Samples were diluted in purified water 
(10 mg/ml), a drop was placed onto freshly cleaved mica for 20 min, and dried with N2 prior 
to analysis. 
 
2.6. Protein loading 
The supernatants from NP centrifugation were collected and the entrapment efficiency 
(EE, %) and the loading capacity (LC, µg/mg) of proteins were quantified indirectly by a 
reverse-phase high-performance liquid chromatography (HPLC) (RP-HPLC) using Beckman 
System Gold: UV-Vis detector (Beckman 166) at 220 nm, Beckman 126 solvent module and 
Midas autosampler. Samples (20 µl) were injected onto a Shodex Protein KW-803 series 
column (8.0 mm ID x 300 mm, 5 µm particle size, 300 Å pore size) and eluted with 50 mM 
sodium phosphate buffer (pH 7.0) plus 0.3 M NaCl at 1 ml/min for 16 min at room 
temperature. Plain NP were used as controls and all measurements were performed in 
triplicate. The amount of protein in each sample was calculated using a linear standard curve 
generated in the range of 0.5 – 5.0 mg/ml, r2 = 0.9987. The EE (%) and the LC (µg/mg) of 
protein were calculated as indicated in Equations 1 and 2.  
 
𝐸𝐸 % =  !"!#!$% !"#$%& !" !"#$%&"!!"#$%& !" !"#$%&" !" !"#$%&'('&(
!"!#!$% !"#$%& !" !"#$%&"
 𝑥 100                                                    (1) 
 
𝐿𝐶 µ𝑔 / 𝑚𝑔 = !"!#!$% !"#$%& !" !"#$%&"!!"#$%& !" !"#$%&" !" !"#$%&'('&(
!"!#$ !"#$%& !" !"#$%&'
 𝑥 100                  (2) 
 
2.7. PVA assay 
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To determine the residual amount of PVA at NP, PVA was indirectly quantified by 
HPLC using Beckman System Gold: UV-Vis detector (Beckman 166), Beckman 126 solvent 
module, Midas autosampler, and Shodex Protein KW-803 column (8.0 mm ID x 300 mm, 5 
µm particle size, 300 Å pore size). The surfactant washing efficiency was calculated as the 
percentage of PVA quantified in the supernatants comparing to the total amount used for NP 
formulation. 
 
2.8. Freeze-drying of NP 
NP were freeze-dried in the presence of the 0.05 % (w/v) sucrose, which was used as a 
cryoprotectant. Prior to lyophilization, all samples were placed into glass vials and frozen at -
80 °C. On the following day, samples were freeze-dried for 24 h at -45 °C, 0.2 mbar in a 
VirTis BenchTop L freeze-drier (SP Scientific, NY, US). Lyophilized NP were only used for 
FTIR and thermal characterization. 
 
2.9. Integrity of the NP-entrapped protein (SDS-PAGE) 
The assessment of protein integrity was determined by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). LALBA standard solution (250 µg/mL) and 
NP suspension (20 mg/ml) were mixed with SDS-containing loading buffer and digested at 95 
°C for 20 min. Samples were loaded at room temperature onto a 10 % (w/w) polyacrilamide 
mini-gel (20 µl for samples and 5µl for MW markers (Thermo Fisher Scientific, 10 - 180 
kDa) and electrophoresis was then performed at a constant voltage of 170 V for 50 min using 
a Bio-Rad 300 power pack (Bio-Rad, Hercules, CA, USA). Gels were further stained with 
Coomassie Blue G250 0.025 % (w/v) to reveal protein bands [34]. 
 
2.10. FTIR characterization 
Each sample was mixed with KBr at a concentration of 0.5 w/w. The mixtures (200 
mg) were compressed into a tablet of 12 mm diameter. The infrared spectras were measured 
at the absorption mode (IR Affinity-1 Shimadzu spectrophotometer, Japan) with 64 scans 
with a resolution of 2 cm-1. 
 
2.11. Thermal characterization 
The thermal properties of the samples were determined using a DSC (TA instruments, 
Q200, USA) after calibration with indium (TA instruments, USA; Tfus =156.55 °C, ΔfusH = 
28.51 J/g). Dry N2(g) was used as the purge gas (Air Liquide, 50 ml/min).  Prior to the 
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experiment, all the samples were kept in dry atmosphere with only 11 % of humidity (Lithium 
chloride supersaturated solution) for one week. The samples (2 to 3 mg) were placed in 
hermetic crucibles and heated up at 5 °C/min from 0 °C to 100 °C. An empty crucible was 
used as reference. 
 
2.12. Stability of NP 
Aseptically prepared polymeric NP were dispersed in PBS pH 7.4 and kept at 4 ˚C. 
After predetermined periods of time over 3 months, samples were collected and particle size, 
PDI, and ζ potential were evaluated. 
 
2.13. In vitro evaluation of target cell viability in the presence of NP 
The murine immature DC line (JAW SII cell line, American Type Culture Collection, 
ATCC#CRL-11904) was cultured in RPMI medium1640 supplemented with GM-CSF (50 
ng/mL) and IL-4 (50 ng/mL) in 5 % CO2 at 37 °C. Cell viability of JAW SII DC was 
quantitatively evaluated by measuring metabolic activity of mitochondrial dehydrogenase by 
AlamarBlue®. DC were incubated with increasing concentrations of different nanoparticulate 
systems in a 96-well plate (Nunc®, Roshilda, Denmark). Cells were seeded with a total 
volume of 5000 cells/100 µl/well. Different concentrations of NP suspension (100, 125, 150, 
200, 250, 500, 1000 µl/ml) were added to wells. Cells in culture medium were used as 
negative control, while the positive control was obtained after cell treatment with a solution of 
0.5 % (v/v) Triton X-100 (Gibco®). After NP incubation for 21 h at 37 °C with 5 % CO2, 10 
µl of AlamarBlue® reagent were added to each well and incubated for additional 3 h. After a 
total of 24 h of incubation, the absorbance of AlamarBlue® was determined with a Fluostar 
Omega microplate reader (BMG LAbtech, Ortenberg, Germany) at 570 nm, using 600 nm as 
a reference wavelength. 
 
2.14. Internalization of antigen-loaded NP by bone marrow derived dendritic 
cells (BMDC) 
DC were derived from bone marrow cells that were isolated from femura and tibiae of 
C57BL/6 mice and cultured in RPMI medium1640 supplemented with GM-CSF (50 ng/mL) 
and IL-4 (50 ng/mL) at 37 °C, 5 % CO2. After 7 days, immature DC were harvested, washed, 
and used for in vitro experiments. 
Cells were seeded in 24 well plate (1.5 × 105 cells per well) 24 h prior administration 
of fluorescent NP (250 µg/mL) to the culture. After incubation with NP for 3, 6, 16 or 24 h, 
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cells were harvested, rinsed three times with PBS and stained with anti-mouse CD11c, CD11b 
antibodies and DAPI (for dead cells exclusion). Cells were analyzed by ImageStreamX, as 
described below. 
 
2.15. Multispectral imaging flow cytometry (ImageStreamX) analysis 
Cells were imaged using multispectral Imaging Flow Cytometry (ImageStreamX 
markII flow cytometer; Amnis Corp, part of EMD millipore, Seattle, WA). A 60x 
magnification was used for all samples. At least 30,000 cells were collected for each sample. 
Data were analyzed using a dedicated image analysis software (IDEAS 6.2; Amnis Corp). 
Images were compensated for fluorescent dye overlap by using single-stain controls. Cells 
were gated for single cells using the area and aspect ratio features, and for focused cells using 
the Gradient RMS feature [35]. Cells were further gated using a bivariate plot for circularity 
(the degree of the mask’s deviation from a circle) based on the Object mask (a segmentation 
mask that creates a tight fit on the cell morphology) and intensity of the side scatter channel 
(illuminated by the 785 nm laser and collected in channel 12).  
Particle internalization was calculated by the Internalization feature, i.e. the ratio of 
the intensity inside the cell to the intensity of the entire cell, mapped to a log scale. To define 
the internal mask for the cell, the object mask of the bright field image was eroded by 5 
pixels.  
 
2.16. In vivo study of activation markers and co-stimulatory molecule 
expressed on DC in draining lymph nodes 
Female C57BL/6 mice, 8-weeks-old (n = 3 / group) were injected into the right flank 
by subcutaneous (s.c.) hock immunization with 50 µl of one of the following fluorescent NP 
formulations (20 mg/ml): EntrapOVA(PVA), EntrapOVA(PF127), AdsOVA(PVA), and 
AdsOVA(PF127). Non-injected left flank served as negative control. All NP were labeled 
with Rhodamine G6 (Sigma-Aldrich). After 16 h post-immunization (p.i.), popliteal and 
inguinal lymph nodes (LN) were harvested and homogenized in a single cell suspension. Cells 
were then stained with fluorescent-labeled anti-mouse antibodies against CD11c, MHCII (I-
Ab), MHCI (H-2Kb), CD80 and CD86 for 20 min at 4 °C. Samples were acquired with an 
LSR II Fortessa flow cytometer (BD Bioscience) and analyzed with FlowJo software 
(Treestar). 
 
2.17. Analysis of in vivo T cell activation after NP immunization 
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Eight-week-old female C57BL/6 mice (n = 6 mice/group) were intravenously (i.v.) 
engrafted with CD8+ OT-I and CD4+ OT-II cells isolated by MACS from spleens and LN of 
the respective TCR transgenic mice. Prior to the transfer, both T cell populations were labeled 
with 5 mM CFSE, for tracking in vivo proliferation [36]. On the following day, animals were 
injected s.c. into the right flank (hock immunization) with 50 µl of NP suspension (20 mg/ml); 
EntrapOVA(PVA), EntrapOVA-CpG(PVA) and AdsOVA(PVA) and AdsOVA-CpG(PVA). 
Non-injected left flank served as negative control. OVA was used as an antigen and CpG as 
an adjuvant. Three days p.i. with NP, inguinal and popliteal LN were isolated. Single cell 
suspension was stained with CD4, CD8α, TCRβ, TCRVα2, and CD45.1 antibodies and 
analyzed by flow cytometry. 
 
2.18. Statistics 
All results are presented as mean ± standard deviation (SD). One-way ANOVA 
analysis, following by a Tukey-Kramer test was applied to demonstrate statistical differences 
(p˂0.001 (***), p˂0.01 (**), p˂0.05 (*)). For direct comparison between two groups of data, 
t-student test was applied. All tests were performed in GraphPad Prism5® (GraphPad 




3.1. Physicochemical characterization of formulated NP 
3.1.1. NP size and ζ potential 
Biodegradable polymeric NP were prepared by the double emulsion solvent 
evaporation technique (w/o/w). This method is based on the emulsification of an organic and 
an aqueous phase where the NP result from single volume shrinkage of the initial emulsion 
droplet by ultrasonication [33]. Formulation parameters, including average size (Size), PDI, ζ 
potential, entrapment efficiency (EE) (%) and loading capacity (LC) (µg/mg) were monitored 
along the preparations with two different surfactants: PVA or Pluronic (PF127) (Table 1). All 
formulations described in Table 1 were developed using 0.5 % (wCS/wpolymer) chitosan (CS) 
solution and antigen-loaded NP were formulated using 2.5 % (wLALBA/wpolymer) LALBA 
solution as aqueous phase (IP). For antigen-adsorbed NP, empty PLGA NP were incubated 
with 5 % (wLALBA/wpolymer) LALBA solution. For each formulation, blank NP were formulated 
as a control. 
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NP size distribution and surface charge are key parameters for preferential passive 
targeting of DC, adequate biodistribution profile and efficient immune response. In addition, 
the size also influences EE and LC [11, 28, 30, 31]. With these parameters in mind, our 
formulation process was adjusted in order to attain particles of a size smaller than 200 nm, 
PDI below 0.2, neutral ζ potential, high loading efficiency and a minimum surfactant residue, 
particularly important to guarantee NP safety and biocompatibility.  
The PVA surfactant concentration in the aqueous phase (10% (w/v)) influences the 
average size of formulated NP and their entrapment capacity [37, 38]. DLS results were 
recorded as average of three independent NP formulations (Table 2). DLS studies yielded 
consistent and reproducible results. ζ potential was determined by LDV. All formulated 
batches of NP were close to neutrality, independent of the surfactant used in the external 
phase (PVA or PF127). This can be explained by the presence of the PEG–chains on the 
surface of the EntrapLALBA(PVA) and EntrapLALBA(PF127) NP, but also to the dispersion 
of the positively charged CS on NP matrix. 
EE and LC were validated by HPLC. The best EE was obtained for the formulation 
EntrapLALBA(PVA), as close to 80 % of initial protein solution was entrapped within the 
PLGA-PEG NP. When PF127 as used at EP (EntrapLALBA(PF127)), the EE was close to 70 
%. However, it is important to highlight that despite the surfactant used to ensure NP stability, 
the overall EE were much higher than those reported in other recently published studies [33, 
39, 40]. The same profile was obtained for LC, which could be due to the CS used in the 
emulsion internal phase. CS increases the viscosity of the aqueous phase and also forms weak 
electrostatic and hydrophilic interactions with the protein [41, 42]. Therefore, both physical 
and chemical stabilities of the internal phase are thus enhanced. Moreover, the adsorption 
efficiency of AdsLALBA(PVA) and AdsLALBA(PF127) NP was considerable close to 40 or 
50 %, respectively. The chemical structure of PF127 is branched, therefore 
AdsLALBA(PF127) NP were able to adsorb protein more efficiently and with higher stability 
than those NP prepared with PVA polymer. 
It was important to assess the residual amount of PVA present within NP matrix by 
HPLC, as a considerable high concentration of PVA was used in the emulsion aqueous phase. 
The percentage of surfactant washing efficiency was higher than 96 % for all formulations.  
 
Table 1: Composition of polymeric NP. 









EntrapPROTEIN(PVA) PLGA- 10 % (w/v) PVA, CS, 2% (w/v) 0.3 % (w/v) - 
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PEG protein PVA PVA 
EntrapPROTEIN(PF127) 10 % (w/v) PVA, CS, protein 




10 % (w/v) PVA, CS 0.3 % (w/v) PVA protein 
AdsPROTEIN(PF127) 10 % (w/v) PVA, CS 0.3 % (w/v) Pluronic protein 
* internal phase  ** external phase 
 
Table 2: Physicochemical characterization of polymeric NP. 
Formulation Size (nm) PDI ζ potential (mV) 





EntrapLALAB(PVA) 171 ± 3 0.15 ± 0.02 0.51 ± 0.1 19.56 - 
EntrapLALBA(PF127) 185 ± 4 0.17 ± 0.05 0.37 ± 0.4 16.96 - 
AdsLALBA(PVA) 188 ± 11 0.18 ± 0.08 -1.89 ± 0.5 - 19.72 
AdsLALBA(PF127) 195 ± 10 0.20 ± 0.09 -1.42 ± 0.2 - 25.10 
 
3.1.2. Atomic force microscopy 
Figure 1: Size and morphology characterization of formulated NP by AFM. Section analysis of NP (A) 
EntrapLALBA(PVA) and (B) EntrapLALBA(PF127) with the matrix polymer PLGA-PEG and with entrapped 
antigen; (C) AdsLALBA(PVA) and (D) AdsLALBA(PF127) with PLGA polymer and adsorbed LALBA 
protein. 
 
The size and surface morphology of NP was also determined by AFM (Figure 2). A 
drop of each sample was placed onto freshly cleaved mica and dried with N2(g) prior to 
examination. All NP had smooth surfaces and spherical topography. The section analyses of 
PLGA-PEG NP with entrapped antigen showed uniform size distributions, which correlated 
with the data measured by DLS analyzer. As the NP were dried and PEG chains could not 
form a corona around the NP, the average diameter was 30 nm smaller than the hydrodynamic 
diameter obtained by DLS. However, there were no considerable differences between the 
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formulations EntrapLALBA(PVA) (Figure 1A) and EntrapLALBA(PF127) (Figure 1B). 
Hence, the different surfactants present at the EP did not greatly influence the size or the 
morphology of the NP. On the other side, PLGA NP with adsorbed antigen demonstrated less 
uniformed size distribution, with an average diameter closer to the one determine by DLS. 
Also here we could not observe any differences between the AdsLALBA(PVA) (Figure 1C) 
and AdsLALBA(PF127) NP (Figure 1D), despite the use of different surfactants in the EP. 
However, with the AFM images we could clearly distinguish between the different polymers. 
Formulations with PLGA-PEG (EntrapLALBA(PVA) and EntrapLALBA(PF127)) show 
nicely spherical NP, which are stuck to each other forming clusters, due to the surrounding 
hydrophilic PEG chains, that tend to accommodate water molecules, precluding a sharp 
imaging of particles boundaries. This latter effect was not observed when only PLGA 
(AdsLALBA(PVA) and AdsLALBA(PF127)) was used for the matrix formation; here we got 
spherical shapes NP with good defined edges. 
 
3.1.3. FTIR and DSC studies on lyophilized NP 
FTIR spectroscopy is one of the important tools for the rapid and efficient 
identification of protein and polymers’ integrity in lyophilized NP, after formulation. In 
addition, the differences related to the presence of the LALBA antigen entrapped into the 
polymeric matrix or adsorbed onto the surface of NP was also evaluated by FTIR (Figure 2A). 
FTIR spectrum of both polymers (PLGA, PLGA-PEG) and all NP showed a strong 
stretching absorption at 1720 cm−1 (§) which corresponds to C=O bond, indicating the 
presence of a carboxylic acid. The band at 2950 cm−1 (ф) indicates the presence of C-H bonds 
(ethylene glycol) that is clearly more pronounced in Entrapblank(PVA) and Entrapblank(PF127), 
when PLGA-PEG was used as a matrix polymer [40]. From the LALBA spectrum, one can 
see two specific absorption bands at approximately 1600 cm-1. One appears at 1662 cm-1 (*) 
and is specific for primary amides, while the peak at 1562 cm-1 (Ϫ) is distinctive for -NH2 
groups. Both of these bands also appear on the FTIR of the samples AdsLALBA(PVA) and 
AdsLALBA(PF127), where LALBA is adsorbed onto the surface of the nanoparticulate 
delivery system. The slight shift to the higher wave numbers indicates changes of the 
hydrogen bonding strength between the protein and the polymer. The broad and strong band 
at 3400 cm-1 (‡) is related to the hydroxyl and amine groups overlapping each other. Also 
these bands are much more pronounced for NP with adsorbed LALBA [43]. The absence of 
these bands in the spectrum of EntrapLALBA(PVA) and EntrapLALBA(PF127) (Table 1) 
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suggests that when entrapped, protein is well protected within the matrix of the polymer, 
therefore this change is not visible on the FTIR spectrum.  
 
 
Figure 2: (A) FTIR spectrographs of NP and the components used for their formulations. The symbols on the top 
of the graph correspond to the specific band. Peak at 1720 cm−1 (§) is a specific band for C=O bond; 1662 cm-1 
(*) is specific for primary amides; peak at 1562 cm-1 (Ϫ) corresponds to vibration of -NH2 groups; 2950 cm−1 
(Ф) indicates the presence of C-H bond; 3400 cm-1 (‡) correlates to the hydroxyl and amine groups overlapping. 
(B) DSC specters of formulated NP and the components used for their formulations. 
 
DSC studies were performed with lyophilized NP at a rate of 5 °C/min from 0 °C to 
100 °C. This thermo-analytical technique provided information on the thermal 
transformations of biodegradable polymers and the LALBA protein in NP (Figure 2B). 
Analysis of PLGA and PLGA-PEG demonstrated, the presence of an endothermic event 
between 40 - 50 ºC. This endothermic band results from the glass transition of the polymers 
followed by an endothermic relaxation peak. The glass temperature (Tg) of polymers depends 
strongly on the MW and their composition. Results show that the Tg values of PLGA 
biodegradable copolymer were lower than those obtained for PLGA-PEG, due to the higher 
MW of PLGA–PEG [44].  
When empty and LALBA entrapped NP were evaluated, their Tg were in the same 
range as the Tg of PLGA and PLGA-PEG, revealing that formulation process did not affect 
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the structure of these polymers. Moreover, no specific interactions between the polymers and 
protein were detected. However, when the protein was adsorbed onto the NP surface, a higher 
Tg was found, indicating that the adsorption of protein at the surface of the NP occured [43, 
45].  
From the LALBA thermogram there was no melting peak visible at 50 - 70 °C, in 
contrast to what has been previously reported in the literature [46, 47], suggesting that the 
protein is in an amorphous phase (which was confirmed by XRPD analysis, data not shown). 
Also, no melting peak of native LALBA was detected in all NP with entrapped protein, 
suggesting that the LALBA protein is in a disordered phase within the polymer matrix of NP 
[44].  
 
3.1.4. Formulation procedures do not affect protein integrity 
SDS-PAGE was used to assess protein integrity after incorporation into NP. Protein 
band patterns of migration obtained for LALBA standard solution and those extracted from 
loaded NP (EntrapLALBA(PVA), EntrapLALBA(PF127), AdsLALBA(PVA), and 
AdsLALBA(PF127)) are identical, suggesting that the MW and integrity of the protein is not 
affected by the NP formulation process (Figure 3). Additionally, these observations are 
corroborated by the absence of those bands next to 14 kDa of the gel in lanes 6, 8, 11 and 13. 
 
Figure 3: SDS–PAGE (12 % separating gel) of protein LALBA before and after entrapment in NP. Lanes: (1) 
standard molecular weight (MW) markers, wide range 10–180 kDa; (2) LALBA standard solution at 2 µg; (3) 4 
µg; (4) 8 µg; (5) 16 µg all LALBA’s bands may be seen at the 14 kDa; (6) Entrapblank(PVA); (7) 
EntrapLALBA(PVA); (8) Entrapblank(PF127); (9) EntrapLALBA(PF127); (10) Adsblank(PVA); (11) 
AdsLALBA(PVA); (12) Adsblank(PF127). (13) AdsLALBA(PF127); A representative image of 3 independent 
experiments is presented. 
 
3.1.5. NP stability over 3 months 
Average size, PDI, and ζ potential of polymeric NP were measured over 3 month 
period when dispersed in PBS pH 7.4 and kept at 4 ˚C. The main challenge of colloidal 
suspensions is to ensure their stability over time. 
As it can be sen in Figure 4, the EntrapLALBA(PVA) and EntrapLALBA(PF127) 
formulations showed high stability over a period of 60 days. The size of the NP was 
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decreasing slowly from 182 to 170 nm for the formulation EntrapLALBA(PVA), and 192 
to175 nm for EncLALBA(PF127), respectively. The ζ potential stayed close to neutrality; 
with a shift from slightly positive (0.3 mV) to negative (-1.2 mV). PDI started to increase 
only after 60 days, suggesting degradation of polymeric matrix through bulk erosion.  
 
 
Figure 4: Circles (●) present formulation EntrapLALBA(PVA), squares (■) EntrapLALBA(PF127), triangles 
(▲) AdsLALBA(PVA) and diamonds (▼) AdsLALBA(PF127) F4. (Figure 1A and 1B) Average size, (Figure 
1C) poydispersity index (PDI), and (Figure 1D) ζ potential of polymeric NP were measured over 3 month period 
when dispersed in PBS pH 7.4 and kept at 4 ˚C. All results are expressed as mean ± SD (n>3). 
 
On the other side, the formulations AdsLALBA(PVA) and AdsLALBA(PF127) with 
adsorbed protein onto the surface of PLGA matrix, showed an increase in size for 80 and 40 
nm, respectively, already after 30 days, suggesting aggregation. This was further supported by 
increased PDI (> 0.35) that occurs after 20 days of NP storage in aqueous suspension at 4 °C. 
Moreover, adsorbed protein may contribute to the rise of compelling forces leading to 
increase NP aggregation. It appears that the PF amphiphilic character and branched chemical 
structure, leads to the formulation of NP (AdsLALBA(PF127)) with higher stability over time 
and increased association affinity towards the protein. 
Overall, the ζ potential for all formulations was close to neutrality, suggesting weak 
repulsive forces between NP. After 60 days even steric and hydrated barrier of PEG, in case 
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of formulations EntrapLALBA(PVA) and EntrapLALBA(PF), were not strong enough to 
maintain NP separated from each other [48, 49]. 
Taken together, we can conclude that all formulations of NP remain stable for a period 
that is relevant for their application as drug delivery systems. In addition, most probably the 
final product would become available as an extemporaneous vaccine, containing the NP in the 
lyophilized form and an adequate buffer for dispersion previous to administration.  
 
3.2. NP have no cytotoxic effect on murine immature DC  
NP cytotoxicity was studied in vitro on a murine immature DC cell line (JAWSII, 
ATCC®, #CRL-11904™). The cells were incubated for 24 h with increasing concentrations 
(100 – 1000 µg/ml) of NP. As shown in Figure 5, cell viability was not affected by any 
composition of NP, in a concentration up to 1000 µg/ml. This corroborates the safety of 
surfactants, polymers biocompatibility and evaporation of the organic solvent used in the 
formulation of NP [50]. 
 
Figure 5: Cell viability (%) determined by the AlamarBlue® assay after 24 h incubation of murine immature 
BMDC with increasing concentrations of NP. Culture medium (0) and triton 0.5 % (w/v) were used as negative 
and positive controls, respectively (Mean ± SD; n = 6). 
 
3.3. In vitro study of internalization of antigen loaded NP by bone marrow-
derived DC 
DC are the most potent APC, and form the interface of innate and adaptive immunity. 
Hence, NP uptake ability and internalization by DC are critical steps of the cascade towards 
an effective immune response. To study these parameters with antigen-loaded NP, we used 
mouse DC that had been generated from BM cells in the presence of GM-CSF and IL-4, for 7 
days [51]. To analyze the NP-exposed BMDC with high throughput and spatial resolution 
nature, we used imaging stream flow cytometry (ImageStreamTM) (Suppl. Figure S1) [52].  
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Figure 6: In vitro NP internalization by BMDC. ImageStream analysis was performed to detect PLGA-Rho 
labeled NP in BMDC; 3, 6, 16 and 24 h after the in vitro incubation. Distribution of at least 30,000 cells was 
calculated by Amnis IDEAS software and presented with the histograms showing the percentages of CD11c+ 
cells interacting with NP (A) and of CD11c+ cells with internalized NP (B). Examples of representative images 
captured by the Amnis ImageStreamX Flow Cytometer of DC incubated for 16 h at 37 °C with AdsOVA(PVA) 
(C). First column shows brightfield (BF) images of the cells, second column shows images of PLGA-Rho 
labeled NP (NP), third column shows APC-labeled CD11c+ DC (CD11c), forth column shows merged images of 
the precedent fields (BF/NP/CD11c) and fifth column shows DAPI signal for dead cells. (C.a) CD11c without 
NP. (C.b) NP on the surface of the CD11c+ cell. (C.c) Various NP, entering the cytoplasm of CD11c+ cell. (C.d) 
DC with various NP. (C.e) DC with start morphology, indicator of the DC maturation process. Results are mean 
± SD, normalized to that of control non-labeled cells, representative of three independent experiments (n = 3). 
Scale bar, 7 µm. 
 
Overall, DC-NP interactions were observed to be time dependent, as total 
fluorescence, max pixel, and median pixel intensities of NP, increased with incubation time, 
as seen in Figure 6A for EntrapOVA(PVA) and AdsOVA(PVA). Percentages of DC with 
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internalized NP ranged from 50 - 60 % and cells with NP persisted for a 1 day period (Figure 
6B). 
Of note, EntrapOVA(PF127) and AdsOVA(PF127) did not show this time dependent 
increase in total fluorescence. Moreover, the percentage of DC interacting with 
AdsOVA(PF127) after 3 h incubation was significantly lower (~60 %) (p ˂ 0.01 (**)) (Figure 
6A) compared to the DC-EntrapOVA(PF127) interactions, with a slight increase after 16 h 
incubation. 
 
3.4. In vivo impact of NP on DC in draining LN of challenged animals 
The in vitro experiments established that all NP formulations that we developed were 
efficiently internalized by BMDC in the cultures. To test if this also holds for a physiological 
setting, we immunized C57BL/6 mice into a flank with NP and used the non-immunized 
contralateral flank as control. Popliteal and inguinal LN were isolated from both flanks 16 h 
after immunization, single cell suspensions were prepared and analyzed by flow cytometry, 
focusing on DC. First, we tested the expression of MHCI, MHCII, and the co-stimulatory 
molecules CD80 and CD86 on all DC (gated as CD11c+, MHCII+; gating strategy is provided 
in the Figure 7A). LN of animals immunized with empty NP (lacking antigen) were compared 
to non-immunized LN. No significant differences were observed between these samples. As 
shown in Figure 7B, there was no significant difference in the expression of CD80 between 
the formulations, but also between the formulations and the control group. However, after 
immunization with EntrapOVA(PVA) and AdsOVA(PVA) formulations, DC expressed 
significantly higher levels of the co-stimulatory molecule CD86, than after injection with 
other types of NP (p ˂ 0.001 (***)). Moreover, AdsOVA NP with PVA in EP induced higher 
CD86 expression than formulation AdsOVA NP with PF as a surfactant in EP (p ˂ 0.001 
(***)). However, there was no significant difference between the NP with entrapped or NP 
with adsorbed antigen. Surface MHCII expression was significantly increased only in animals 
immunized with AdsOVA(PVA), compared to control (p ˂ 0.05 (*)). Otherwise, there was no 
significant difference between the NP capture in vivo by DC of animals treated with 
formulations or between the different formulations and the control.  
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Figure 7: (A) Gating strategies for CD11c+/MHCII+/NP+ or NP- DC in immunized and non-immunized female 
C57BL/6 mice 16 h following immunization. Histograms of expressed activations markers on DC with and 
without NP after hock immunization.  (B) Percentages of activated DC 16 h after immunization with different 
formulations of NP. (C) Expression of surface activation markers on DC with internalized NP and the DC 
without internalized NP in the same LN, 16 h after immunization with different formulation of NP. 
 
Next we focused on differences in activation between DC with and without 
internalized NP in the same LN (Figure 7C). Rho-labeling of the NP allowed us to distinguish 
these populations by flow cytometry (Figure 7A). Statistical analysis showed generally a 
significantly higher expression of activation markers (p ˂ 0.001 (***) for CD86, MHCI, 
MHCII, and p ˂ 0.01 (**) in case of CD80) on the surface of DC with internalized NP 
compared to the DC lacking NP. DC expressed significantly higher CD86 and MHCII levels 
after vaccination with AdsOVA(PVA) formulation than after AdsOVA(PF127) (p ˂ 0.01 
(**)). Moreover, the activation markers MHCI (p ˂ 0.001 (***)) and MHCII (p ˂ 0.01 (**)) 
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were significantly higher expressed after the immunization with EntrapOVA(PVA) NP than 
EntrapOVA(PF127) NP. Furthermore, a significant difference in the activation markers 
(MHCI and MHCII p ˂ 0.05 (*)) for the formulations EntrapOVA(PVA) and AdsOVA(PVA) 
was observed. Collectively, this establishes that, rather surprisingly, the surfactant used in the 
EP has a major impact on the APC activation. 
 
3.5. Characterization of the immune response to NP: T cell proliferation 
Efficient adaptive immune responses are characterized by the stimulation of antigen-
specific CD4+ and CD8+ T lymphocytes to rapidly proliferate and differentiate into effector T 
cells. Based on the above in vitro and in vivo results, we decided to test the efficiency of the 
two NP formulations that showed the best in vitro uptake profile and most efficient 
upregulation of activation markers on DC, i.e. EntrapOVA(PVA) and AdsOVA(PVA),  to 
induce T cell proliferation. Specifically, we analyzed the expansion of antigen-specific CD4+ 
and CD8+ T cells in response to OVA antigen carrying NP with and without adjuvant (CpG). 
Therefore, we formulated the following NP: EntrapOVA(PVA), EntrapOVA-CpG(PVA), 
AdsOVA(PVA), and AdsOVA-CpG(PVA). 
Proliferative responses were assessed according to the CFSE label dilution of the 
adoptively transferred OVA-specific T cells in response to different NP formulations. 
Specifically, the animals that had been engrafted with CFSE-labelled OT-I and OT-II T cell 
were immunized with 1 mg of NP s.c. into the right flank, while the left flank was challenged 
with PBS for control. Three days following immunization, inguinal and popliteal LN were 
collected and analyzed by flow cytometry (Suppl. Figure S2). CD4+ OT-II and CD8+ OT-I T 
cells extensively proliferated after immunization with EntrapOVA(PVA), with  peaks of the 
divided daughter cells could be detected up to eight generations (Figure 8).  
Interestingly, the formulation EntrapOVA-CpG(PVA) showed the most profound 
antigen-specific response, with CD4+ OT-II and CD8+ OT-I T cells approaching the 
autofluorescence level of unlabeled lymphocytes in the recipient animal. This confirms that 
adjuvant and the associated DC maturation as expected, significantly contributes to boost T 
cell stimulation.  
The AdsOVA(PVA) and AdsOVA-CpG(PVA) formulations induced both CD4+ and 
CD8+ T cells to respond 3 days p.i. . However, no significant differences in the T cell 
proliferation efficiency between AdsOVA(PVA) and AdsOVA-CpG(PVA) were detected. 
Notably, in our experiment the CpG in the formulation AdsOVA-CpG(PVA) did not boost the 
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antigen-specific response. This deviation could be due to the low co-delivery of antigen and 
adjuvant into APC, leading to unaltered T cell proliferation.  
Collectively, these results suggest that rapid and efficient antigen-specific immune 
responses can be elicited through co-delivery of antigen and adjuvant NP. Moreover, the 




Figure 8: T cell proliferation was studied using dilution of CFSE fluorescence of OVA-specific TCR-transgenic 
CD4+ OT-II and CD8+ OT-I T cells in vivo 3 days post-immunization with NP. The histogram plots show the 
CFSE profiles of viable CD4+ OT-II  and CD8+ OT-I T cells after the immunization with different NP (dark gray 
histogram) relative to the generation zero CFSE profile of viable transferred CD4+ OT-II and CD8+ OT-I T cells 
in the absence of OVA NP (light gray histogram). Representative histogram plots were selected from tree 
independent experiments (n = 6). 
 
4. Discussion 
Designing safe and efficacious NP vaccines requires a thorough understanding of the 
physical and chemical features of the carrier and their interaction with biological systems. The 
unique properties of NP, such as chemical composition, size, surface charge, shape, and 
hydrophobicity, impart their characteristics in the interaction and uptake efficiency by APC 
that elicit T cell immunity [31, 53].  
In this study, we focused on the reproducibility and stability of the colloid suspension 
with different types of protein association to NP and their chemical composition. The latter 
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was influenced by using either PLGA-PEG or PLGA polymers in combination with two 
different non-ionic surfactants, PVA and PF127, respectively.  
PLGA-PEG and PLGA have been chosen for their biodegradability [11-13] and 
excellent biocompatibility with immune cells. PLGA is contained in medicinal products 
approved by EMA (European Medicines Agency) and FDA (Food and Drug Administration) 
for the topical, oral and parenteral usage [29]. PEG was used to modify PLGA hydrophobic 
surface with a hydrophilic shielding properties that increase polymer water-solubility, and 
thus biocompatibility, and greatly reduce immunogenicity and toxicity [17]. 
PVA is a commonly used polymeric emulsifier with amphiphilic properties [37]. 
PF127 on the other hand is a triblock copolymer (polyoxyethylene-block–polyoxypropylene-
block-polyoxyethylene; PEO-b-PPO-b-PEO) and the most cytocompatible among the 
Pluronics. Both surfactants have non-ionic and amphiphilic character and obtain quite similar 
MW, PVA with 13 - 23 kDa and PF127 with 13 kDa, respectively [54, 55].  
For NP to act as immune potentiators, presence of the antigen either entrapped within 
or adsorbed onto NP surface can be expected to be an important factor of delivery. Hence, we 
developed various NP platforms to address this factor. Entrapment ensures antigen release 
only after NP uptake and degradation inside the APC [31]; therefore it may lead to slower 
antigen release or longer preservation of antigen stability [25]. Additionally, entrapment could 
also represent an efficient way of delivering of antigens that are highly degradable, cause 
tissue necrosis or would change/ reduce their effectiveness in immune response upon the 
injection [11, 29]. 
On the other hand, antigens can be adsorbed onto NP surface based on charge and 
hydrophilic interactions, which are usually much weaker. Adsorbed antigen is expected to 
dissociate from the NP faster and to a higher extent. Thus, antigen adsorption may 
simulate/emulate pathogen presentation to immune systems [11]. However, both high 
entrapment and adsorption strongly depend on physicochemical properties of the 
nanoparticulate delivery system [26, 28, 29]. 
A wealth of research explored numerous nanoparticulate systems and has shown that 
size and surface charge of NP are the most pivotal and critical factors for their application as 
drug delivery system. NP smaller than 200 nm [28, 31] can be directly transported by lymph 
drainage to lymphoid organs, where they are internalized by immature DC, while larger NP 
require peripheral immature DC and active cellular migration to the draining LN [27-29, 33]. 
Surface charge of NP, on the other hand, profoundly influences the internalization capability 
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by APC, as the negative charge of the cell membrane has higher affinity for positively 
charged particles [11, 30].  
In this study, we developed and precisely characterized four different NP delivery 
systems for a systemic delivery of protein antigen to DC, the key APC that trigger T cell 
immunity. We aimed to develop a highly stable and reproducible colloidal suspension of NP 
smaller than 200 nm with narrow size distribution, PDI below 0.2 and ζ potential close to 
neutrality, in order to potentiate NP-APC interaction. Therefore we used biodegradable 
aliphatic polyester copolymers PLGA-PEG or PLGA, together with CS, to form a polymeric 
matrix; and two different stabilizers, PVA or PF127, to ensure NP best physical and chemical 
characteristics, including size, surface charge and antigen association. 
Four highly reproducible and homogeneous nanoplatforms have been developed, all 
with narrow particle size distribution (Table 2), which was also confirmed by AFM. 
EntrapLALBA(PVA) and EntrapLALBA(PF127) with entrapped antigen presented an 
average size ranging from 171 and 185 nm, respectively. While NP with adsorbed LALBA 
protein, AdsLALBA(PVA) and AdsLALBA(PF127), were slightly bigger, showing 188 nm 
and 195 nm, respectively.  
CS was used in the IP in all formulations, due to its positive charge (+30 mV) [56, 57] 
to establish electrostatic interactions with the negatively charged groups of biodegradable 
polymers, thus increasing the ζ potential of NP. Many research studies have used PLGA or 
PLGA-PEG polymers in the past. However, most of the reported formulations, despite their 
high biocompatibility, displayed quite negative surface charge, from -5.2 to -20 mV for 
PLGA NP [58, 59] and −2.8 mV to −5.3 mV [60] for PLGA-PEG NP, as the PEGylation 
reduces the overall negative surface charge of PLGA. Overall, the amount of CS (0.5 % 
(wcs/wploymer)) used in all our formulated NP was enough to display surface charge close to 
neutrality. This was especially important for PLGA NP (AdsLALBA(PVA) and 
AdsLALBA(PF127)) to augment the electrostatic bonds and therefore affinity of the adsorbed 
antigen onto the surface of the polymeric matrix. NP with adsorbed protein, 
AdsLALBA(PVA) and AdsLALBA(PF127), had ζ potential 1.89 and -1.42 mV, respectively. 
With an isoelectric point (pI) at 4.2, LALBA (and OVA at pI = 4.5) protein exhibit negative 
charge under physiological pH (7.4) and thus could be adsorbed more efficiently onto the 
positively surface of PLGA-CS NP.  
In the formulations EntrapLALBA(PVA) and EntrapLALBA(PF127), CS not only 
contributed to the increase of surface charge, but also raises the viscosity of the IP and is 
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expected to establish electrostatic interactions with negatively charged protein, which may 
explain the obtained higher EE values. 
In order to verify if the protein is degraded during the NP formulation process, SDS-
PAGE was performed. LALBA-loaded NP (EntrapLALBA(PVA), EntrapLALBA(PF127), 
AdsLALBA(PVA) and AdsLALBA(PF127)) their plain control NP (Entrapblank(PVA), 
Entrapblank(PF127), Adsblank(PVA) and Adsblank(PF127)) were applied together with 
LALBA standard solutions and commercial MW standards, which were used as a control. 
Overall, in all formulations of NP where LALBA was used, entrapped or adsorbed, its MW 
was identical to the ones obtained for LALBA standard solutions (14 kDa). Moreover, no 
other bands were detected with a different MW (Figure 3), supporting the absence of protein 
fragmentation or aggregation. Therefore, the integrity of the LALBA protein was maintained 
after the NP formulation. 
The stability of the NP was followed for 3 months in PBS at 4 °C. Such robust 
stability of EntrapLALBA(PVA) and EntrapLALBA(PF127) NP could be explained by steric 
hindrance and repulsion of hydrophilic PEG chains, also known as a “stealth” effect [61, 62]. 
Therefore the stability study does not show any significant changes and deviation in size or 
PDI of NP over a period of 2 months. However, following 2 months a drastic increase in size 
andI was detected, while ζ potential was decreased. These data demonstrate the PLGA-PEG 
bulk erosion, swelling and degradation of NP, which is in accordance with the characteristics 
of these aliphatic polyesters [63]. 
In case of AdsLALBA(PVA) and AdsLALBA(PF127) NP, PLGA polymer was used 
and therefore these NP lack PEG stealth effect [32]. However, adsorbed protein on the 
hydrophobic polymeric matrix may form a protein corona that probably prevents NP 
aggregation, thus contributing to their stabilization via steric repulsion. Clustering and 
aggregation of AdsLALBA(PVA) and AdsLALBA(PF127) NP has been detected after 14 
days, which is relatively late taking into consideration the time lag between the preparation of 
the extemporaneous suspension and their administration to the patients. Given the fact that the 
adsorption of antigens onto NP is based simply on charge and hydrophobic interaction, the 
interaction between NP and antigen is relatively weak. A size increase was obviously due to 
the long incubation time in PBS that resulted in an increase of electrostatic repulsion and 
therefore influenced the protein affinity and redistribution.  
The influence of NP different chemical composition on their interaction with targeted 
cells was investigated on a murine immature DC line. A wide range of concentrations was 
screened for the toxicity of the NP over a 24 h of incubation time No significant differences 
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were observed as a function of NP concentration. None of the NP formulations led to a 
reduction in cell viability. 
However, a number of challenges remain, not only related to the lack of fundamental 
understanding of how the physicochemical properties of NP affect their uptake, and how these 
properties influence their interactions with the biological system, but also due to the lack of 
adequate in vitro and in vivo models to support the evaluation of immune-adjuvant potential, 
ensuring an antigen-specific induction. Presently, in the area of immunotherapy, we have a 
well-established animal model to help us to study the effect of a model antigen – the highly 
immunogenic protein ovalbumin (OVA).  In order to ensure reliable results, all in vitro and in 
vivo experiments were performed with OVA as model antigen [64, 65]. Subsequently our 
findings will be extrapolated to other antigenic system. 
To verify, if the produced NP were internalized by BMDC in vitro, and were able to 
efficiently induce the activation and maturation of DC in vivo with subsequent T cell 
proliferation, we formulated the nanoplatforms with OVA. All formulations presented a 
uniform size distribution, below 200 nm, and ζ potential close to neutrality. There was no 
significant difference between the chemical and physical properties of formulated NP, when 
LABLA was replaced with OVA. Despite their difference in MW, both proteins possess quite 
similar chemical characteristics, such as pI, solubility (10 mg/mL) and expected amphiphilic 
properties [66]. 
The efficacy of immuno-nanotherapeutics is contingent on particle uptake and 
internalization by DC. The NP we developed in this study have all the advantageous 
characteristics, such as narrow size distribution, rounded shape, and ζ potential, for a highly 
efficient uptake by APC. To verify this prediction, we incubated BMDC with rhodamine-
tagged, fluorescent NP up to 24 h. The influence of surface chemistry and charge of NP on 
BMDC uptake was then investigated in living cells by image flow cytometry. Overall, we 
would expect that the uptake of antigen-adsorbed NP would allow faster internalization, due 
to the similarity to the pathogens [11]. However, the slightly negative charge of protein 
covering the NP surface can influence the endocytosis of NP [67]. Our in vitro studies 
demonstrate that the interaction profile between the BMDC with NP with adsorbed antigen 
(AdsOVA(PVA) and AdsOVA(PF127)) was slower and time dependent, especially for the 
NP formulation AdsOVA(PVA). After 3 h of incubation, only 55 percent of CD11c+ cells 
were interacting with the AdsOVA(PVA), while this amount almost doubled after 24 h 
(~90%). In addition, no significant difference could be observed for AdsOVA(PF127) NP and 
different incubation times. This suggested that NP with antigen adsorbed on the surface, do 
Chapter 4 
94 
not necessarily emerge with higher interaction and phagocytosis by APC. On the other hand, 
NP with entrapped antigen were covered with the hydrophilic PEG, which contributes to the 
“stealth-like” effect which should delay their internalization by DC [68], exhibiting a higher 
phagocytic uptake. This could be explained by the slightly positively charge NP 
(EntrapOVA(PVA) and EntrapOVA(PF127), which can facilitate the interaction with the 
negative cell membrane. Overall, we can conclude that the chemical difference of NP 
influences their internalization by BMDC. All of the formulations with the PF127 emulsifier 
in the EP, present steady interaction and phagocytic uptake by CD11c+ cells, which is time 
independent. This could be explained not only by the influence of more negative surface 
charge of NP, but also by the steric repulsion effect of PF127 triblock copolymer (PEO-b-
PPO-b-PEO). PPO polymer present the hydrophobic chain which is normally oriented to the 
matrix of the NP, while PEO the two edges of the polymer is hydrophilic, and is similar to 
PEG, usually oriented away from the core of NP [69, 70]. 
This phenomenon cannot be observed in NP formulations EntrapOVA(PVA) and 
AdsOVA(PVA), when PVA is used in the EP. The interaction and internalization of latter NP 
was time dependent. Despite their different surface properties, and their divergent tendency of 
interaction, all formulated NP were efficiently internalized by BMDC. 
Physiological activation of DC populations in organism context was examined in skin-
draining LN of wild-type mice upon a single immunization with NP injection. Rho-labeled 
NP allowed us to distinguish and compare subpopulations of DC with and without 
internalized NP. Vehicles (empty NP) by themselves did not induce immune responses. DC 
with internalized NP expressed significantly higher levels of the co-stimulatory molecule 
CD86, especially after the immunization with EntrapOVA(PVA) and AdsOVA(PVA) 
formulations. Furthermore, there was no significant difference between the NP with 
encapsulated and NP with adsorbed antigen. Formulation AdsOVA NP with PVA in EP 
induced higher expression of the co-stimulatory molecule CD86 and activation marker 
MHCII than AdsOVA NP with PF127 as a surfactant in EP. This demonstrates that more than 
antigen association into the NP (entrapment vs. adsorbed), the chemical composition of NP is 
a pivotal parameter that determines the activation of DC after NP uptake. From these results, 
we can conclude that not only the size and charge, but also a slight change in the composition 
of NP has an extensive impact on the DC uptake following their maturation. Phagocytic 
uptake of AdsOVA(PVA) NP resulted in upregulation of the MHCII activation marker which 
presents the peptides that can be recognized by the TCR, leading to the CD4+ T cell activation 
and boosting humoral immune responses [29, 71]. 
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On the other side, internalized EntrapOVA(PVA) NP preferentially led to upregulation  
of MHCI on the DC, driving the antigen processing and presentation pathway towards the 
activation of a cytotoxic phenotype of CD8+ T cells which is essential for the control of tumor 
and infectious diseases. [72, 73]. Nanoparticulate vaccines for immunotherapy can drive the 
immune response toward exogenous antigens through the cross-presentation pathway by 
MHCI complexes after their internalization by DC [29, 72, 74]. Although a certain NP 
formulation has a preferential pathway, it does not mean the exclusion of the other antigen 
presentation pathway.  
Among all NP, those without PF127 in their composition were far more efficient, thus 
showing the highest activation levels of co-stimulatory molecules and activation markers. 
This could be explained by the observation that NP EntrapOVA(PF127) and 
AdsOVA(PF127) show very slow or no increase in NP-DC interaction during incubation 
time. It could mean that the NP were internalized and degraded inside the DC much slower 
and therefore, overall activation markers are not upregulated. 
Our in vitro study and the in vivo experiment on DC activation were conclusive in 
showing that minor differences in the chemical composition of the NP and protein affinity 
(entrapped or adsorbed) in the NP can have an extensive impact on their uptake and activation 
of DC. It has been demonstrated before, that the NP uptake by DC, antigen processing and 
presentation is essential parameter for the activation and differentiation of T cells [75]. The 
expansion of T cells is also dictated by the affinity of the TCR for its MHC-peptide ligand 
[76]. Therefore we went a step further and studied the T cell response. We chose the best two 
PVA formulations, that drove the most efficient upregulation and activation of DC 
(EntrapOVA(PVA) and AdsOVA(PVA)). For this study we engrafted mice with antigen-
specific OT-I CD8+ and OT-II CD4+ T cell, one day prior the immunization with the 
nanoparticulate vaccine, which allow us to follow the cell proliferation and expansion in 
draining LN of the wild type C57BL/6 mice.  
We were interested to improve potential of the vaccination with the boost in the 
primary T cell responses, therefore we incorporated adjuvant, CpG oligodeoxynucleotide, a 
toll-like receptor 9 (TLR9) agonists in the matrix of the NP. Specifically, we formulated the 
following NP: EntrapOVA(PVA), EntrapOVA-CpG(PVA), AdsOVA(PVA), and AdsOVA-
CpG(PVA). Immunization with EntrapOVA(PVA), resulted in very balanced expansion and 
proliferation of CD4+ OT-II and CD8+ OT-I T cells. For a potent CD8+ T cell activation and 
clonal expansion, efficient support of CD4+ T cells is needed [77, 78]. Interestingly the 
formulation EntrapOVA-CpG(PVA) showed the fastest antigen-specific response, as the 
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fluorescence of CFSE-labeled CD4+ OT-II and CD8+ OT-I T cells were mainly concentrated 
at the autofluorescence level of unlabeled lymphocytes in the recipient animal [36]. The 
percentage of proliferating OT-II CD4+ and OT-I CD8+ T cells was lower for EntrapOVA-
CpG(PVA) NP, compared to immune responses of other NP formulations 
(EntrapOVA(PVA), AdsOVA(PVA), and AdsOVA-CpG(PVA)). EntrapOVA-CpG(PVA) 
enhanced both uptake of antigen and adjuvants effect on DC and augmented vigorously the 
nascent adaptive immune response, which implicates that incorporation of adjuvant 
contributes to the boost of the T cell proliferation and expansion.  
The variation of proliferated T cells, 3 days after the immunization with the 
AdsOVA(PVA) or AdsOVA-CpG(PVA) NP, was minor, compared to the difference between 
EntrapOVA(PVA) and EntrapOVA-CpG(PVA). Remarkably, CpG in the formulation 
AdsOVA-CpG(PVA) could not boost the antigen-specific response as powerful as when 
entrapped into the EntrapOVA-CpG(PVA) NP. This deviation could be due to a lower co-
delivery of antigen and adjuvant into APC by AdsOVA-CpG(PVA), as in this formulation 
CpG is entrapped inside the NP and OVA is adsorbed onto the surface of the polymeric 
matrix. Therefore, it is possible that DC do not process the antigen and adjuvant together, 
leading to comparable T cell clonal expansion.  
Taken together, our results suggest that fast and efficient antigen-specific specific 
primary T cell responses occur upon co-delivery of antigen and adjuvant. Moreover, the 




In this study, we aimed to develop simple, highly reproducible and highly efficient 
uniformed delivery system to target DC. Designing safe and efficacious nanoparticulate 
vaccines requires a thorough understanding of physiochemical characteristics of NP, their 
composition and also each individual component. The combination of all of these parameters 
determines the fate and efficiency of NP. 
Our study highlights the importance of composition and physicochemical properties of 
nanoparticulate vaccines that are absolutely essential for good cellular uptake which generate 
prompt and efficient immune response. Developed NP possess desirable physicochemical 
properties, with good loading capacity, colloidal stability in biological media. All NP showed 
prompt and efficient DC activation and maturation, following by CD4+ T OT-II and CD8+ 
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OT-I cell proliferation and activation through the antigen-specific immune response. These 
are pivotal steps in the immunology that leads to a complete and effective immune response.  
Therefore, this type of nanoparticulate system could potentially be more widely 
applied in vivo; from prophylactic to therapeutic cancer vaccines to the vaccines for infectious 
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In vitro study of internalization of antigen loaded nanoparticles by bone marrow-derived 
DC: 
 
Figure S1: Gating strategy of in vitro experiment on BM-derived DC with GM-CSF and IL-4. ImageStream 
analysis was performed to detect PLGA-Rho labeled NP internalized by DC; 3, 6, 16 and 24h after the in vitro 
incubation. At least 30,000 cells were collected for each sample. Data were analyzed using a dedicated image 
analysis software (IDEAS 6.2; Amnis Corp). Images were compensated for fluorescent dye overlap by using 
single-stain controls. Cells were first gated for single cells using the area and aspect ratio features, and for 
focused cells using the Gradient RMS feature [35]. Cells were further gated using a bivariate plot for circularity 
(the degree of the mask’s deviation from a circle) based on the Object mask (a segmentation mask that creates a 
tight fit on the cell morphology) and intensity of the side scatter channel (illuminated by the 785 nm laser and 
collected in channel 12). Particle internalization was calculated by the Internalization feature, i.e. the ratio of the 
intensity inside the cell to the intensity of the entire cell, mapped to a log scale. To define the internal mask for 
the cell, the object mask of the bright field image was eroded by 5 pixels. Data are representative of tree 
independent experiments after the 16 h incubation of DC with NP. Scale bar, 7 µm. 
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In vivo characterization of immune response to the NP: T cell proliferation 
 
Figure S2: Gating strategies for expression of TCRβ, TCRVα2, CD8α or CD4 of T cells isolated from 
immunized and non-immunized LN, 3 days following immunization. Data shown are representative of three 
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Nanoparticulate vaccines present a promising strategy to activate and generate anti-
tumor immune responses. Here we designed an aliphatic polyester-based nanoparticle (NP) 
vaccine as a potential effective anti-tumor strategy aiming for co-delivery of antigens, as 
ovalbumin (OVA) and tumor associated antigens, and the Toll-like receptor (TLR) ligands 
oligodeoxynucleotide cytosine-phosphate-guanine motifs (CpG) and Monophosphoryl lipid A 
(MPLA). Two classes of NP have been developed to investigate the effect of antigen-loading 
method on the nature of ensuing immune responses. Accordingly, the antigen was adsorbed 
onto NP surface (Ads NP), or entrapped within the polymeric matrix (Entrap NP).  
This work evidences the development of safe, biocompatible and effective 
nanoparticulate vaccines both under steady-state conditions and in tumor-bearing mice. In 
fact, this novel antigen-loaded PLGA nanoparticulate vaccine successfully triggered OVA-
specific T cell cytotoxicity, T helper (Th)1-type cytokine production and consequent tumor 
growth reduction in OVA expressing B16.MO5 melanoma tumor-bearing mice. Most 
importantly, the induced activation and expansion of different immune cells was further 
confirmed at lymphoid organs and tumor site. This deeper understanding of the effect of 
antigen-loaded method on the overall immune-modulatory ability of these PLGA-based 
cancer vaccines is particularly important to design future treatment schedules to ensure 
optimal and prolonged efficacy, while preventing unexpected side effects related to their 
mechanisms of action. 
 
 
Keywords PLGA nanoparticles; cancer vaccine; antigen presenting cells (APC); dendritic 
cells (DC); cytotoxic T cells (CTL); melanoma; tumor-infiltrating lymphocytes (TIL) 
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1. Introduction 
One of the fundamental roles of the immune system is the immunosurveillance and the 
maintenance of tissue homeostasis, thereby detecting and destroying foreign invaders, such as 
pathogens. This process actively involves the coordination of innate and adaptive immunity 
and the discrimination between self and non-self-antigens [1-3]. 
Dendritic cells (DC) are the most important antigen presenting cells (APC) and play a 
prominent role in bridging innate and adaptive immune responses [4-6]. DC ingest foreign 
antigens and present them in an immunostimulatory context as major histocompatibility 
complex (MHC)-peptide complexes (MHCp) to the CD8+ cytotoxic T lymphocytes (CTL) 
and CD4+ T helper (Th) cells, respectively [7]. This cell-mediated immunity is pivotal, and 
has been widely investigated and exploited for vaccine benefit as cancer immunotherapies. 
Vaccination with tumor-associated antigens (TAA) is a promising approach to boost tumor-
specific CTL, which are crucially dependent on the adequate delivery of the vaccine to DC [8-
10]. Consequently, vaccine delivery systems can improve the outcome of antigen-specific T 
cell mediated immunotherapy in the destruction of cancer cells [11]. For T cells to become 
activated, next to the antigen presentation through MHCp, two additional signals need to be 
guaranteed, namely co-stimulation molecules and cytokine signals [12]. Accordingly, it has 
been shown that efficient immunity requires the simultaneous co-delivery of antigens and 
adjuvants, such as the Toll-like receptor (TLR) ligands, to DC [13, 14].  
Nanoparticle (NP)-based vaccines with well-defined physicochemical properties are 
versatile delivery platforms that can improve the targeted delivery of TAA, amplify immune 
activation and augment the efficacy of anti-cancer therapies [15]. Generally, major advantages 
of NP include the stability of entrapped antigen, as well as heightened immunogenicity, 
bioavailability and efficacy, by enhancing their recognition and internalization by APC. In 
fact, the controlled release of NP payloads can be influenced and dictated by carrier 
physicochemical parameters, such as chemical composition, size, surface charge, geometry 
and hydrophobicity. These properties can be relatively easy to manipulate on aliphatic 
polyester-based particulate delivery systems [16, 17]. Among aliphatic polyester polymers, 
poly(lactic-co-glycolic acid) (PLGA)-based carriers have shown a high immunomodulation 
capacity, mostly related to the passive targeting of immune cells. Their particulate nature and 
versatile physicochemical characteristics resulting from the manipulation of polymer 
properties are fundamental to increase antigen capture, but also to modify the antigen release 
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kinetics within the targeted immune cells, thus prolonging antigen presentation and resultant 
expansion of effector T cells [18, 19]. 
The major goal of this research work was to characterize the immune modulatory 
effect of a novel vaccine based on PLGA nanodelivery systems. These particulate vaccines 
have been designed to potentiate the systemic delivery of antigens to DC, under both steady 
state and cancer disease. Therefore, to further assess their potential as an effective anti-tumor 
strategy, it was important to analyze the levels of internalization of antigen-associated PLGA 
NP by distinct APC subpopulations, as well as their effect on the activation of effector 
immune responses. Accordingly, these studies evaluated their impact on the activation and 
proliferation of T cells at different time points, as well as on priming antigen-specific 
cytotoxic T cells and inducing a long-lasting memory CTL response, 8 weeks after 
immunization. These studies indicated the most efficient and thus most promising anti-cancer 
vaccine, which immune therapeutic efficacy was further evaluated in melanoma tumor-
bearing mice. Accordingly, the effect of PLGA NP entrapping a combination of ovalbumin 
(OVA) and TLR ligands (oligodeoxynucleotide cytosine-phosphate-guanine motifs (CpG) 
and monophosphoryl lipid A (MPLA)) on immune cells and overall tumor growth and mice 
survival was studied. Nanoparticulate vaccines were able to induce an effective anti-tumor 
immune response in this melanoma-bearing mice model, after a single or triple vaccination. 
We further investigated multiple factors known to have a critical impact on the efficacy of a 
therapeutic cancer vaccine, focusing on the characterization of antigen-specific CTL cells, 
which are crucial for the control or rejection of malignancies [20]. Various techniques have 
been used to provide detailed information about these antigen-specific T cells, namely 
regarding their frequency, phenotype and/or functionality. Of particular interest was the 
evaluation of the cell surface activation marker on CD8+ T cells, the selective expression of 
cytotoxic T-lymphocyte-associated-antigen 4 (CTLA-4) receptors and the cytokine 
production by effector cells at different organs, namely spleen, lymph nodes (LN) and tumor 
microenvironment. In addition, these studies also explored the frequency of tumor-infiltrating 
lymphocytes (TIL) induced after the animals’ immunization with one or three doses of PLGA 
NP.  
 
2. Materials and methods 
2.1. Materials 
Poly(lactic-co-glycolic acid) (PLGA) conjugated with polyethylene glycol (PEG), i.e. 
PLGA-PEG (5050 DLG mPEG 5000, 10 wt % PEG, molecular weight (MW) = 17 kDa), 
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Resomer® RG 502 Poly(lactic-co-glycolic acid) PLGA (MW = 7–17 kDa), Ovalbumin (OVA, 
average MW = 45 kDa), Poly(vinyl alcohol) (PVA, MW = 13-23 kDa and hydrolyzation 87-
89 %), Glycol Chitosan (CS), and Dichloromethane (DCM) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All other chemicals and reagents used in the study were of 
analytical grade.  
The adjuvants (Adjs) CpG ODN 1826 (TCCATGACGTTCCTGACGTT) and MPLA-
SM VaccigradeTM were purchased from InvivoGen (San Diego, CA, USA).  
Double distilled water (DDW) was used after filtration in a Millipore® (Millipore, 
Billerica, MA) system. 
Dulbecco’s Phosphate Buffered Saline (PBS) (1×), RPMI® medium, fetal bovine serum 
(FBS), trypsin EDTA 0.05 %, penicilin/streptomycin (PenStrep) 10,000 Unit/ml/10,000 
µg/ml, sodium pyruvate 100 mM, HEPES 1 M, non-essential amino acids and ACK lysing 
buffer were purchased from Life Technologies (Carlsbad, CA, USA). 
Fixation/Permeabilization Kit (BD Cytofix/CytopermTM Cat: 554714) was purchased 
from BD Bioscineces, San Diego, CA, USA. 
Proteome Profiler Mouse XL Cytokine Array Kit was purchased from R&D Systems, 
Inc (Minneapolis, MN, USA).  
Matrigel Matrix (Cat. no. 356234) was purchased from BD Biosciences- Discovery 
Labware, Erembodegem, Europe. 
Paraformaldehyde (PFA) 4 % (v/v) was purchased from Fisher Scientific. 
Antibodies anti-mouse CD11c (clone: N418), CD11b (clone: M1/70), CD45.1 (clone: 
A20), TCRβ (clone: H57-597), TCR Vα2 (clone: B20.1), CD3e (clone: 145-2C11), CD4 
(clone: CK1.5), CD8α (clone: 53-6.7), CD107 (clone: 1D4B), PD-1 (clone: 29F.1A12), 
CTLA-4 (clone: UC10-4B9), CD62L (clone: MEL-14), CD44 (clone: IM7), CD69 (clone: 
H1.2F3), CD25 (clone: PC61.5), IL-4 (clone: 11B11), IFN-g (clone: XMG1.2), TNF-a (MP6-
XT22), I-Ab (MHCII; clone: AF6-120.1), and Carboxyfluorescein diacetate succinimidyl 
ester (CFSE) and DAPI were purchased from BioLegend (San Diego, CA, USA). 
 
2.2. Cell line   
OVA transfected, highly metastatic B16.MO5 melanoma cell line [21] was cultured in 
RPMI 1640 with 10 % (v/v) heat-inactivated FCS, 2 mmol/L glutamine, 1 % (v/v) sodium 
pyruvate, 25 mM HEPES, 1 % (v/v) nonessential amino acids and combined antibiotics 




2.3. Mice  
Female C57BL/6 mice (6-8 weeks old) were purchased from the Envigo RMS LTD 
(Jerusalem, Israel). Female OT-I (C57BL/6) TCR transgenic mice harboring OVA-specific 
CD8+ T cells [22] and OT-II (C57BL/6) TCR transgenic mice harboring OVA-specific CD4+ 
T cells [23] were in-house bred at the Weizmann Institute of Science (Rehovot, Israel), under 
conventional, specific pathogen-free (SPF) conditions. All animals were handled according to 
protocols approved by the Weizmann Institute Animal Care Committee as per international 
guidelines. 
 
2.4. Preparation of NP 
Biodegradable polymeric NP were prepared by the double emulsion solvent 
evaporation technique (w/o/w), as previously reported with modifications [24]. Briefly, the 
aqueous solution was added to the polymer previously dissolved in the organic solvent DCM. 
The single emulsion (o/w) was formed using an ultrasonic processor (Sonifier Vibracell VC 
375, Sonics & Materials Inc, USA) at 70 W for 15 s. Two different types of NP were 
formulated: 1) the antigen dissolved in the internal aqueous solution (IP) (Entrapped (Entrap) 
protein-NP) and 2) antigen adsorbed onto the surface of the NP (Adsorbed (Ads) protein NP). 
Fluorescent NP were formulated by replacing 50 µL of organic polymer solution with 
Rhodamine 6G (Sigma-Aldrich, St. Louis, MO, USA) solution (2 mg/mL) in DCM. A 2 % 
(w/v) PVA solution was added to the (o/w) primary emulsion, and a second sonication was 
performed under the same conditions. The double emulsion (w/o/w) was added dropwise to 
the external surfactant phase (EP) with 0.3 % (w/v) PVA, and stirred at 37 °C for 1 h. The NP 
suspension was washed twice with ultrapure water by centrifugation (22000 x g, 45 min, 4 ˚C; 
Beckman Coulter, lnc, Avanti® J-E Centrifuge JA-20, USA). Final pellet of NP was 
resuspended in phosphate buffered saline (PBS) pH 7.4 and kept at 4 ˚C for further analysis. 
OVA was adsorbed onto NP after 1 h of incubation at room temperature. NP were washed 
with ultrapure water and centrifuged for 20 min (22000 x g, 4 ˚C; Beckman Coulter, lnc, 
Avanti® J-E Centrifuge JA-20, USA). 
 
2.5. Physicochemical characterization of NP 
NP size and polydispersity index (PDI) were inferred by Dynamic Light Scattering 
(DLS) using the Malvern Nano S (Malvern Instruments, UK). Nanoparticles’ surface charge 
was determined by their ζ potential, assessed by Laser Doppler Velocimetry (LDV) with 
Malvern Nano Z (Malvern Instruments, UK). Since ζ potential is highly dependent on 
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measurement conditions, NP suspension (20 mg/ml) was re-suspended in PBS to the final 
concentration 1 mg/ml and all measurements were performed at 25°C in triplicate. 
 
2.6. Atomic force microscopy 
The morphology of formulated NP was investigated at room temperature by tapping 
mode atomic force microscopy (AFM) (Nanoscope IIIa Mulimode AFM, Digital Instruments, 
Veeco), using silicon tips (ca. 300 kHz) at a scan rate of ca. 1.6 Hz. Prior to examination, all 
samples were diluted in DDW to the concentration 10 mg/ml. A drop of sample was placed 
onto freshly cleaved mica for 20 min, and dried with N2(g). 
 
2.7. Determination of antigen and adjuvants loading 
The supernatants obtained from NP centrifugations were collected to quantify 
indirectly the entrapped agents. The entrapment efficiency (EE % (w/w), Eq. (1)) and the 
loading capacity (LC µg/mg, Eq. (2)) of OVA were determined by the MicroBCATM assay 
according to the manufacturer’s instructions [14, 25]. CpG was quantified by the Oligreen® 
ssDNA quantitation kit [14]. RFU were measured using the fluorometer at 485 nm excitation 
and 530 nm emission wavelengths. 
 
𝐸𝐸 % =  !"!#!$% !"#$%& !" !"#$%&"!!"#$%& !" !"#$%&" !" !"#$%&'('&(
!"!#!$% !"#$%& !" !"#$%&"
 𝑥 100                                                    (1) 
 
𝐿𝐶 µ𝑔 / 𝑚𝑔 = !"!#!$% !"#$%& !" !"#$%&"!!"#$%& !" !"#$%&" !" !"#$%&'('&(
!"!#$ !"#$%& !" !"#$%&'
 𝑥 100                                           (2) 
 
2.8. In vivo study of antigen-loaded NP internalization by DC in draining LN 
Female C57BL/6, 8 weeks old mice (n = 6 / group) were injected into the right flank 
by the subcutaneous (s.c.) hock immunization with one of the Rhodamine 6G fluorescently-
labeled NP formulations: EntrapOVA or AdsOVA. Left non-injected flank served as negative 
control. All formulations contained OVA as the antigen. Popliteal and inguinal LN were 
harvested 16 h post-immunization (p.i.). A single-cell suspension was stained with 
fluorescent-labeled anti-mouse antibodies against CD11c, MHCII (I-Ab), CD11b and PDCA 
for 20 min at 4 °C and cells were analyzed by multispectral imaging flow cytometry 
(ImageStreamX markII flow cytometer; Amnis Corp, part of EMD millipore, Seattle, WA), as 
described below.  
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2.9. Multispectral imaging flow cytometry analysis 
Cells were imaged using Multispectral Imaging Flow Cytometry (ImageStreamX 
markII flow cytometer; Amnis Corp, part of EMD millipore, Seattle, WA). A 60 x 
magnification was used for all analyzed samples. At least 30,000 cells were collected for each 
sample. Data were analyzed using a dedicated image analysis software (IDEAS 6.2; Amnis 
Corp). Images were compensated for fluorescent dye overlap by using single-stain controls. 
Cells were gated for single cells using the area and aspect ratio features, and for focused cells 
using the Gradient RMS feature [26]. Cells were further gated using a bivariate plot for 
circularity (the degree of the mask’s deviation from a circle) based on the Object mask (a 
segmentation mask that creates a tight fit on the cell morphology) and intensity of the side 
scatter channel (illuminated by the 785 nm laser and collected in channel 12). Particle 
internalization was calculated by the Internalization feature, i.e. the ratio of the intensity 
inside the cell to the intensity of the entire cell, mapped to a log scale. To define the internal 
mask for the cell, the object mask of the bright field image was eroded by 5 pixels. 
 
2.10. Adoptive cell transfer of T cells 
For adoptive cell transfer of CD8+ cells and CD4+ T cells, spleens from 6 - 8 weeks 
old naïve OT-I and OT-II mice were positively selected for CD45.1 donor spleens, using anti-
CD8α and anti-CD4 MACS Antibody-labeled microbeads (Miltenyi Biotec, Bergisch 
Gladbach), respectively. Cells were counted and mixed in ratio 1:1, and a total volume of 200 
µL in PBS was injected intravenously (i.v.) into the tail vein, if not stated otherwise. 
 
2.11. In vivo T cell activation and proliferation at 6, 16, 24 and 48 h after 
immunization with NP 
Female mice C57BL/6, 8 weeks old (n = 6 mice/ group) had an i.v. graft of CD8+ OT-I 
and CD4+ OT-II cells. Prior to the cell transfer, both populations of cells were labeled with 5 
mM CFSE, for tracking in vivo proliferation [27]. On the following day, animals were 
injected s.c. into the right flank (hock immunization) with 50 µl of NP (20 mg/ml), 
EntrapOVA or AdsOVA. Left non-injected flank served as negative control. At the previous 
determined time points (6, 16, 24 and 48 h) after p.i. with NP, inguinal and popliteal LN were 
isolated. Cells were stained with fluorescent-labeled antibodies against CD4, CD8α, TCRβ, 
TCRVα2, CD45.1, CD25, CD69, and CD44 for 20 min at 4 °C, protected from light. Samples 
were acquired with an LSR II Fortessa flow cytometer (BD Bioscience) and analyzed with 
FlowJo software (Treestar). 
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2.12. In vivo cytotoxicity assay 
The in vivo killing assay was performed as described before [28]. Briefly, OT-I T cells 
were transfer into naive C57BL/6 mice on the first day. On the following day, mice were s.c. 
immunized with 2 mg of NP (AdsOVA, AdsOVA-Adjs, EntrapOVA, EntrapOVA-Adjs), 
OVA and Adjs in solution or PBS. Seven days following the immunization, splenocytes were 
isolated from CD45.1+ donor mice. Half of the cells were pulsed with 10 µg/ml of the OVA 
peptide SIINFEKL for 2 h at 37 °C. Un-pulsed cells served as control. Un-pulsed and pulsed 
cells were stained with 0.5 CSFElow or 5 µM CFSEhi, respectively. A mixture of both cells in 
the ratio 1:1 was transferred i.v. to C57BL/6 mouse. The differential clearance of both target 
cell populations was evaluated 16 h later in single-cell suspensions collected from LN and 
spleens. OT-I-specific CTL activity was evaluated by flow cytometry. T cells were gated for 
CD45.1+, TCR Vα2+, CD8α+ based OT-I-specific, and diluted series of CFSE fluorescence 
per cells were analyzed. 
 
2.13. Assessment of T cell memory 
C57BL/6 female mice were grouped into 7 groups of 5 animals. CFSE labeled CD8+ 
OT-I and CD4+ OT-II cells in ratio 1:1 were transferred i.v. one day prior to hock 
immunization with one of the following treatments: (1) PBS, (2) OVA & Adjs in solution, (3) 
AdsOVA, (4) AdsOVA-Adjs, (5) EntrapOVA. Two groups were treated with (6) EntrapOVA-
Adjs. Seven weeks after the immunization with one of the treatments, all animals were re-
stimulated i.v. with the 100 µg of OVA, except one of the EntrapOVA-Adjs group that served 
as a control. Seven days after the re-stimulation, spleens were collected and analyzed by flow 
cytometry. Antigen specific CTL were gated for DAPI-, CD45.1+, TCRβ+ and CD8α+. 
 
2.14. Therapeutic efficacy of the nanoparticulate vaccines against B16.MO5 
melanoma challenge 
Female C57BL/6 mice (8 weeks old) were randomized into one of the following 
treatment groups (n=7): (1) PBS, (2) Empty NP, (3) AdsOVA-Adjs NP, (4) EntrapOVA-Adjs 
NP, (5) AdsOVA-Adjs NP (3 x immunization), (6) EntrapOVA-Adjs NP (3 x immunization). 
All animals were s.c. challenged with 2 x 105 B16.MO5 tumor cells in 200 µL of sterile PBS. 
Weight of the animals was monitored twice a week and tumor growth was followed every 2 
days with a caliper. When tumors reached the size of 3 mm in diameter (day 10 post tumor 
inoculation), 1 x 106 splenocytes from OT-I and OT-II CD45.1 naïve donor spleens were 
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administered i.v.. To explore anti-tumor therapeutic efficacy of the NP, a single vaccination 
or a 3-time immunization treatment, seven days apart (Figure 4A) were performed on these 
B16.MO5 melanoma tumor-bearing mice.  
Final mean tumor volumes were calculated using the equation: V = ½ x (L x W2), 
where V is the volume (mm3), L the length (mm) and W the width (mm) of the tumor. Mice 
were sacrificed on day 31. Blood, spleens, LN and tumors were collected. Serum from the 
blood samples was separated by centrifugation (1,000 × g, 10 min at 22 °C, Allegra 64R, 
Beckman, USA) and stored at -20 °C until further quantification. A single cell suspension 
from spleens, draining LN and tumors of five animals from each treatment group was 
prepared and analyzed for infiltrated lymphocytes (CD45.1, CD3e, CD8α, CD4, CD44, 
CD62L, PD-1, CTLA-4) and cytokines (IFN-γ, TNF-α, IL-4) by flow cytometry. 
 
2.15. Therapeutic efficacy of the nanoparticulate vaccines without a transfer 
of transgenic T cells 
A second experiment was performed without the transfer of OT-I splenocytes. Eight 
weeks old female C57BL/6 mice were randomized and s.c. challenged with 2 x 105 B16.MO5 
melanoma cells. Ten days after tumor inoculation animals were immunized with a single dose 
of one of the treatments: (1) PBS, (2) Empty NP, (3) AdsOVA-Adjs NP, and (4) EntrapOVA-
Adjs NP. Tumor growth and mice weight were monitored as mentioned before (section 2.14). 
 
2.16. Cytokine quantification in spleens and tumors of treated mice 
Intracellular cytokine staining was performed using the Cytofix/Cytoperm plus kit 
(PharMinigen) [29]. Briefly, single-cell suspensions of splenocytes were treated with ACK 
lysis buffer for 1 min at 37 °C to remove red blood cells. Splenocytes were washed with PBS 
and resuspended in 1 mL of RPMI. The tumors obtained from five mice in each treatment 
groups were processed into the single-cell suspension, washed with PBS and resuspended in 1 
ml of RPMI. Two aliquots of 500 µL for each sample were prepared in FACS tubes and 
incubated for 2 h at 37 °C and 5 % CO2 with media alone (for the negative control) or with 
Phorbol 12-myristate 13-acetate (PMA; 25 µL/mL) and ionomycin (25 µL/mL). After 
incubation, a secretion inhibitor brefeldin A (Sigma, Steinheim, Germany), at a final 
concentration of 3 µg/mL was added and incubated for additional 4 h to block the secretory 
pathways and to keep the cytokines trapped intracellularly. Extracellular antigens (CD3e+, 
CD4+, CD8α+) were stained, prior to the cell fixation and permeabilization with 250 µL 
Cytofix/Cytoperm permealized/wash solution for 20 min. The staining of the intracellular 
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cytokine was performed with anti-cytokine fluorescent antibody conjugates to detect 
accumulated IFN-γ, TNF-α and IL-4 cytokines. Cells were washed in permealized/wash 
solution and resuspended in 400 µL of FACS buffer prior to flow cytometry analysis. All 
samples were analyzed by FlowJo software (TreeStar, San Carlos, CA, USA). 
 
2.17. Tumor histology 
From each group of C57BL/6J tumor bearing mice, two of the removed tumors were 
fixed for 24 h in 4 % (v/v) paraformaldehyde (PFA) at 4 °C, washed with PBS (pH 7.4) and 
stored into 70 % (v/v) ethanol (EtOH) for processing in paraffin-embedded blocks. Samples 
were cut in 2 µm thick slices. After the deparaffinization in xylene and rehydratation by 
sequential incubation in EtOH/water solutions, the samples were stained with both 
hematoxylin and eosin (H&E) staining, and fluorescent antibodies for detection via 
immunofluorescence. The latter was done by an overnight incubation with primary CD3 
(1:50), CD8 (1:50), CD4 (1:100) antibodies (R&D Systems, Minneapolis, MN) in cold room. 
Slides were washed with PBS three times for 15 min and stained with biotinylated secondary 
antibodies (1:50) for 60 min at the room temperature in a humidified atmosphere. After 
incubation, slides were washed and rabbit streptavidin antibodies were applied to enhance 
biding affinity of antibodies, thus improving the overall staining. After rinsing with PBS, 
sections were stained with DAPI (1:1000) and mounting medium (Invitrogen) was applied for 
cover slipping. The images were acquired with Nikon Eclipse Ni fluorescent microscope 
using Carl Zeiss Axioskp 2 mot plus and their analysis to quantify the immunofluorescence 




All results are presented as mean ± standard deviation (SD). One-way ANOVA 
analysis, following by a Tukey-Kramer test was applied to demonstrate statistical differences 
(p ˂ 0.001 (***), p ˂ 0.01 (**), p ˂ 0.05 (*)). For direct comparison between two groups of 
data, t-student test was applied. All tests were performed in GraphPad Prism 5® (GraphPad 






3.1. Characterization of developed NP 
Polymeric NP were prepared by the double emulsion solvent evaporation technique 
(w/o/w), using PLGA or PLGA-PEG aliphatic polyester copolymers [24]. Formulation 
parameters such as average size, PDI, ζ potential, EE (%) and LC (µg/mg) were monitored for 
both types of antigen-loaded NP: Entrap NP or Ads NP (Table 1). EntrapOVA NP presented a 
size range between 188 ± 8 nm with a narrow particle size distribution (PDI range 0.16 ± 
0.05). When the antigen was adsorbed onto the surface of the NP (AdsOVA NP), these 
carriers presented size of 195 ± 14 nm and PDI of 0.19 ± 0.10 (Table 2). Thus, regardless of 
the type of antigen association to the nanoparticulate formulation, both NP presented similar 
sizes. All formulations were developed using 0.5 % (wCS/wpolymer) CS solution. NP with 
entrapped antigen were formulated using 2.5 % (wOVA/wpolymer) OVA solution as the aqueous 
phase (IP), while for antigen-adsorbed NP, empty PLGA NP were incubated with 5 % 
(wOVA/wpolymer) OVA solution. The amount of PVA present in the supernatants obtained from 
NP washing procedures was quantified by HPLC. It was observed that 96 ± 2.1 % of the PVA 
initially used for the emulsification process was efficiently removed during NP isolation.  
The ζ potential was measured in PBS (pH 7.4) mimicking the intracellular cytosolic 
environments. Although the ζ potential varied between 0 to -1.5 mV in all formulations, it 
was still close to neutrality (Table 2). The slightly lower surface charge obtained for AdsOVA 
NP may be due to the negative charge of the OVA protein, which is expected to be on the 
surface of NP, when compared to its dispersion within the polymeric matrix in the 
EntrapOVA NP. Moreover, the presence of PEG chains shields the negative charge of PLGA 
at NP surface in these EntrapOVA NP.  
Both EE and LC were validated with two different methods: MicroBCA and HPLC. 
EntrapOVA NP showed 80 % entrapment of the initial protein solution, while the adsorption 
efficiency of AdsOVA NP was close to 50 %.  
Atomic force microscopy (AFM) was used to further characterize the size, shape and 
surface morphology of NP (Figure 1). Both NP had a smooth surface and spherical 
topography with uniform size distribution, which correlated with the data obtained by DLS 
analyzer. Section analysis of PLGA-PEG NP with entrapped antigen demonstrated an average 
diameter of 30 nm smaller than the hydrodynamic diameter obtained by DLS. This can be 
explained by the fact that for dried NP, the PEG chains were not in a hydrated state, hence not 
being extended in the form of corona as they were during the DLS measurements. 
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Table 1: NP composition. 





EntrapOVA  PLGA-PEG 10 % PVA, CS, OVA 
2% (w/v) 
PVA 
0.3 % (w/v) 
PVA 
- 
EntrapOVA-Adjs PLGA-PEG, MPLA 10 % PVA, CS, CpG, OVA - 
AdsOVA PLGA 10 % PVA, CS,  OVA 
AdsOVA-Adjs PLGA, MPLA 10 % PVA, CS, CpG OVA 
* internal phase, ** external phase 
 
Table 2: Physicochemical characterization of OVA-loaded NP. (Mean ± SD; n ≥ 5). 
Formulation Size (nm) PdI ζ-potential (mV) 





EntrapOVA 188 ± 8.0 0.160 ± 0.05 0.41 ± 0.20 19.56 - 
EntrapOVA-Adjs 198 ± 7.0 0.180 ± 0.03 0.66 ± 0.30 18.97 - 
AdsOVA 195 ± 14 0.190± 0.10 -1.15 ± 0.50 - 19.72 
AdsOVA-Adjs 197 ± 12 0.200 ± 0.04 -1.32 ± 0.40 - 21.17 
 
3.2. In vivo uptake study of antigen loaded NP by APC 
DC and macrophages are both very effective APC [30]. However, macrophages are 
large phagocytic cells that play a critical role in the innate immune response [31]. On the 
other side, DC are considered the bridge between the innate and adaptive immunity, as they 
initiate innate immune responses and control critical steps in the cascade of adaptive 
immunity, thereby contributing to the initiation and regulation of specific T cell responses 
[32, 33]. Moreover, DC have an extensive capacity for NP internalization in the periphery. 
They migrate to draining LN where they process and present antigenic peptides to naïve T 
cells.  
For the in vivo uptake study of antigen-loaded NP, female C57BL/6 mice (8 weeks 
old) were injected s.c. with one of the fluorescent-labeled NP formulations: EntrapOVA or 
AdsOVA. The contralateral non-immunized flank served as negative control, lacking both NP 
and antigen. NP-internalized APC were analyzed with high throughput and spatial resolution, 
by imaging stream flow cytometry (Suppl. Figure S1) [34]. We isolated popliteal and inguinal 
LN, prepared single cell suspensions and analyzed CD11b+, CD11c+CD11b- and 
CD11c+CD11b+ cells, as representatives of the LN myeloid compartment [35]. 
No significant difference in the total fluorescence was detected 16 h upon 
administration of EntrapOVA or AdsOVA NP. This indicated that the same cell populations 
internalized a similar amount of NP (Figure 1C-D). Among all studied cells, the 
CD11c+CD11b+ population internalized the highest amount of NP. Both EntrapOVA and 
AdsOVA NP were also equally taken up by CD11b+ cells. On the other side, CD11c+CD11b- 
cells presented slightly lower NP internalization (30-35 %) (Figure 1C). Additional surface 
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markers for plasmacytoid DC (pDC; anti-PDCA-1) were used to discern differences in the 
uptake of EntrapOVA or AdsOVA NP. Interesting, AdsOVA NP yielded significantly higher 
number of pDC in the draining LN, than EntrapOVA NP (Figure 1F). 
To address the changes of the activation molecule MHCII, before and after NP 
internalization, the total fluorescence and median pixel intensities of the MHCII fluorescent 
signal was quantified for each studied cell population (Figure 1E). As shown in Figure 1E, a 
significant increase of the MHCII activation marker occurred after the internalization of 
EntrapOVA NP and AdsOVA NP in all of studied cell populations (CD11b+, CD11c+CD11b-, 
and CD11c+CD11b+). 
 Figure 1: Section analysis and diameter distribution of nanoparticle by atomic force microscopy. (A) PLGA-
PEG NP with entrapped OVA protein (EntrapOVA NP), (B) PLGA NP with adsorbed OVA protein (AdsOVA 
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NP). ImageStream analysis was performed to detect in vivo Rho labeled NP internalization by APC 16 h p.i. at 
37 °C. Distribution of at least 30,000 cells was calculated by Amnis IDEAS software and presented with the 
histograms showing the percentages of APC with internalized NP (C) and % of MHCII activated APC (E). 
Examples of representative images with AdsOVA NP (D). First column shows brightfield (BF) images of the 
cells, second column shows images of Rho labeled NP (NP), third column shows CD11b+ cells (CD11b), forth 
column CD11c+ cells (CD11c), fifth column shows MHCII+ cells (MHCII), sixth column presents merged 
images of the precedent fields (BF/NP). (D.a) CD11c+ with upregulated MHCII. (D.b) NP internalized by 
CD11b+ cell. (D.c) NP taken up by double positive cells CD11b+CD11c+ cell. Results are represented as mean ± 
SD, normalized to that of control non-labeled cells, representative of three independent experiments (n = 3). 
Scale bar, 7 µm. (F) ImageStream representative plots showing the gating of cells with surface makers CD11b, 
CD11c and PDCA-1. 
 
3.3. In vivo T cell activation and proliferation at 6, 16, 24 and 48 h after NP 
immunization 
This study focused on the in vivo kinetics of the activation and proliferation capacity 
of antigen-specific CD4+ and CD8+ T lymphocytes, first step towards an effector T cell 
phenotype. Different time points were assessed by flow cytometry after hock immunization 
with PBS, EntrapOVA NP or AdsOVA NP. To determine the activation profiles of CD4+ 
(OT-II) and CD8+ (OT-I) T cells in draining LN, the phenotypic changes in the expression of 
surface molecules (CD25, CD69, and CD44) were measured in combination with CFSE 
(Suppl. Figure S2). CD25 and CD69 are early activation markers [36, 37]. Conversely, CD44 
is upregulated on activated T cells, firstly more gradually but persists at high levels on 
memory T cells [38, 39].  
After immunization with EntrapOVA NP and AdsOVA NP, the percentages of CD4+ 
and CD8+ T cells expressing CD25 and CD69 increased exponentially over time (Figure 2A-
B). The number of CD25+ CD4+ and CD25+ CD8+ T cells increased 3- or 4-fold respectively, 
within 48 h p.i.. Compared to other time points, a modest decline in the percentage of CD69+ 
CD8+ T cells was observed in the LN 24 and 48 h after immunization. Consistent with the 
results observed for CD25+ and CD69+ T cells, the percentage of CD4+ and CD8+ T cells 
expressing CD44 activation marker was gradually upregulated over time. However, there was 
not only an increase in the percentage of activated T cells, but also an increase in the absolute 
number of activated T cells, as shown by the serial dilution of CFSE dye indicating new 
generation of activated T cells (Figure 2A-B).  
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Overall, the activation and expansion of antigen-specific CD4+ and CD8+ T 
lymphocytes into effector T cells represent key steps in the development of an efficient 
adaptive immune response [40]. 
 
 
Figure 2: Activation profiles of T cells isolated from the draining LN. Time dependent phenotypic changes in the 
expression of activation surface molecules (CD25, CD69, and CD44) on CD4+ (A) and CD8+ (B) transgenic T 
cell stimulated in vivo. The expression of CD25, CD69, and CD44, was measured on freshly isolated cells by 
flow cytometry. Histograms present the mean values of three independent experiments, each with n=3 mice per 
time point.  
 
3.4. In vivo cytotoxicity assay 
The aim of every successful vaccination is an effective activation and priming of 
antigen-specific cytotoxic CD8+ T (CTL) cells that recognize and kill target cells. To explore 
whether the immunization with formulated NP results in efficient cross-priming, an in vivo 
cytotoxicity assay was performed. Naïve C57BL/6 mice were engrafted with CD8+ (OT-I) 
cells and 24 h later immunized with PBS, OVA & Adjs in solution, AdsOVA NP, AdsOVA-
Adjs NP, EntrapOVA NP or EntrapOVA-Adjs NP. Five days after immunization, mice were 
injected with CD45.1+ splenocytes. The graft consisted of an equal mix (1:1) of target cells: 
pulsed with the OT-I specific OVA-derived peptide (SIINFEKL) pulsed cells labeled with 
higher dose of CFSE (CFSEhi) and un-pulsed control cells labeled with a lower dose of CFSE 
(CSFElow). The differential in vivo clearance of both target cell populations was evaluated 16 
h later in single-cell suspensions collected from LN (Figure 3, Suppl. Figure S3) and spleens 
by flow cytometry. 
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Antigen-specific OT-I CTL with acquired cytotoxic function selectively kill 
SIINFEKL-pulsed target cells and do not affect the proliferation of un-pulsed target T cells 
[41]. The results from the isolated LN (Figure 3), demonstrated that all immunizations with 
NP formulations, with or without adjuvants, generated the most efficient in vivo killing 
activity towards the SIINFEKL-pulsed cells, as shown by the disappearance of the CFSEhi 
peak of cells [28]. Likewise, OVA & Adjs in solution induced a moderate cytotoxicity. The 
control group without OVA antigen did not display detectable killing activity. Similar data 
was obtained for the cytotoxic ability of T cells in spleens of the animals (data not shown), 
indicating the successful induction of a systemic immune response. 
 
 
Figure 3: Cytotoxicity ability of antigen-specific cytotoxic T lymphocytes (CTL) in LN from naïve C57BL/6 
mice seven days after treatment with PBS, OVA & Adjs in solution, AdsOVA NP, AdsOVA-Adjs NP, 
EntrapOVA, or EntrapOVA-Adjs. 
 
3.5. Establishment of memory CTL cells 
Immunological memory is the prime feature of adaptive immunity and guaranty rapid 
and effective response to foreign antigens that have been previously encountered. Therefore, 
long-lasting and stable memory is essential for successful vaccination. We evaluated the long-
lasting memory of CTL eventually induced 8 weeks after the first immunization in response 
to the different ways of antigen delivery. Naïve C57BL/6 mice were immunized with PBS, 
OVA in solution, OVA & Adjs in solution, AdsOVA NP, AdsOVA-Adjs NP, EntrapOVA 
NP, or EntrapOVA-Adjs NP after engraftment with CD8+ (OT-I) cells. Seven weeks p.i., 
animals were re-stimulated i.v. with 100 µg of OVA, except for one EntrapOVA-Adjs group, 
which served as a control. One week later, spleens were isolated, and the presence of antigen-
specific CD8+ (OT-I) CTL was assessed by flow cytometry (defined as DAPI-, TCRβ+, 
CD45.1+, and CD8α+ cells, Suppl. Figure S4). 
Antigen recall induced a remarkable proliferation of CD8+ (OT-I) in mice that had 
been immunized with EntrapOVA-Adjs NP 8 weeks earlier (Figure 4). Interestingly, re-
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stimulation did not induce efficient CTL recall after immunization with AdsOVA-Adjs NP, 
AdsOVA NP, EntrapOVA NP or OVA & Adjs in solution. 
Two groups, PBS and EntrapOVA-Adjs NP without re-stimulation, were used as 
controls and did not show expansion of CD8+ (OT-I) T cells. All memory cells uniformly 
expressed high levels of CD44 and low levels of CD62L (data not showed) as previously 
reported [42].  
 
 
Figure 4: Immunization with protein and adjuvant in the uniformed delivery system drives development of 
memory CTL. Proliferation of antigen-specific memory T cells was determined by flow cytometry 8 weeks p.i. 
FACS plots are representative of at least three independent experiments with 2-3 mice per group. 
 
3.6. Therapeutic efficacy of the nanoparticulate vaccines against B16.MO5 
melanoma challenge 
Two treatment schedules were followed to explore the therapeutic efficacy of the anti-
tumor nanoparticulate vaccines in B16.MO5 melanoma tumor-bearing mice: single 
vaccination and 3-time immunization treatment, seven days apart (Figure 5A). B16.MO5 are 
characterized by a constitutive production of OVA protein, which render them targetable by 
immune cells instructed to recognize OVA as antigen. Nine days after tumor inoculation, 1 x 
106 CD45.1 OT-I and 1 x 106 CD45.1 OT-II splenocytes were engrafted into tumor-bearing 
mice to follow an antigen-specific immune response against tumor cells. Mice were then 
randomized into one of the following treatment groups: (1) PBS, (2) Empty NP, (3) AdsOVA-
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Adjs NP, (4) EntrapOVA-Adjs NP, (5) AdsOVA-Adjs NP (3x immunization), (6) 
EntrapOVA-Adjs NP (3x immunization).  
 
 
Figure 5: Anti-tumor therapeutic efficacy of the nanoparticulate vaccines. (A) Schedule of the assay. (B) Mean 
tumor growth curves given by mean tumor volume over time, determined by V = ½ × (L × W2), where L (length) 
is the longest dimension and W (width) is the perpendicular dimension to the length. (C) Representative images 
of removed melanoma tumors from each treatment group at the end of the assay. (D) The tolerability of the 
vaccine was evaluated by monitoring body weight of the treated mice. (E) Mean final tumor weight per 100 g of 
final body weight. Mean ± SD, n = 6, ***p < 0.001. 
 
The groups immunized with PBS and Empty NP served as a control and presented 
similar tumor growth. All treated groups showed a significant reduction in tumor growth, 
compared to control groups (p < 0.001) (Figure 5B). EntrapOVA-Adjs NP (3x immunization) 
presented the slowest tumor growth, followed by the group immunized with AdsOVA-Adjs 
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NP (3x immunization) and EntrapOVA-Adjs NP. This can be also appreciated in the 
representative images of removed melanoma from each treatment group at the end of the 
assay (Figure 5C). The mean mass of tumors per 100 g of final body weight are presented on 
Figure 5E. The mean mass of tumors was in accordance with the obtained mean tumor growth 
curves, with the group 3-times immunized with EntrapOVA-Adjs NP presenting the lowest 
mean tumor mass per 100 g of final body weight. 
The vaccine tolerability and safety in vivo were evaluated by monitoring body weight 
of the treated animals and further calculated by the mean ratios of body weight to the initial 
body weight of mice. Body weights in all groups increased during the treatment, therefore no 
abrupt weight loss was observed (Figure 5D). 
 
3.7. T cell infiltration in the tumor microenvironment 
It has been previously reported that tumor-infiltrating lymphocytes (TIL) confer a 
positive prognostic value [43-45]. 
To identify the immune cells infiltrating the B16.MO5 melanoma-bearing mice, a 
single cell suspension of tumors was prepared, and the presence of antigen-specific (CD3e) 
TIL was assessed by flow cytometry (Figure 6A & B; Suppl. Figure S5 show a representative 
plots of gating strategy, cells were gated by TCRβ+, CD45.1+,CD3e+, CD4+ and CD8α+). It 
was observed an increased level of TIL in all treated groups. Moreover, besides that increase 
in the percentage of intra-tumoral T cells, there was also a dramatic increase in the absolute 
number of T cells, as shown by the flow cytometry plots (Figure 6A).  
 
 
Figure 6: (A) Representative flow cytometry plots of the percentages of tumor infiltrated lymphocyte (TIL) 
CD45.1+ versus CD3e+ T cells. (B) Mean percentages of TIL present on tumor suspensions obtained from each 
treatment group. Mean ± SD, n = 6. *p < 0.05, **p < 0.01 
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Figure 7: Images are representative histology sections with H&E staining and immunohistochemistry staining 




The 3-time immunization with AdsOVA-Adjs NP or EntrapOVA-Adjs (p < 0.01) was 
more efficient in supporting T cell recruitment into tumor tissues than a single vaccination (p 
< 0.05), when compared to the control group (Figure 6B).  
Hematoxylin and eosin (H&E)-stained sections were prepared for diagnostic purposes 
of stromal TIL, which are usually dispersed in the spaces between the carcinoma nests and do 
not directly contact carcinoma cells (Figure 7; first column with H&E staining) [2]. 
Generally, the H&E-stained sections showed that vaccination with the nanoparticulate 
vaccine generated the formation, growth and high density of stromal TIL (Figure 7; indicated 
with the arrow), compared to the groups treated with PBS or empty NP. 
Figure 7 with CD8-staining shows a generally increase of CD8+ TIL levels after a 
single dose of the nanoparticulate vaccines, particularly after immunization with EntrapOVA-
Adjs. Finally, 3-time immunization with AdsOVA-Adjs NP or EntrapOVA-Adjs led to an 
increased infiltration of both CD8+ and CD4+ TIL. 
 
3.8. Flow cytometry analysis of antigen-specific T cells 
To characterize activation of antigen-specific T cell response to the tumor, we 
measured cell surface expression of the: i) activation marker CD107a (also known as 
lysosomal-associated membrane glycoproteins; LAMP-1) ii) inhibitory receptor programmed 
death-1 (PD-1) and iii) cytotoxic T-lymphocyte-associated-antigen 4 (CTLA-4) on antigen-
specific CD8+ (OT-I) T cells of different organs, namely spleen, LN and tumor, by flow 
cytometry (Supp. Figure S6).  
CD107a has been described as a marker of CD8+ T-cell degranulation upon its 
stimulation [46]. The results showed CD107a upregulation after immunization with one of the 
formulated NP (AdsOVA-Adjs NP or EntrapOVA-Adjs NP) (p < 0.001), while the CD107a 
levels in the control groups were below 5 % (Figures 8A-C). Interestingly, no differences 
were detected in the levels of CD107a after single or 3-time vaccinations. However, the 
overall number of antigen-specific cells was higher after the 3-time immunization. Therefore, 
one would predict higher mediated cytotoxic activity in animals immunized with three doses 
of the nanoparticulate vaccines. 
CTLA-4 recruitment antagonizes the activation of T cell at the initiation of an immune 
response in the draining LN, while PD-1 mainly regulates effector T cell activity in response 
to tumor progression [1, 47, 48]. 
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Interestingly, our study showed that the 3-time vaccination protocol with AdsOVA-
Adjs NP or EntrapOVA-Adjs NP induced the expression of CTLA-4 in T cells isolated from 
the spleen and LN (Figure 8D-E). A significant upregulation was observed in the group 
vaccinated with AdsOVA-Adjs NP, compared to mice immunized with EntrapOVA-Adjs NP 
(p < 0.05). 
 
Figure 8: Activation of cytotoxic CD8+ (OT-I) T lymphocytes in (A) spleen and (B) LN. (A & B) Histograms 
show frequency of the activated CD107a+ CD8+ CTL. (C) Representative flow cytometry plots of LN single–cell 
suspension from the control and EntrapOVA-Adjs NP (3x) groups, gated for CD45.1, CD3e, TCR Vα2 cells. (D 
& E) Histograms show frequency of the activated CTLA-4 T cells in (D) spleens and (E) LN in tumor-bearing 





3.9. Cytokine quantification in spleens and tumors of treated mice 
In order to understand the type of the immune response induced by the different 
nanoparticulate vaccines and tested schedules, the levels of IFN-γ, TNF-α and IL-4 cytokines 
were determined by intracellular staining (Figure 9). For the detection of produced cytokines, 
single cell suspension of tumors and spleens were gated for CD45.1+, CD3e+ and CD8α+, 
which includes engrafted antigen-specific OT-I T cells (Suppl. Figure S7). 
The groups vaccinated with single dose of AdsOVA-Adjs NP or EntrapOVA-Adjs 
presented the highest levels of the splenic IFN-γ-producing (p < 0.001) and TNF-α-producing 
(p < 0.001) CD8+ (OT-I) T cells, compared to the control and 3-time vaccination groups. 
Surprisingly, the 3-time immunization protocol, with the same nanoparticulate vaccine, did 
not induce further the secretion of either IFN-γ or TNF-α by T cells. This could be due to the 
compromised activation or exhaustion of T cells.  
Tumor infiltrating CD8+ (OT-I) T cells (TIL) secrete/produced significantly higher 
levels of TNF-α upon one immunization with EntrapOVA-Adjs and 3-time immunizations 
with both NP formulations, compared to control groups. Levels of IFN-γ+ CD8+ TIL cells are 
increased only upon one application of the NP vaccination, whereas upon 3-time application 
they return to the same level as in the control groups.  
No differences were observed between IL-4 cytokine levels detected in different 
groups, which were in fact undetectable (data not shown). 
 
3.10. Therapeutic efficacy of the nanoparticulate vaccines without a transfer 
of transgenic T cells 
To explore the intrinsic potential of the developed anti-cancer nanoparticulate vaccine, 
a new group of animals was challenged with B16.MO5 melanoma, and treated without any 
engraftment of antigen-specific (OT-I) cells. After a single immunization, both AdsOVA-
Adjs NP and EntrapOVA-Adjs NP delayed tumor growth (p < 0.001, Figure 10A-C). 
However, EntrapOVA-Adjs NP were more efficient, which is in accordance with the results 
reported with the previous experiment. These results indicate that the presence of previously 
transfer antigen-specific OT cells did not influence the outcome of the treatment. Even in the 
absence of OT-I cells, the vaccination with NP was efficient and led to the development of an 
adaptive immune response starting with the endogenous pool of T cells. Therefore, with this 
study we have confirmed the efficacy and safety of the developed nanoparticulate vaccine. 
 
Anti-tumor efficacy of developed nanoplatforms 
127 
Figure 9: Intracellular staining of CD8+ T cells and cytokine levels in (A-C) spleens and (D-F) tumors. 
Representative flow cytometry plots of TNF-α and IFN-γ in (A) spleens and (D) tumors from the control, 
AdsOVA-Adjs NP EntrapOVA-Adjs NP, AdsOVA-Ajs NP (3x), and EntrapOVA-Adjs NP (3x) groups. (B & E) 
Histograms show frequency of the activated TNF-α T cells in (B) spleens and (E) tumors. (C & F) Histograms 





Figure 10: Anti-tumor therapeutic efficacy of the nanoparticulate vaccines without the previous transfer of 
transgenic T cells. (A) Mean tumor growth curves given by mean tumor volume over time. (B) Representative 
images of removed melanoma tumors from each treatment group at the end of the assay. (C) Mean final tumor 
weight per 100 g of final body weight. Mean ± SD, n = 6, ***p < 0.001. 
 
4. Discussion 
Nanodelivery systems are promising platforms for cancer immunotherapy due to their 
nanoscale size, successful co-entrapment of various active agents, and intrinsic 
biocompatibility [49]. In addition, nanosystems have extensively shown to positively alter 
payload biodistribution and increase therapeutic efficiency, while reducing a nonspecific 
toxicity [50]. 
Here, we report the use of PLGA NP as an antigen delivery carrier to investigate how 
different antigen-loading nanovaccines affect antigen uptake by APC and generation of DC-
mediated antigen-specific immune responses. We developed two highly reproducible and 
homogeneous nanoplatforms - AdsOVA NP and EntrapOVA NP – based on the hydrophobic 
aliphatic polyester PLGA which allows the association of the antigen (OVA) and 
incorporation of adjuvants (CpG and MPLA) into the core of the its matrix. The presence of 
PEG polymer on the surface of EntrapOVA NP may be responsible for the similar size 
distribution, polarity of ζ potential and hydrophobicity presented by both OVA adsorbed and 
entrapped formulations. Narrow particle size distribution, mean diameter close to 190 nm and 
spherical geometry were also confirmed by AFM. The two classes of NP allowed us to 
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investigate the affect of antigen-loading method on the nature of ensuing immune responses. 
We hypothesize that the resulting immune responses would be significantly affected by the 
different nature of initial antigen exposure to APC.  
To test this hypothesis, we firstly evaluated the in vivo uptake profile of NP by APC at 
predetermined time points (6 h, 16 h and 24 h). At 6 h, the amount of NP in the draining LN 
was too low to be detected. However, it has been reported before that it usually takes 8-16 h 
for pathogens to migrate within the lymph drainage or be actively transported by DC [51,52]. 
It was visible a peak in the fluorescence 16 h p.i, indicating the presence of the highest 
amount of Rhodamine-6G labeled NP in the draining LN. The fluorescence peak decreased at 
24 h, which may suggests that a certain amount of Rhodamine-6G NP was already digested 
and degraded inside the APC. In addition, it can also indicate a possible release of this probe 
from the carrier. Therefore, we selected the time point 16 h p.i. for the in vivo uptake studies 
analyzed by imaging stream flow cytometry. We explored the myeloid compartment of the 
LN subdivided into different APC populations: macrophages, classical DC (cDC) and 
plasmacytoid DC (pDC) [35].  
The in vivo kinetic study of NP internalization clearly indicated the efficient ability of 
APC to capture both types of NP, despite the antigen association method. In fact, no 
significant difference was detected in the total fluorescence for EntrapOVA or AdsOVA NP 
once internalized by the CD11b+, CD11c+CD11b- and CD11c+CD11b+. On the other side, 
pDC yielded significantly higher uptake of AdsOVA NP than EntrapOVA NP. Antigen 
presented on the NP surface (AdsOVA NP) may have enhanced affinity for pDC, whereas 
EntrapOVA NP may have rapidly escaped peripheral internalization by pDC, most probably 
due to the PEG present on the outer surface of NP. It is widely known that PEG “stealth” 
effect prevents NP premature capture [53,54], and thus prolongs their circulation under in 
vivo conditions.  
To verify the specificity of DC-mediated antigen-specific activation and characterize 
the proliferation of T cells induced by the antigen-associated NP, a well-established animal 
model within the immunology field was used. Accordingly, a highly immunogenic protein, 
OVA, served as an antigen, in combination with the engraftment of CD4+ (OT-II) and CD8+ 
(OT-I) T cell, carrying a transgenic OVA-responding T cell receptor to better trace and 
characterize antigen-specific immune response upon NP vaccination.  
To test the cytotoxic nature of the immune response developed in immunized animals, 
an in vivo killing assay was carried out. Vaccination with developed OVA-loaded NP 
(AdsOVA NP, Entrap OVA NP, AdsOVA-Adjs NP or EntrapOVA-Adjs NP) was efficient in 
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activating antigen-specific OT-I CTL and selective killing of SIINFEKL-pulsed targeted 
cells. Interestingly, the nature of antigen delivery, entrapped vs. adsorbed, in the presence or 
absence of the Adjs, did not have a significant influence on the resultant primary immune 
response. Therefore, both delivery systems efficiently drove the immune system towards a 
cross-presentation and cross-priming of antigen-specific cytotoxic CD8+ T (CTL) cells, which 
is especially important in cancer immunotherapy [55].  
To obtain deeper insight into the nature of immune response and better understand the 
effect of antigen association and combination with adjuvants, it was further important to 
characterize expansion of different subpopulations of T lymphocytes. Thus, in the in vivo 
kinetic study, we focused on the activation profile and proliferation capacity of antigen-
specific CD4+ (OT-II) and CD8+ (OT-I) T lymphocytes in draining LN. We observed that the 
activation of CD8+ T cells upon EntrapOVA NP was more prominent compared to the 
quantified in animals immunized with AdsOVA NP. This data suggested that EntrapOVA NP 
can generate stronger antigen-specific CD8+ immune responses towards an effective memory 
T cells [40], even if no differences were previously observed in the in vivo killing assay for 
both Entrap and Ads NP. 
These evidences were further supported by the long-lasting memory study, where a 
remarkable proliferation of CD8+ (OT-I) was induced in mice that had been immunized with 
EntrapOVA-Adjs NP and re-stimulated with antigen (OVA boost) 7 weeks after treatment. A 
recall of antigen-specific CTL was not so efficient after immunization with AdsOVA-Adjs 
NP or OVA & Adjs in solution. Although all AdsOVA-Adjs NP were efficient internalized by 
APC and led to an equally strong OVA-specific cytotoxic immune response, these NP were 
not able to generate long-lasting effector memory, in contrast to EntrapOVA NP. This 
observation may be explained by an absent or delayed TLR signal. OVA is adsorbed on the 
NP surface through the establishment of weak electrostatic interactions, while the Adjs (CpG 
and MPLA) are dispersed into the matrix of the nanoparticulate vehicle. Therefore, OVA can 
be desorbed from NP surface prior to the release of Adjs, which will be rather controlled by 
the digestion and erosion of NP matrix. Consequently, the administration of AdsOVA-Adjs 
NP may not guarantee the co-stimulatory signal essential for an efficient generation of 
activated and long-lasting memory CD8+ T cells. In addition, animals immunized with 
vaccines free of Adjs (AdsOVA NP, EntrapOVA NP or OVA in solution) failed to generate 
memory CD8+ (OT-I) T cells. To the best of our knowledge, with this study we are the first to 
report the induction of a long-lasting effector memory CTL, even 8 weeks after a single 
immunization with a nanoparticulate vaccine. Thus, this long-term memory study provides 
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important insights into the effect of antigen delivery on the overall nanovaccine efficiency. 
Our findings have important implications for future vaccine development, as they suggest that 
protein boosting with adjuvant in a uniformed and unique delivery system (EntrapOVA-Adjs 
NP) can generate long-term functional memory CTL. 
Having in consideration the above discussed promising effects on immune cells, it was 
important to clarify if the induced immune response would be able to fight against cancer 
growth. Therefore, the anti-tumor therapeutic efficacy of the developed nanovaccines 
(AdsOVA-Adjs NP and EntrapOVA-Adjs NP) has been tested on B16.MO5 melanoma-
bearing C57BL/6 mice. When choosing this tumor model, authors were aware of the severity 
of its epigenetic phenotype, high enzymatic activity and multiple immune escape tumor-
mediated mechanisms [56]. However, there is an important advantage of this system mostly 
related to the xenograft nature of the OVA antigen, constituting a clean and distinct read-out 
model that allows detailed and controlled characterization of the antigen-specific nature of the 
overall immune response. This model thus constitutes a perfect intermediate that may support 
a possible correlation of the data obtained under steady-state conditions and later evidenced in 
a proof of concept study using a cancer mouse model expressing an immunodominant TAA, 
such as the Her2-expressing cancer model. 
Tumor growth was significantly delayed by the administration of the developed 
nanovaccines. The slowest tumor growth was achieved after the 3-dose immunization 
schedule with EntrapOVA-Adjs NP, followed by the group that has been vaccinated 3-times 
with AdsOVA-Adjs NP and once with EntrapOVA-Adjs NP. Both control groups (PBS and 
Empty NP) presented similar tumor growth, indicating that the nanoparticulate-vehicle itself 
did not possess an immunotherapeutic effect. As nanovaccine efficacy could be attributed to 
the adoptive transfer of OT-I (CD8+) and OT-II (CD4+) T cells, we addressed this hypothesis 
by triggering the immune response with only developed nanoparticulate vaccine. Similar 
immunotherapeutic efficiency was obtained in animals vaccinated with the antigen-associated 
NP (AdsOVA-Adjs and EntrapOVA-Adjs NP) without previous transfer of the antigen-
specific splenocytes. A single vaccination with EntrapOVA-Adjs NP or AdsOVA-Adjs NPs 
was able to significantly decrease mean tumor development and growth, when compared to 
control group. The strongest effect was observed in animals treated with EntrapOVA-Adjs NP 
thus attesting the prominent anti-tumor immunity induced by this particular nanovaccine. 
Next to the phenotypic determination and quantification of the therapeutic efficacy of 
developed nanovaccines, the presence and the activation of TIL were further addressed 
following two immunization protocols: single vaccination or 3-time vaccination with 
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AdsOVA-Adjs or EntrapOVA-Adjs NP. Our studies suggest that a repetitive immunization 
was more efficient than a single vaccination in promoting lymphocyte recruitment into tumor 
microenvironment, as both CD8+ and CD4+ T cells were infiltrated at the tumor site, thus 
anticipating a more efficient tumor rejection. After a single vaccination with either AdsOVA 
NP or EntrapOVA NP, mainly CD8+ T cells were infiltrated at the tumor sites, suggesting a 
low infiltration of CD4+ T cells after a single dose of antigen-associated NP.  
The activation of CD8+ T cells was also studied in the spleens and LN of tumor-
bearing animals. Interestingly, the upregulation of CD107a activation marker was detected 
after a single and 3-dose vaccination. On the other side, the expression levels of the immune-
checkpoint receptor CTLA-4 were upregulated on T cells isolated from the spleens and LN 
after the 3-time immunization with AdsOVA-Adjs or EntrapOVA-Adjs NP, indicating lower 
T cell priming. Moreover, we detected altered cytokine production. Tumor infiltrating CD8+ T 
cells secrete significantly high levels of TNF-α but not IFN-γ upon 3-time immunizations. 
High levels of TNF-α in tumor microenvironment kept the tumor growth under control. 
However, splenic CD8+ T cells of these immunized animals presented low levels of IFN-γ and 
TNF-α secretion, indication an abasance of any systemic inflammation. On the other side, 
single vaccination with EntrapOVA-Adjs upregulated both TNF-α and IFN-γ in the spleens 
and in tumor microenvironment. However, it was more efficient after the immunization with 
AdsOVA-Adjs NP. Moreover, lymphoid organs removed from animals treated with single 
dose of NP did not express upregulated levels of CTLA-4.  
Overall, the anti-tumor therapeutic efficacy presented the best outcomes in tumor-
bearing mice immunized 3-times with EntrapOVA-Adjs NP. However, based on these 
cytokine results and levels of immune-check point receptors at T cells, we anticipate that the 
schedule of 3-time immunization may soon led to the anergy and exhaustion of the antigen-
specific T cells. Consequently, having in consideration the above results, alterations in the 
vaccination schedule may be suggested.  
 
5. Conclusions 
In this study we present the successful development of a cancer immunotherapeutic 
strategy by using biodegradable polymeric NP. This nanovaccine was able to efficiently co-
entrap various TAA and immunoadjuvants, such as TLR to enhance their co-delivery towards 
APC, and consequently induce an antigen-specific anti-tumor immune response. Several in 
vivo studies under steady-state conditions and cancer disease have been performed, to 
evaluate vaccine efficacy.  
Anti-tumor efficacy of developed nanoplatforms 
133 
Altogether, the results lead us to the following conclusions; APC, particularly DC, 
efficiently internalized both types of nanovaccines: EntrapOVA NP and AdsOVA NP. 
Differences in antigen-loading nanovaccines did not significantly alter their uptake by APC 
and the overall antigen-specific T cell activation within first 48 h p.i.. However, in a wider 
timeframe functional memory CTL were generated only when the antigen and adjuvants were 
co-delivered within the NP matrix (EntrapOVA-Adjs NP). The anti-tumor therapeutic 
efficacy of EntrapOVA-Adjs NP was also superior comparing to the vaccination with antigen 
adsorbed onto the surface of NP (AdsOVA-Adjs NP). These results highlight the importance 
of understanding the in vivo behavior of NP under both steady-state and tumor environment, 
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Gating strategy for in vivo determination of antigen loaded nanoparticle uptake by APC with ImageStreamX: 
Figure S1: Gating strategy of the in vivo experiment of antigen-loaded nanoparticle uptake by APC. At least 
30,000 cells were collected for each sample. ImageStream analysis was performed to detect Rho-labeled NP 
internalized by DC 16 h after the immunization. Images were compensated for fluorescent dye overlap by using 
single-stain controls. Cells were gated for single cells using the area, aspect ratio features, and bivariate plot for 
circularity (the degree of the mask’s deviation from a circle) based on the Object mask (a segmentation mask 
that creates a tight fit on the cell morphology) and intensity of the side scatter channel (illuminated by the 785 
nm laser and collected in channel 12). Particle internalization was calculated by the Internalization feature, i.e. 
the ratio of the intensity inside the cell to the intensity of the entire cell, mapped to a log scale. To define the 
internal mask for the cell, the object mask of the bright field image was eroded by 5 pixels. To measure the 
activation of CD11b+, CD11c+CD11b+, and CD11c+CD11b-, intensity of MHCII was compared against the 
intensity of CD11c or CD11b, respectively. Data are representative of tree independent experiments after the 16 
h incubation of DC with NP. Scale bar, 7 µm. 
 
T cell activation: 
 
Figure S2: Gating strategies for the expression of CD45.1, TCRVα2, CD3e or CD4 of T cells isolated from 
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immunized and non-immunized LN, 6, 16, 24 and 48 h following immunization. Data shown are representative 
of three different animals and three independent experiments form the 16 h p.i.. 
 
In vivo cytotoxic assay: 
Figure S3: Gating strategies for the expression of CD45.1, TCRVα2, CD8α or CD4 of T cells isolated from 
immunized and non-immunized LN. Data shown are representative of three different animals and three 
independent experiments. 
 
Memory CTL cells undergo an effective and rapid activation of naïve T cells 8 weeks after first immunization: 
Figure S4: (A) Single-suspension of LN was gated for DAPI-, TCRβ+, CD45.1+, and CD8α+. (B) Representative 
FACS plots 8 weeks p.i. after the immunization. Protein and adjuvant in the uniformed delivery system drives 
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development of memory CTL. Data shown are representative of at least three independent experiments with 2-3 
mice per group. 
 
Gating strategy of T cell infiltration in the tumor microenvironment: 
 
Figure S5: Extracellular staining of tumors infiltrated lymphocytes (TIL). This is a representative gating strategy 
for the analyzed tumor cell suspensions from two independent experiments, n = 6-8 animals/group. 
 
Gating strategy of CD8α T cells for CD107a and expression of PD-1 and CTLA-4: 
Figure S6: (A) Representative gating strategy for CD45.1, CD3, CD8, PD-1, CTLA-4 and CD107a in spleens 
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and LN (B & C) Representative flow cytometry plots of PD-1 and/or CTLA-4 upregulation in spleens (B) and 
LN (C) from the control, AdsOVA-Adjs NP EntrapOVA-Adjs NP, AdsOVA-Ajs NP (3x), and EntrapOVA-Adjs 
NP (3x) groups in tumor-bearing mice. Representitive FACS plots were chosen from two independent 
experiments, n = 6-8 animals/group 
 
Gating strategy of cytokine quantification in spleens and tumors of treated mice: 
 
Figure S7: Intracellular staining of tumor and splenic IL-4, TNF-α, IFN-γ producing cells. This is a 
representative gating strategy for tumor CD45.1+, CD3e+, CD8α+ or CD4+ cells from two independent 























Chapter 6 – General discussion and conclusions  
 
Cancer remains one of the most challenging diseases. Among the treatment modalities, 
immunotherapy and particularly the cancer vaccines are among the most challenging but 
promising tools for the successful eradication of malignant cells. Generally, cancer vaccines 
are envisioned to be administered after the disease detection of thus to treat patients rather 
than protect individuals from the cancer development [1-3]. These vaccines present multiple 
theoretical advantages over other conventional therapies like low toxicity, high specificity, 
and prolonged anti-tumor effect associated to the effective induction of an immunologic 
memory. The successful use of cancer vaccines allows one to target TAA expressed by tumor 
cells to induce a specific and long-lasting anti-tumor immune response that would specifically 
target and destroy malignant cells [4, 5]. TAA may be tumor restricted or widely expressed; 
mutated, overexpressed or aberrantly expressed; and may be derived from proteins usually 
expressed on cell surface, secreted or exclusively present at intracellular level. Antigens are 
chosen based on their ability to induce robust anti-tumor immune responses, including 
cellular (CD4+ and CD8+ T cell) and humoral (B cell) responses. The antigens should be 
immunogenic in a broad range of Human Leukocyte Antigen (HLA) types and effector 
responses should be followed by long-lasting memory responses, while causing minimum or 
no side effects in normal tissues [6-8]. The recent developments in tumor immunology have 
stemmed from the identification of TAA overexpressed in these malignant cells, as well as the 
deeper understanding of the interplay between the immune system and cancer cells. 
Effective immune responses result from a complex interplay between the innate 
(antigen-nonspecific) and the adaptive (antigen-specific) immune cell compartments. DC are 
the most potent APC and have, owing to this property, an important role in translating innate 
into adaptive immunity. Given their capacity to capture and process internalized antigens, DC 
efficiently prime naïve T cells against foreign antigens and polarize them towards distinct 
effector fates [8-10]. Moreover, antigen engulfment and the mode of DC activation are pivotal 
steps for clinically relevant responses which are dominated by cytotoxic CD8+ T cells, or 
CD4+ T cells with helper activity, and determines tolerance/immunity balance [2, 6, 11]. 
Thus, vaccination protocols that target DC are promising strategies for the initiation and 
enhancement of immune responses for cancer treatment. 
The use of nanotechnology in cancer immunotherapy gives many advantages over the 
delivery of the immunotherapeutic agents in solution. Therefore, nanoparticulate delivery 
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systems have been widely explored as promising platforms for cancer vaccination. Major 
advantages of the NP are a large surface area to volume ratio, with well-defined 
physicochemical properties, improved antigen stability, immunogenicity, bioavailability and 
efficacy, and possibility for control release and targeted delivery. In addition to their tunable 
sub-cellular size, these nanoparticulate systems are able to improve antigen stability of 
different types of molecules, including drugs, polypeptides, proteins and oligonucleotides 
[10,12-14] and, thus increase their loading capacity. The major advantage of the NP vaccines 
is the recognized versatility of formulation procedures and raw materials, leading to carriers 
with physicochemical properties best suited to the in vivo effective targeting of different 
immune cells within TME [6, 15]. Therefore, these NP are potential systems to amplify the 
immune activation and augment the efficacy of anti-tumor therapies [3]. The success of the 
nanoparticulate vaccines as a cancer immunotherapeutic strategy strongly depends on the 
composition, size, geometry, hydrophobicity and surface properties of the system [16].  
An ideal nanoparticulate cancer vaccine designed for the systemic delivery of 
payloads to DC, must comprise three main components: antigen, adjuvant, and a delivery 
system. Targeting antigen is defined as a protein, preferentially exclusively expressed on 
tumor cells, against which adaptive immune responses will be induced. An adjuvant acts as a 
“danger” signal stimulating the innate immune system. On the other hand, a delivery system 
is a vehicle with a well-established and defined physicochemical properties that enhances the 
delivery of single or multiple vaccine antigens and/or adjuvants to DC, and ensures optimal 
presentation in a targeted and prolonged manner [17, 18]. Moreover, a cancer vaccine has to 
be easy to manufacture and effective in all vaccinated population [4, 19]. 
The main goal of the research work presented in this thesis was the rational 
development of different nanoparticulate platforms with the ability to deliver TAA and 
immunoadjuvant molecules to DC as potential toold for anti-cancer treatment. Designing safe 
and efficacious NP vaccines requires a thorough understanding of the physical and chemical 
features of the carrier and their interaction with the biological systems. The unique properties 
of NP potentiate their interaction and uptake efficiency by APC that elicits T cell immunity 
[19, 20]. We aimed to develop a highly stable and reproducible colloidal suspension of NP 
smaller than 200 nm with narrow size distribution, PDI below 0.2 and ζ potential close to 
neutrality, in order to potentiate NP-APC interaction.  
Extensive research, including the development and optimization of experimental 
protocols were carried out towards the development of a novel nanoparticulate vaccine. CS 
was a promising material to be included into the NP formulation due to its positive charge, 
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which was expected to increase NP LC through the electrostatic interactions established 
between cationic amines and negatively charged antigens dispersed in the IP. This was of 
particular importance when entrapping MHC I and MHC II peptides. However, the high 
viscosity of this polysaccharide constituted a challenge for the development of a stable NP 
formulation. Therefore, in Chapters 2 and 3 various combinations of surfactant at different 
percentages were explored to produce a highly stable and reproducible colloid system. 
Sodium-cholate, an anionic emulsifier could not stabilize the double emulsion w/o/w, leading 
to the flocculation of this emulsion prior to NP sedimentation. On the other side, PF127 
possess good amphiphilic properties and lead to stable formulations when used as a stabilizer 
of both internal and external phases. Nevertheless, NP size was outside the specifications 
previously defined for the optimal NP-induced immune modulatory effect. PF127 has a 
complex branched triblock structure. The optimal NP were produced using PVA as an 
emulsifier of the internal aqueous phase (IP). However, the concentration of PVA solution 
had to be optimized in order to a reproducible NP formulation procedure, while leading to 
optimized physicochemical parameters, namely size, PDI, ζ potential with high yield. The NP 
that best fitted the previously established specifications for these targeted nanoparticulate 
vaccine were developed using 10% (w/v) PVA solution at IP, and PVA or PF127 in the 
external phase.  
Particularly interesting was to investigate how different methods of antigen association 
to the developed particulate carriers could affect the antigen uptake by APC and modulate the 
overall antigen-specific immune responses. As described in Chapter 4, four highly 
reproducible and homogeneous nanoplatforms have been developed, two of those presented 
the antigen adsorbed onto NP surface (AdsPROTEIN NP), while the other two had the 
antigen entrapped ((EntrapPROTEIN NP) within NP matrix NP. All NP were based on the 
hydrophobic aliphatic polyester PLGA that forms a matrix of a nanoparticulate vehicle and 
allows the incorporation of chitosan (CS), antigens (LALBA; a breast cancer antigen) and 
adjuvants. CpG ODN stimulates TLR9 and was entrapped into the core of the polymeric 
matrix of NP. Two different stabilizers (PVA or PF127,) of the external aqueous phase were 
tested, to ensure NP best physical and chemical characteristics, including size, surface charge 
and antigen association. PEG polymer was used for the formulation of EntrapOVA NP in 
contrast to AdsOVA NP to improve the stability of the emulsion, thus leading to NP with 
similar size distribution, polarity of ζ potential and hydrophobicity, despite the method used 
for the association of the antigen. The similarity between the physical and chemical properties 
of both types of NP was particularly important in order to allow the rational characterization 
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of the effect of the method of antigen delivery on the overall efficacy of the developed cancer 
vaccine. If the nanoparticulate systems presented distinct properties, than the eventual 
different activity on immune cells could not be clearly associated to the adsorbed or entrapped 
antigen. An extensive characterization of the experimental parameters, such as nature of 
protein association (adsorbed vs. entrapped), polymers and surfactant concentrations were 
investigated for their effect on particle size, polydispersity index, ζ potential, EE, LC, protein 
integrity, percentage of surfactant residual amount, and formulation stability. These study 
allowed the identification of the best formulations to attain the previously described NP 
specification for the optimal modulation of immune cells owards the destruction of cancer 
cells.  
Spherical NP with an average size between 170-180 nm were produced in a 
reproducible way and were highly stable over a period of 3 moths in suspension. Antigen-
loading efficiency of developed nanovaccines was similar despite the entrapment or 
adsorption of the antigens, which was ideal for further evaluation of the immune response. 
Moreover, the protein integrity, investigated by SDS-PAGE, indicated that protein molecular 
weight was not affected by NP formulation process. However, a western-blot could have been 
performed in order to assess the maintenance of the antigen activity after the formulation 
procedure. Even though, having in consideration the data reported for in vitro and in vivo 
studies, it is now possible to state that the different antigens associated to the developed NP 
maintained their activity after the formulation. The in vitro studies on BMDC provided a 
better understanding on the importance of the chemical composition of the developed NP on 
their interaction with APC. This research data definitely evidenced the potential of the 
optimal nanoparticulate vaccine for targeting and modulating DC, prompted the evaluation of 
the efficacy of the two best formulation candidates as a potential cancer immunotherapeutic 
approaches at preclinical settings. 
Chapter 5 describes the development of the best two PVA formulations (AdsOVA NP 
and EntrapOVA NP) that drove the most efficient upregulation and activation of DC in vitro 
(chapter 4). Developed NP presented an average mean diameter close to 190 nm, with a 
uniformed size distribution, ζ potential close to neutrality and high loading efficiency. Both 
AdsOVA NP and EntrapOVA NP were investigated in vivo, with or without adjuvants. Next 
to the CpG ODN, the lipophilic adjuvant MPLA (TLR4 agonist), was introduced into the NP 
scaffold. Herein, several factors that could affect the performance of the vaccine and could 
potentially have an impact on the anti-tumor immune response were addressed, such as (i) the 
advantage of using a carrier for vaccine delivery; (ii) the impact of antigen delivery by 
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different means on the systemic internalization by APC, principally DC; (iii) the influence of 
the simultaneous delivery of antigens with co-stimulatory TLR ligands; (iv) the ability of the 
delivery system to allow the antigen active cross-presentation, thus promoting the active 
generation of CTL; (v) the impact of the antigen and adjuvant co-delivery on long-lasting 
memory; (vi) the impact of single vs. three-dose immunization schedule in a tumor-bearing 
mice; and (vii) the effect of antigen-associated particulate vaccines on the cytokine production 
and TIL trafficking into the tumors of B16.MO5 challenged mice.  
APC, particularly classical DC, presented a good internalization profile for both 
classes of NP (AdsOVA NP and EntrapOVA NP), despite the difference in the initial antigen 
exposure to APC, thus anticipating similarity in the overall triggered immune response. 
However, this hypothesis was not confirmed as AdsOVA NP were extensively engulf by 
pDC, while EntrapOVA NP escaped this rapid peripheral internalization by pDC, most 
probably due to the presence of PEG at EntrapOVA NP and its “stealth” effect that protects 
NP from premature capture [60, 61 in EVA1]. The further identification of DC-mediated 
antigen-specific T cell cytotoxicity was accomplished through the in vivo kinetic evaluation of 
the levels of the activation molecules CD25, CD69, and CD44. These studies indicated that 
the DC-T cell interactome at the LN is already activated 16 h p.i.. Moreover, EntrapOVA NP 
were more efficient in the upregulation of CD44 activation marker on CD8+ T cells, 
suggesting the induction of a stronger antigen-specific immune response towards an effective 
memory immunity. EntrapOVA NP without adjuvants were not efficient in inducing long-
lasting memory. However, the inclusion of adjuvants in EntrapOVA-Ajds NP lead to the 
expansion of a long-lasting memory, which was superior to that obtained in all of the 
remaining treated animals.  
Prior to the tumor challenge, nanovaccines were tested for their ability to drive cross-
presentation and cross-priming. During the short-time experiment (7 day), all NP were able to 
induce the effective activation and priming of antigen-specific cytotoxic CD8+ T (CTL) cells 
that will thus recognize and kill targeted cells. 
Anti-tumor therapeutic efficacy of developed nanovaccines (AdsOVA-Adjs NP and 
EntrapOVA-Adjs NP) co-delivering OVA antigen and adjuvants (CpG and MPLA) has been 
tested on OVA transfected melanoma B16.MO5 bearing C57BL/6 mice. Mice immunized 
with three-dose schedule for EntrapOVA-Adjs NP presented the slowest tumor growth, with 
the highest amount of TIL in the tumors, suggesting a good prognosis for vaccine outcome. 
However, the secretion of cytokines was lower in animals treated with the three doses of the 
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vaccine, when compared with those quantified in animals immunized with the single dose of 
EntrapOVA-Adjs NP.  
Taken together, our studies highlight the importance of the composition and related 
physicochemical properties of nanoparticulate vaccines for their cellular uptake by APC, and 
overall nature of induced immune response. Developed NP possess the desirable 
physicochemical properties, with good LC and colloidal stability in biological media. All 
antigen-associated NP promptly induced the efficient DC activation and maturation. 
However, animals immunized with EntrapOVA NP and EntrapOVA-Adjs NP presented 
higher CD8+ OT-I cell proliferation and activation through the antigen-specific immune 
response. These are pivotal steps in the immunology that leads to a complete and effective 
immune response. In addition, the immune response induced by the delivery of both OVA and 
Adjs by these optimal PLGA carriers was able to decrease tumor growth and therefore 
additional studies can clarify their ability to improve animal survival. One can expect this 
overall output, having in consideration the evidenced ability of the developed nanovaccine to 
induce a long-lasting memory immune response.  
Therefore, the developed nanovaccine definitely has a promising potential for 
therapeutic cancer vaccines.  
Massive data have been released from clinicals trials focused on the evaluation of the 
effect of the combination of different cancer treatment modalities of cancer treatments in the 
reduction of tumor growth, overall side effect and prolonged disease-free survival. Therefore, 
having in consideration the promising effect of the developed nanovaccine in the modulation 
of immune cells both at under steady-state and cancer disease, future studies should assess the 
overall therapeutic effect of its combination with the currently most promising alternative 
cancer treatment options, such as the administration of immune check points. Of particular 
interest would be the assessment of their ability to reduce the dose of the administered 




















Chapter 7 – Future perspectives 
 
Improved understanding on the role of the immune system in controlling tumor growth 
and recent developments in the field of nanoparticulate cancer vaccines have triggered 
scientific community attention towards a novel anti-tumor immunotherapeutic approach.  
However, it is clear that preclinical tumor model systems are poorly predictive for 
clinical trials. This is not only due to the highly tumor heterogeneity, but also considerable 
differences between the rapidly growing transplantable tumors in murine models compare to 
usually slow-growing clinical disease [1]. Thus, a great demand for novel preclinical models 
for better prediction and detailed characterization of tumor treatments are needed. 
The work described in this doctoral thesis highlights and characterizes the potential of 
nanoparticles (NP) as cancer vaccines to target tumor antigens and adjuvants to DC for 
priming antigen-specific cytotoxic T lymphocytes (CTL). Despite the potential recognized for 
these particulate vaccines, there is still limited knowledge underlying their biological effect 
on immune cells, and on cancer-immune cell interactions within tumor microenvironment. 
Deeper understanding on the impact of NP properties on those signaling mechanisms can 
rationally guide the selection of treatment schedules, as well as, the best combination 
approaches to achieve a long period of disease-free survival.  
Due to tumors’ heterogeneity and phenotypic diversity, targeting of a single antigen 
may not be sufficient for the induction of an immune response capable of destroying cancer 
cells. As a result, it is anticipated that effective cytotoxic immune responses may be obtained 
with multivalent cancer vaccines rather than monovalent. The immune system will be able to 
generate strong and long-lasting anti-tumor responses against each antigen. Therefore, this 
type of vaccine is expected to target a higher number of cancer cells in comparison with 
single-antigen containing vaccine. However, a potential problem that may arise from the use 
of a multivalent vaccine may be the stimulation of a dominant response against one particular 
antigen, due to steric hindrance [2, 3]. 
In addition, it must be kept in mind that tumor vaccines capacity to combat an already 
established malignant disease, will correlate with the stage of the disease. Ideally, cancer 
vaccine would be the first choice of treatment, when the tumor is in stage I/II, inducing an 
immune response that would have a fair chance to prevent tumor relapse. Moreover, 
evaluation of individual host immunity should be considered in the selection of the most 
appropriate treatment protocols. Even though, the use of cancer vaccines at clinical settings 
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has been mainly restricted to advanced stages of the disease, due to the limited therapeutic 
options still available for those patients.  
However, the strategy to use two immunotherapeutic approaches to achieve immune-
mediated tumor cell killing, looks promising, to shift favorably the balance between anti-
cancer effector cells and tumor-induced immune suppression. We observed that the three-dose 
schedule treatment using the antigen-entrapped NP induced the overexpression of Cytotoxic 
T-Lymphocyte Associated Protein 4) CTLA4 and programmed cell death 1 (PD-1) immune 
checkpoints at tumor infiltrated T lymphocytes. Therefore, the combination of the cancer 
vaccine and monoclonal antibodies blocking the CTLA-4 and PD-1 may function 
synergistically and thus induce more effective anti-tumor immune responses, leading to 
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